Von Hippel-Lindau disease type 2 in a Chinese family with a VHL p.W88X truncation
PMID: 25069792
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
Von Hippel-Lindau disease type 2 in a Chinese family with a VHL p.W88X truncation
PMID: 25069792
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
PatientID: None
KindredID: 49
Case: F, 15Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CohortInfo: A total of 190 patients recruited by the COMETE network over 15 years were included in the study.
CasePresentingHPOs: HP:0002666 (pheochromocytoma)
CaseHPOFreeText: The patient had one benign pheochromocytoma.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET, SDHB, SDHC, SDHD
PreviouslyPublished: N/A
SupplementalData: Patient information was extracted from Table 1 of Supplementary.
Variant: p.R167Q (c.500G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVar: 2216 https://www.ncbi.nlm.nih.gov/clinvar/variation/2216/
CAID: N/A
gnomAD: 0.000003977 https://gnomad.broadinstitute.org/variant/3-10191507-G-A
VariantEvidence:N/A
MutationType: missense_variant;transition
CivicName: R167Q (c.500 G >A)
MultipleGeneVariants: N/A
PatientID: None
KindredID: 51
Case: M, 41Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CohortInfo: A total of 190 patients recruited by the COMETE network over 15 years were included in the study.
CasePresentingHPOs: HP:0002666 (pheochromocytoma)
CaseHPOFreeText: The patient had one benign pheochromocytoma.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET, SDHB, SDHC, SDHD
PreviouslyPublished: N/A
SupplementalData: Patient information was extracted from Table 1 of Supplementary.
Variant: p.Y175* (c.525C>G)
CaseProblemVariantFreeText: The protein change was written as Thr175 in the Supplemental but the nucleotide change corresponds to Tyr175.
LegacyVariant: N/A
ClinVarID: 182974 https://www.ncbi.nlm.nih.gov/clinvar/variation/182974/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: Y175* (c.525C>G)
MultipleGeneVariants: N/A
PatientID: None
KindredID: VHL12
Case: M, 25Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CohortInfo: A total of 190 patients recruited by the COMETE network over 15 years were included in the study.
CasePresentingHPOs: HP:0002666 (Pheochromocytoma)
CaseHPOFreeText: The patient had two benign pheochromocytomas.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET/SDHB/SDHC/SDHD
PreviouslyPublished: N/A
SupplementalData: Table 1 of Supplementary
Variant: p.R161Q (c.482G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 182983, https://www.ncbi.nlm.nih.gov/clinvar/variation/182983/
CAID: N/A
gnomAD: N/A
VariantEvidence: The patient had LOH found in the BAC array CGH data.
MutationType: missense_variant;transition
CivicName: R161Q (c.482G>A)
MultipleGeneVariants: N/A
Next-generation sequencing in familial breast cancer patients from Lebanon
PMID: 28202063
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
PatientID: V-37
KindredID: 2
Case: F, Age Unknown, German
DiseaseAssertion: VHL
FamilyInfo: Family 2 is comprised of 131 individuals over six generations including 65 members (50% of those at risk) with VHL type 2A (72% clinically affected, 12% obligate carriers, and 15% positive genetic analysis alone) and nearly equal gender distribution for affected status (54% male). An additional six members (II-3, II-4, II -5, III-1, III-2, and III-3) are suspected to have VHL without confirmation. Of note, the nuclear family (branch IV-13) contains 13 siblings, of whom 12 have been diagnosed with pheo. The presenting tumor types in Family 2 were pheo (70%), HB (17%), and RA (13%). No Family 2 member had RCC as the initial manifestation. Distribution of HB and RA are not described except for patient IV-8.
CasePresentingHPOs: HP:0002666 (Pheochromocytoma)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0005584 (Renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 7759077
SupplementalData: N/A
Variant: p.Y98H (c.292T>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2223, https://www.ncbi.nlm.nih.gov/clinvar/variation/2223/
CAID: N/A
gnomAD: 0.00001343, https://gnomad.broadinstitute.org/variant/3-10183823-T-C
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: Y98H (c.292T>C)
MultipleGeneVariants: N/A
PatientID: V-24
KindredID: 2
Case: F, Age Unknown, German
DiseaseAssertion: VHL
FamilyInfo: Family 2 is comprised of 131 individuals over six generations including 65 members (50% of those at risk) with VHL type 2A (72% clinically affected, 12% obligate carriers, and 15% positive genetic analysis alone) and nearly equal gender distribution for affected status (54% male). An additional six members (II-3, II-4, II -5, III-1, III-2, and III-3) are suspected to have VHL without confirmation. Of note, the nuclear family (branch IV-13) contains 13 siblings, of whom 12 have been diagnosed with pheo. The presenting tumor types in Family 2 were pheo (70%), HB (17%), and RA (13%). No Family 2 member had RCC as the initial manifestation. Distribution of HB and RA are not described except for patient IV-8.
CasePresentingHPOs: HP:0002666 (Pheochromocytoma)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0005584 (Renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 7759077
SupplementalData: N/A
Variant: p.Y98H (c.292T>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2223, https://www.ncbi.nlm.nih.gov/clinvar/variation/2223/
CAID: N/A
gnomAD: 0.00001343, https://gnomad.broadinstitute.org/variant/3-10183823-T-C
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: Y98H (c.292T>C)
MultipleGeneVariants: N/A
GroupID/ KindredID: F15
Case: Sex unknown, 32Y0M, Spanish
DiseaseAssertion: assumed VHL
FamilyInfo: Noted of familial antecedents of phaeochromocytoma.
CasePresentingHPOs: HP:0002666 (pheochromocytoma)
CaseHPOFreeText: Unilateral pheo. Age of onset is 32Y0M.
CaseNotHPOs: HP:0006770; HP:0000107; HP:0006880; HP:0001737; HP:0009711 (clear cell renal cell carcinoma, renal cysts, cerebellar hemangioblastoma, pancreatic cysts, retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Y175C (c.524A>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 36905 https://www.ncbi.nlm.nih.gov/clinvar/variation/36905/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transition
CivicName: Y175C (c.524A>G)
MultipleGeneVariants: N/A
GroupID/ KindredID: F2
Case: Sex unknown, 26Y0M, Spanish
DiseaseAssertion: assumed VHL
FamilyInfo: None. Microsatellite analysis excluded nonpaternity for this patient, leading to the assumption that this variant was de novo in character. (assumed de novo without confirmation of maternity).
CasePresentingHPOs: HP:0006880; HP:0001737 (cerebellar hemangioblastoma, pancreatic cysts)
CaseHPOFreeText: cerebellar hemangioblastoma had multiple lesions. Age of onset is 26Y0M.
CaseNotHPOs: HP:0006770; HP:0002666; HP:0000107; HP:0009711 (clear cell renal cell carcinoma, pheochromocytoma, renal cysts, retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.V130L (c.388G>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2229 https://www.ncbi.nlm.nih.gov/clinvar/variation/2229/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: V130L (c.388G>C)
MultipleGeneVariants: N/A
GroupID/ KindredID: F66
Case: Sex unknown, 12Y0M, Spanish
DiseaseAssertion: assumed VHL
FamilyInfo: familial antecedents found of pancreatic cysts
CasePresentingHPOs: HP:0009711 (retinal capillary hemangioma)
CaseHPOFreeText: Multiple lesions on their retinal hemangioblastoma. Age of onset is 12Y0M.
CaseNotHPOs: HP:0006880; HP:0002666; HP:0000107; HP:0001737; HP:0006770 (cerebellar hemangioblastoma, pheochromocytoma, renal cysts, pancreatic cysts, clear cell renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Q96* (c.286C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 428804 https://www.ncbi.nlm.nih.gov/clinvar/variation/428804/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: Q96* (c.286C>T)
MultipleGeneVariants: N/A
All registrants provided 10 ml EDTA-anticoagulated blood for molecular genetic analyses. The analyses comprised testing of all exons including the splice sites of the VHL (RefSeq:NM_000551.2) and MEN1 (RefSeq:NM_130803.1) genes for germline mutations. DNA extraction, primers, PCR conditions, and sequencing methods followed published protocols of international standards (Lemmens et al. 1997, Franke et al. 2009). The primers are available on request. Of note, analyses also included screening for large deletions or rearrangements of the VHL and MEN1 genes. For screening for intragenic mutations, we used the PCR-based denaturing HPLC. For detection of large deletions/rearrangements, we used two commercially available kits for multiplex ligation-dependent probe amplification, the SALSA MLPA KIT P016 VHL, and the SALSA MLPA KIT P017-B1 MEN1 respectively (MLPA, MRC Holland, Amsterdam, The Netherlands). The primers are available on request. All analyses for the VHL gene and the analyses for intragenic mutations in the MEN1 gene have been performed in Freiburg. The analyses for the large deletions and rearrangements of the MEN1 gene have been performed in Madrid.
ArticleReferenceSequence: NM_000551.2
GenotypingMethod: PCR; and the SALSA MLPA KIT P016 VHL for detection of large deletions/rearrangements.
SamplingMethod: blood (EDTA-anticoagulated blood).
c.393 C>Aap.N131K
53 patients with a molecularly confirmed VHL mutation (by PCR through EDTA-anticoagulated blood) and a pancreatic neuroendocrine tumor (ICT) were collected from the German NET-Registry and the German VHL-registry. An additional 296 patients were stated in this paper with a VHL associated germline mutation, but without pancreatic neuroendocrine tumors. 1 patient was found to have the above mutation (c.393C>A). This was a VHL patient with an ICT (pancreatic neuroendocrine tumor) taken from the VHL-registry. Other clinical manifestations outside of a pancreatic neuroendocrine tumor are possible, but were not discussed. ACMG evidence codes: 'PP2' because they observe a missense variant in a gene where missense variants are a common mechanism of disease.
35 (45%) had missense variant
PatientID: 29
KindredID: 29
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0006770; HP:0009711 (hemangioblastoma; clear cell renal cell carcinoma; retinal capillary hemangioma)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0100634; HP:0030405; HP:0030421 (Neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm, Epididymal neoplasm)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Yes; see table S1 for VHL subject genetic and manifestation information.
Variant: p.P86L (c.257C>T)
LegacyVariant: p.P157L (c.470C>T)
CaseProblemVariantFreeText: converted from legacy notation c.470C>T; Pro157Leu; authors contacted
ClinVarID: 182977 https://www.ncbi.nlm.nih.gov/clinvar/variation/182977/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transition
CivicName: P86L (c.257C>T)
MultipleGeneVariants: N/A
17 (22%) had frameshift variants
PatientID: 46
KindredID: 46 **
Case: Sex, Age, Ethnicity unknown
DiseaseAssertion: VHL
FamilyInfo: ** Patients 46, 50, 71, and 72 were reported previously in Aronoff et al, 2018 (PMID: 29437867) as family 5
CasePresentingHPOs: HP:0010797 (hemangioblastoma)
CaseHPOFreeText: CNS hemangioblamstoma
CaseNotHPOs: HP:0030421; HP:0009711; HP:0030405; HP:0006770; HP:0100634 (epididymal tumour, retinal capillary hemangioma, pancreatic endocrine tumour, clear cell renal cell carcinoma, neuroendocrine neoplasm)
CaseNotHPOFreeText: patient was not recorded to have an epididymal tumor, a pancreatic endocrine tumour (pancreatic neuroendocrine neoplasm), CCRCC, nor a neuroendocrine neoplasm (pheochromocytoma/paraganglioma)
CasePreviousTesting: N/A
PreviouslyPublished: 29437867
SupplementalData: Yes; see table S1 for VHL subject genetic and manifestation information.
Variant: p.F136Lfs*23 (c.408delT)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 43601 https://www.ncbi.nlm.nih.gov/clinvar/variation/43601/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant
CivicName: F136Lfs*23 (c.408delT)
MultipleGeneVariants: N/A
missense variants
PatientID: 32
KindredID: 32
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0006770; HP:0010797; HP:0100634 (clear cell renal cell carcinoma, hemangioblastoma, neuroendocrine neoplasm)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0030405; HP:0009711; HP:0030421 (pancreatic neuroendocrine neoplasm, retinal capillary hemangioma, Epididymal neoplasm)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 29437867 (Family 1 - see here for more info)
SupplementalData: Yes; see table S1 for VHL subject genetic and manifestation information.
Variant: p.S65A (c.193T>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 223160 https://www.ncbi.nlm.nih.gov/clinvar/variation/223160
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: S65A (c.193T>G)
MultipleGeneVariants: N/A
missense variants
PatientID: 61
KindredID: 61
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0030405; HP:0009711; HP:0030421 (hemangioblastoma; pancreatic neuroendocrine neoplasm, retinal capillary hemangioma; Epididymal neoplasm)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0100634; HP:0006770 (Neuroendocrine neoplasm, clear cell renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 29437867 (Family 7 - see here for more info)
SupplementalData: Yes; see table S1 for VHL subject genetic and manifestation information.
Variant: p.R107G (c.319C>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 43599 https://www.ncbi.nlm.nih.gov/clinvar/variation/43599
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: R107G (c.319C>G)
MultipleGeneVariants: N/A
13 (17%) had large deletions,
PatientID: 38
KindredID: 38
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0006770; HP:0100634; HP:0030405 (hemangioblastoma; clear cell renal cell carcinoma; Neuroendocrine neoplasm, pancreatic neuroendocrine neoplasm)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0009711; HP:0030421 (retinal capillary hemangioma, Epididymal neoplasm)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 29437867 (Family 4 - mother - see here for more info)
SupplementalData: Yes; see table S1 for VHL subject genetic and manifestation information.
Variant: Deletion of Exon 2
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: exon_loss_variant
CivicName: Exon 2 deletion
MultipleGeneVariants: N/A
p.F76del
PatientID: None (II)
KindredID: 1
Case: Sex and Ethnicity unknown; Age >18Y0M
DiseaseAssertion: hemangioblastoma
FamilyInfo: Total of 4 family members belonging to Family 1 (see Table 2; or follow KindredID 1)
CasePresentingHPOs: HP:0010797 (hemangioblastoma)
CaseHPOFreeText: 3 HB at first screening, and same by final screening (5 year follow up).
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 16572651
SupplementalData: N/A
Variant: p.F76del (c.227_229del)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 223166 https://www.ncbi.nlm.nih.gov/clinvar/variation/223166/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: inframe_deletion
CivicName: p.F76del
MultipleGeneVariants: N/A
VHL c.505 T>C mutation confers a high age related penetrance but no increased overall mortality
PMID: 11483638
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
PatientID: None
KindredID: 26
Case: Sex Unknown, Age Unknown, Japanese
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0009711; HP:0005584 (Hemangioblastoma, Retinal capillary hemangioma, Renal cell carcinoma)
CaseHPOFreeText: CNS hemangioblastoma, retinal angioma and renal cell carcinoma.
CaseNotHPOs: HP:0001732 (Abnormality of the pancreas)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 8634692 (variants differ by one base pair; unclear which is accurate)
SupplementalData: N/A
Variant: p.D143Efs*13 (c.429_438del)
LegacyVariant: c.642del10bp
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA2573131814, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA2573131814
gnomAD: N/A
VariantEvidence: N/A
MutationType: deletion; minus_1_frameshift_variant
CivicName: D143Efs*13 (c.429_438del)
MultipleGeneVariants: N/A
PatientID: None
KindredID: 16
Case: Sex Unknown, Age Unknown, Japanese
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0005584 (Hemangioblastoma, Renal cell carcinoma)
CaseHPOFreeText: CNS hemangioblastoma and renal cell carcinoma.
CaseNotHPOs: HP:0009711; HP:0001732 (Retinal capillary hemangioma, Abnormality of the pancreas)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 8634692
SupplementalData: N/A
Variant: p.C77Sfs*82 (c.230del)
LegacyVariant: c.443del
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA2573106239, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.230del
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant; deletion
CivicName: C77Sfs*82 (c.230del)
MultipleGeneVariants: N/A
PatientID: None
KindredID: 105
Case: Sex Unknown, Age Unknown, Japanese
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0005584; HP:0001732 (Hemangioblastoma, Renal cell carcinoma, Abnormality of the pancreas)
CaseHPOFreeText: CNS hemangioblastoma, pancreatic cyst or tumor (unspecified) and renal cell carcinoma.
CaseNotHPOs: HP:0009711 (Retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.E173Rfs*29 (c.516del)
LegacyVariant: c.729del
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA645525089, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.516del
gnomAD: N/A
VariantEvidence: N/A
MutationType: deletion; minus_1_frameshift_variant
CivicName: E173Rfs*29 (c.516del)
MultipleGeneVariants: N/A
GroupID: 362
DiseaseAssertion: VHL
GroupSize: 2
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: French
GroupAgeRange: N/A
GroupInfo: 2 members of this family were found to harbor the c.395A>C germline variant of the VHL gene. Member 8813 had unknown renal involvement. Member 5862 presented with mild renal disease. Families were recruited from the French VHL Registry. Enrolment in the study required identification of the germline VHL mutation (currently 85% of the families included in the French VHL Registry) and available data regarding renal phenotype. A total of 126 families fulfilled these criteria.
GroupPresentingHPOs: HP:0009726 (Renal neoplasm)
GroupHPOFreeText: Mild renal disease (simple renal cyst, multicystic kidney[s], small lesion [less than 10 mm in size] of unknown significance, or small solid tumor without indication for surgical removal [less than 30 mm in size]).
GroupNotHPOs: N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: Paper states that this family is previously reported in PMID 12202531, where 1 individual with this mutation is reported. It is unclear which of the members of this family this previously reported patient corresponds to.
SupplementalData: Phenotype and genotype information can be found in Supplementary Table S1.
Variant: p.Q132P (c.395A>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 496063, https://www.ncbi.nlm.nih.gov/clinvar/variation/496063/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: Q132P (c.395A>C)
MultipleGeneVariants: N/A
PatientID: 6321
KindredID: 343
Case: Sex Unknown, Age Unknown, French
DiseaseAssertion: VHL
FamilyInfo: N/A
CohortInfo: Families were recruited from the French VHL Registry. Enrolment in the study required identification of the germline VHL mutation (currently 85% of the families included in the French VHL Registry) and available data regarding renal phenotype. A total of 126 families fulfilled these criteria.
CasePresentingHPOs: HP:0005584 (Renal cell carcinoma)
CaseHPOFreeText: Severe renal disease (any solid lesion before 25 years of age, five or more solid lesions within one or two kidneys, or metastasis of renal cell carcinoma). Individual RCC phenotype is noted as positive.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Phenotype and genotype information can be found in Supplementary Table S1.
Variant: p.R69Afs*63 (c.204dup)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA913189244, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.204dup
gnomAD: N/A
VariantEvidence: N/A
MutationType: duplication; plus_1_frameshift_variant
CivicName: R69Afs*63 (c.204dup)
MultipleGeneVariants: N/A
Molecular and clinical analysis of 126 French VHL families tested for renal involvement revealed 92 different mutations. 90 of these families had renal involvement. The p.Y175* (c.525C>A) germline variant of the VHL gene was detected in a family (ID 7). Members 6548 and 6362 had unknown renal involvement. Member 6364 presented with mild renal disease. Member 6728 presented with moderate renal disease (RCC). The paper states that this family is previously reported in PMID 12202531. Another family (ID 320) was found with this variant. Member 7851 presented with severe renal disease (RCC) and member 7547 presented with moderate renal disease (RCC). This family has not been previously reported.
Medical records of 26 patients with germline mutations of the VHL gene who had been diagnosed with VHL disease in Severance Hospital (Seoul, Republic of Korea) and Samsung Medical Center (Seoul, Republic of Korea) between 2003 and 2012 were respectively reviewed. Three unrelated probands were genetically confirmed with a germline missense mutation at c.499C>T of the VHL gene. Patients 42 and 44, 10Y and 30Y males respectively, both presented with multiple and/or bilateral pheochromocytoma and CNS hemangioblastomas. Patient 43, 30Y male, presented with multiple and/or bilateral pheochromocytoma and retinal hemangioblastoma. Patients 42 and 43 had a family history negative for VHL disease while patient 44 had a positive family history of VHL disease. Patient 43s phenotypes were revised from a previous report (PMID 19949673). Patient 44 was previously reported in PMID 16142346 as well as Kim et al., 2005 (reference 15 in the current paper). All of these patients were diagnosed with VHL Type 2A.
Figure 6. Functional study of synonymous mutations in VHL E2. (A) Functional hypoxia response element (HRE)–dependent reporter assays were performed in 786-O cells to evaluate the impact of VHL mutations in E2 (P138L and G144R) on VHL protein activity. The VHL protein lacking E2 (pVHL172/VHLΔE2) was used as a negative control. The results are expressed as firefly luciferase activity relative to Renilla luciferase as an internal control; 1.0 unit denotes the basal activity of endogenous HIF-2α using the HRE luciferase reporter plasmid. Immunoblots using an antibody specific for the hemagglutinin tag (HA) were used to detect HA-VHL. (B) Characterization of VHL E2 skipping by minigene analyses. Minigene experiments were performed in a variety of cell lines relevant to the studied diseases: renal (293T, 786-O, and HK2), pheochromocytoma (pheo; PC12), erythroid cell line (UT7 cultured with erythropoietin), and LCL. RT-PCR was performed on mRNA obtained from cell lines transfected with a minigene construct containing VHL E2 flanked by intronic sequences cloned between the SERPING1 exons (exons A and B; targeted by the RT-PCR primers). Bands corresponding to EA and EB spliced together or with VHL E2 are indicated on the right. (C) Sashimi plots from RNA-seq data. The positions of the different VHL exons are indicated, with the maximum number of reads for each exon indicated at the right. Splice junctions are denoted by the horizontal links, with details provided in supplemental Figure 15A. (D) Heatmap of pheochromocytoma transcriptome data. A comparison of transcriptome data for the pheochromocytoma from patient F11 III.1 (with P138P mutation) vs Affymetrix data from the largest available cohort of paragangliomas/pheochromocytomas (recruited by the French COMETE network) that identified homogeneous molecular subgroups associated with susceptibility genes (Burnichon et al30).
F1, II.1c.429C>T/c.340+770T>CVHL p.Asp143Asp/X1 p.Ser179Pro?1991/15 yM16.6576.9163Erythrocytosis, kidney ischemic infarct—
PatientID: II.1
KindredID: F1
Case: M, 15Y0M, Ethnicity Unknown
DiseaseAssertion: Polycythemia
FamilyInfo: N/A
CasePresentingHPOs: HP:0001901 (Polycythemia)
CaseHPOFreeText: Diagnosed with erythrocytosis (Polycythemia) and kidney ischemic infarct at age 15 (DOB: 1991).
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: c.340+770T>C
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 816685, https://www.ncbi.nlm.nih.gov/clinvar/variation/816685/
CAID: N/A
gnomAD: N/A
VariantEvidence: Variants are heterozygous.
MutationType: missense_variant;transition; splice_site_variant
CivicName: D143= (c.429C>T) and c.340+770T>C
MultipleGeneVariants: Germline, VHL, c.429C>T (p.Asp143Asp)
c.429C>T/c.429C>T
The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. Patient II.1 (family F9) was found to have the germline variant D143= (c.429C>T). The patient was diagnosed with erythrocytosis at 5 months old (DOB: 1997). This variant is homozygous in the patient. This patient was also found to have the HB Sitia germline variant. Both asymptomatic parents were genetically sequenced and found to be carriers of the variant. Patient II.1 (family F10) was also found to have this variant. This patient was diagnosed with erythrocytosis (Polycythemia) and splenomegaly at 4.5 years old (DOB: 2002). This patient was also found to have the Beta Thalassemia germline variant. This patient’s asymptomatic patients were both found to be carriers of the same variant in VHL. Their other child (II.2) also carried the gene. Patient II.1 was the only one who was homozygous for the variant.
Expression study of the new VHL isoforms in patients' cellsRNA sequencing (RNA-seq) analysis of patients' LCLs and tumors demonstrated that genomic variants in E1′ were associated with an upregulation of transcripts containing the E1′ cryptic exon compared with controls (Figure 3A; supplemental Figure 8). In addition, the mutated allele was preferentially expressed (>70%), suggesting a causal relationship between the genetic variants and E1′ retention (supplemental Figure 8C).Figure 3. Expression study of the new VHL transcript isoforms in patient cells. (A) Sashimi plots from RNA-seq data obtained from samples (LCLs or pheochromocytomas [Pheo]) of 3 patients from F8. The positions of the different VHL exons are indicated, with the maximal number of reads indicated at the right. Splice junctions are denoted by the horizontal links, with details provided in supplemental Figure 8. (B) TaqMan quantification of the different VHL isoforms from samples of F8 performed using probes specific to VHL E1-E2, the translated sequence upstream E1′, or E1-E1′ junctions. Relative gene expression was normalized to LCL control (C1) fixed at 1 (mean results of technical duplicates). (C) TaqMan quantification of the different VHL isoforms in LCLs (established from 2 independent controls and from patients of F1, F2, and F8) cultured in the absence or presence of puromycin (puro), an inhibitor of nonsense-mediated mRNA decay. TaqMan probes were specific to the VHL E1-E1′ or E1-E2 junction. The graph resumes experiments performed on LCLs cultured independently 3 times and quantified in duplicate. Data are represented as the mean ± standard error of the mean. (D) RT-PCR using primers specific for E1 and E3 was performed on mRNA extracted from LCLs established from controls and patients of F6 (carrying the mutation c.340+574A>T that targets the SA site of E1′). Patient with erythrocytosis is indicated in red. On the right, the spliced isoforms are schematically represented. **P < .05, ***P < .01 based on Student t test. *Denotes larger fragments that contained E1′ spliced with E1, but with 15 nucleotides deleted (represented in red) by the use of an alternative SA site (sequences of the cloned bands are detailed in supplemental Figure 10).Download : Download high-res image (230KB)Download : Download full-size imageFigure 3. Expression study of the new VHL transcript isoforms in patient cells. (A) Sashimi plots from RNA-seq data obtained from samples (LCLs or pheochromocytomas [Pheo]) of 3 patients from F8. The positions of the different VHL exons are indicated, with the maximal number of reads indicated at the right. Splice junctions are denoted by the horizontal links, with details provided in supplemental Figure 8. (B) TaqMan quantification of the different VHL isoforms from samples of F8 performed using probes specific to VHL E1-E2, the translated sequence upstream E1′, or E1-E1′ junctions. Relative gene expression was normalized to LCL control (C1) fixed at 1 (mean results of technical duplicates). (C) TaqMan quantification of the different VHL isoforms in LCLs (established from 2 independent controls and from patients of F1, F2, and F8) cultured in the absence or presence of puromycin (puro), an inhibitor of nonsense-mediated mRNA decay. TaqMan probes were specific to the VHL E1-E1′ or E1-E2 junction. The graph resumes experiments performed on LCLs cultured independently 3 times and quantified in duplicate. Data are represented as the mean ± standard error of the mean. (D) RT-PCR using primers specific for E1 and E3 was performed on mRNA extracted from LCLs established from controls and patients of F6 (carrying the mutation c.340+574A>T that targets the SA site of E1′). Patient with erythrocytosis is indicated in red. On the right, the spliced isoforms are schematically represented. **P < .05, ***P < .01 based on Student t test. *Denotes larger fragments that contained E1′ spliced with E1, but with 15 nucleotides deleted (represented in red) by the use of an alternative SA site (sequences of the cloned bands are detailed in supplemental Figure 10).We performed quantitative RT-PCR using TaqMan probes specific for the different splicing junctions or for the region upstream of E1′ (location of probes shown in Figure 1C), which showed a strong upregulation of a unique isoform containing E1′ spliced with E1 in LCLs and tumors from patients of F8 compared with controls (Figure 3B). The study therefore focused on the isoform E1-E1′. Transcripts that retained E1′ spliced with E1 contained (in-frame with E1) a premature termination codon (Figure 1C) and could likely be targeted for degradation according to nonsense-mediated mRNA decay (NMD) mechanisms. We therefore investigated the expression of transcripts that contained E1 spliced with E1′ in the absence or presence of puromycin, an inhibitor of NMD. Without puromycin, higher levels of expression were seen in samples with mutated E1′ (Figure 3C) compared with samples containing WT E1′. Exposure to puromycin resulted in a profound induction of isoforms containing E1 spliced with E1′ vs other isoforms (Figure 3C; supplemental Figure 9). These results indicated that isoforms with E1-E1′ junction were degraded by NMD and may have failed to produce proteins. We performed RT-PCR on LCL samples of F6 carrying the mutation in the SA site, using primers in VHL exons E1 and E3. We observed fragments of larger size in samples from patients carrying the mutation, which were highly visible in the presence of puromycin (Figure 3D). Cloning and sequencing of these fragments demonstrated a dysregulated splicing of E1′ with the use of an alternative SA site located 15 nucleotides downstream (supplemental Figure 10).To measure the impact of the splicing dysregulation on pVHL expression, we performed an immunoblot with an antibody able to recognize the amino acids encoded by E1 and therefore able to detect the different pVHL isoforms.8 The antibody detected overexpressed exogenous X1 protein after transfection of the plasmid encoding X1 (Figure 4A). However, it failed to detect the endogenous protein, even in patients' samples that overexpressed the mRNA containing E1-E1′. Instead, the immunoblots showed a lower expression of all the VHL protein isoforms in patients with mutated E1′ (Figures 4A-B).Figure 4. Functional studies of mutations in VHL E1′. (A-B) Immunoblot analysis of patient LCLs. A representative immunoblot (A) and quantification of 3 different immunoblots (B) are presented. Relative gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression, and results obtained with LCL control (C1) were fixed at 100%. Data are represented as the mean ± standard error of the mean. A VHL antibody that recognized VHL E1 was able to detect the hypothetical X1 protein. In the most left lane, control LCLs were transfected with an expression vector containing the coding sequence for X1; 5 µg of proteins were blotted vs 45 µg for other samples to avoid signal saturation with overexpressed X1. Patients with erythrocytosis are indicated in red. (C) Functional hypoxia response element (HRE)–dependent reporter assays were performed in 786-O cells (ie, VHL− cells that constitutively express HIF-2α). The results are expressed as relative firefly luciferase activity with Renilla luciferase as an internal control; 1.0 unit denotes the basal activity of endogenous HIF-2α using the HRE luciferase reporter plasmid. The ability of WT and mutated X1 to downregulate firefly luciferase activity (related to HIF activity) was compared with pVHL and in competition with pVHL. An immunoblot using an antibody specific to the hemagglutinin tag (HA) was used to detect HA-VHL and HA-X1. X1-L128V+L138P corresponds to a potential impact of the c.340+648T>C and c.340+617C>G mutations on the hypothetical X1 protein. Three independent experiments were performed. (D) Characterization of VHL E1′ retention by the minigene experiment (representative picture of agarose gel; n = 3). RT-PCR was performed on mRNA obtained from cell lines transfected with a minigene construct containing VHL E1′ (WT or mutated) flanked by large intronic sequences cloned between the SERPING1 exons (exons A and B, targeted by the RT-PCR primers). The plasmids were transfected, and the expression of the spliced chimeric transcripts (containing EA and EB ± E1′) was analyzed. Two WT constructs containing E1′ were used; 1 contained the single-nucleotide polymorphism c.340+1150T>C (rs779808). Bands corresponding to EA and EB spliced together or with VHL E1′ are indicated on the right. *P < .05, **P < .01, ***P < .001, ****P < .0001 based on Student t test. †Corresponds to unspecific bands verified by sequencing. The minigene experiment performed with the construction carrying the mutation c.340+574A>T (that targets the SA site of E1′ in F6) confirmed the use of an alternative SA site (right panel) with the deletion of 15 nucleotides (represented in red). ns, not significant.Download : Download high-res image (204KB)Download : Download full-size imageFigure 4. Functional studies of mutations in VHL E1′. (A-B) Immunoblot analysis of patient LCLs. A representative immunoblot (A) and quantification of 3 different immunoblots (B) are presented. Relative gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression, and results obtained with LCL control (C1) were fixed at 100%. Data are represented as the mean ± standard error of the mean. A VHL antibody that recognized VHL E1 was able to detect the hypothetical X1 protein. In the most left lane, control LCLs were transfected with an expression vector containing the coding sequence for X1; 5 µg of proteins were blotted vs 45 µg for other samples to avoid signal saturation with overexpressed X1. Patients with erythrocytosis are indicated in red. (C) Functional hypoxia response element (HRE)–dependent reporter assays were performed in 786-O cells (ie, VHL− cells that constitutively express HIF-2α). The results are expressed as relative firefly luciferase activity with Renilla luciferase as an internal control; 1.0 unit denotes the basal activity of endogenous HIF-2α using the HRE luciferase reporter plasmid. The ability of WT and mutated X1 to downregulate firefly luciferase activity (related to HIF activity) was compared with pVHL and in competition with pVHL. An immunoblot using an antibody specific to the hemagglutinin tag (HA) was used to detect HA-VHL and HA-X1. X1-L128V+L138P corresponds to a potential impact of the c.340+648T>C and c.340+617C>G mutations on the hypothetical X1 protein. Three independent experiments were performed. (D) Characterization of VHL E1′ retention by the minigene experiment (representative picture of agarose gel; n = 3). RT-PCR was performed on mRNA obtained from cell lines transfected with a minigene construct containing VHL E1′ (WT or mutated) flanked by large intronic sequences cloned between the SERPING1 exons (exons A and B, targeted by the RT-PCR primers). The plasmids were transfected, and the expression of the spliced chimeric transcripts (containing EA and EB ± E1′) was analyzed. Two WT constructs containing E1′ were used; 1 contained the single-nucleotide polymorphism c.340+1150T>C (rs779808). Bands corresponding to EA and EB spliced together or with VHL E1′ are indicated on the right. *P < .05, **P < .01, ***P < .001, ****P < .0001 based on Student t test. †Corresponds to unspecific bands verified by sequencing. The minigene experiment performed with the construction carrying the mutation c.340+574A>T (that targets the SA site of E1′ in F6) confirmed the use of an alternative SA site (right panel) with the deletion of 15 nucleotides (represented in red). ns, not significant.Functional characterization of the mutated VHL E1′Because the hypoxia pathway represents the major pathway involved in the genesis of secondary erythrocytosis and VHL disease,13, 14, 1528 we performed functional studies of the hypothetical WT or mutated X1 proteins using hypoxia response element–dependent reporter assays. These functional tests failed to reveal any substantial effects of X1 on this pathway, either alone or in competition with pVHL (Figure 4C; supplemental Figure 11). We next focused our study on a potential impact of the E1′ variants on splicing by performing splicing reporter minigene assays in various cell lines. The experiments showed that splicing of WT E1′ was barely detected (Figure 4D). Interestingly, higher molecular weight bands corresponding to the expected spliced isoforms containing E1′ appeared in the presence of the mutations. Cloning and sequencing of the isoforms confirmed a retention of E1′ at the expected splicing sites. The level of expression of this upper isoform, specific to E1′ inclusion, was higher for mutations associated with cancers than for those with erythrocytosis, independently of the cell lines. Notably, the combination of both variants associated with cancer had a more pronounced effect than each variant individually (the single-nucleotide polymorphism showing very low effect), suggesting a synergistic effect of the variants on splicing (supplemental Figure 12). In silico analysis of c.340+617C>G consistently predicted a severe alteration of splicing by the creation of an exonic splicing enhancer site (supplemental Figure 13).The minigene experiment performed with mutated E1′ at the SA site (F6) confirmed the inclusion of E1′ during splicing (Figure 4D, right panel), using the same downstream alternative SA site identified in mRNA extracted from patients' LCLs (supplemental Figure 10).Synonymous mutations in VHL E2 induce exon skippingWe then focused our study on the synonymous heterozygous D143D mutation in E2, identified in the proband of F1. This mutation was also identified in the homozygous state in 2 patients with erythrocytosis (F9 and F10; Figure 5A; Table 1). The mRNA extracted from LCLs established from the different members of these 2 families was reverse transcribed and sequenced. Comparison of chromatograms obtained by sequencing of DNA vs cDNA displayed a weaker peak of the mutated allele in cDNA, reflecting a decreased expression of the mRNA transcripts carrying the mutation.Download : Download high-res image (221KB)Download : Download full-size imageFigure 5. Genetic and expression study of synonymous mutations in VHL E2. (A-B) Pedigree and sequence chromatograms of germline DNA, tumor (pheochromocytoma) DNA, or cDNA prepared from 2 families (F9 and F10) with erythrocytosis (A) and 2 families (F11 and F12) with VHL disease (B). (C) Results of RT-PCR using mRNA extracted from LCLs (F9 and F10) and leukocytes and tumor material (pheochromocytoma) (F11 and F12). (D) TaqMan quantification of the different VHL isoforms in LCLs (established from patients of F9, F10, and F11) cultured in the absence or presence of puromycin. TaqMan probes are specific to the VHL E1-E2 or E1-E3 junction. Relative gene expression was normalized to LCL control (C1). (E) Immunoblot analysis of patient LCLs. Patients with erythrocytosis are indicated in red. A representative immunoblot (upper panel) and quantification of 4 different immunoblots are displayed (lower panel). Relative gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression, and results obtained with C1 were fixed at 100%. Data are represented as the mean ± standard error of the mean. *P < .05, **P < .01, ***P < .001, ****P < .0001 based on Student t test. CNS, central nervous system.A different synonymous mutation in E2, c.414A>G p.Pro138Pro (P138P), was identified in 2 families (F11 and F12) with VHL disease (Figure 5B). This heterozygous mutation segregated with the disease in 3 generations. Sequencing of DNA extracted from the pheochromocytoma of F11-III.1 showed a loss of the WT allele in the tumor, demonstrating loss of heterozygosity as currently described in classical VHL disease.Suspecting an effect of the synonymous mutations on splicing, we next assessed the expression of the VHL transcripts in patients' samples by RT-PCR (Figure 5C). We found a significant change in the ratio of expressed VHL isoforms, with a higher expression of the E1-E3 transcripts in LCLs of patients homozygous for D143D and in the pheochromocytoma with P138P mutation. These results suggest an effect of the mutation on splicing regulatory elements, leading to E2 skipping. In silico analysis of the synonymous mutations indicated a potential effect on exonic splicing enhancer motifs (supplemental Figure 14).To specifically quantify the different VHL isoforms, we performed quantitative RT-PCR on LCLs using TaqMan probes complementary to the VHL E1-E2 or E1-E3 junction (Figure 5D). All mutated samples displayed an increase of the isoform with skipped E2 (E1-E3). The patients carrying a homozygous D143D mutation presented a severe decrease of the WT isoform expression level. These results demonstrated that synonymous mutations in E2 affected mRNA isoform production.To evaluate a potential impact on protein expression, we performed a western blot analysis. We did not observe any overexpression of the pVHL172 isoform as expected from mRNA quantification studies. However, in patients homozygous for D143D, we detected a strong downregulation of all the pVHL isoforms, which was also observed to a lesser extent in LCL samples from heterozygous patients (Figure 5E).Proportion of VHL E2 skipping is correlated with disease severity in minigene experimentsTo study the impact of the synonymous E2 mutations on splicing in different cell lines, we performed minigene assays. We tested the implications of the D143D and P138P mutations on splicing in addition to the nearby mutations described in patients with erythrocytosis (P138L and G144R).4,6,29 Indeed, these mutations may also affect splicing rather than VHL protein function. We first evaluated the loss of function of these mutants by reporter assays. We found that these could downregulate HIF in a manner similar to the WT protein, in contrast to VHL proteins lacking E2 (pVHLΔE2), which are described as nonfunctional in terms of their regulation of HIF activity8, 9, 1012 (Figure 6A). Minigene experiments were performed in a variety of cell lines relevant to the studied diseases, using LCLs as control (Figure 6B). We demonstrated that all mutations caused E2 skipping in LCLs. In other cell lines, these experiments demonstrated a major impact on the VHL E2 splicing of the P138P mutation, which is associated with cancer. The mutations P138L, D143D, and G144R, which are all associated with erythrocytosis, displayed a weaker effect on splicing, with slight variations among cell lines but with a stronger effect in the erythroid cell line (UT7 cultured with erythropoietin).Figure 6. Functional study of synonymous mutations in VHL E2. (A) Functional hypoxia response element (HRE)–dependent reporter assays were performed in 786-O cells to evaluate the impact of VHL mutations in E2 (P138L and G144R) on VHL protein activity. The VHL protein lacking E2 (pVHL172/VHLΔE2) was used as a negative control. The results are expressed as firefly luciferase activity relative to Renilla luciferase as an internal control; 1.0 unit denotes the basal activity of endogenous HIF-2α using the HRE luciferase reporter plasmid. Immunoblots using an antibody specific for the hemagglutinin tag (HA) were used to detect HA-VHL. (B) Characterization of VHL E2 skipping by minigene analyses. Minigene experiments were performed in a variety of cell lines relevant to the studied diseases: renal (293T, 786-O, and HK2), pheochromocytoma (pheo; PC12), erythroid cell line (UT7 cultured with erythropoietin), and LCL. RT-PCR was performed on mRNA obtained from cell lines transfected with a minigene construct containing VHL E2 flanked by intronic sequences cloned between the SERPING1 exons (exons A and B; targeted by the RT-PCR primers). Bands corresponding to EA and EB spliced together or with VHL E2 are indicated on the right. (C) Sashimi plots from RNA-seq data. The positions of the different VHL exons are indicated, with the maximum number of reads for each exon indicated at the right. Splice junctions are denoted by the horizontal links, with details provided in supplemental Figure 15A. (D) Heatmap of pheochromocytoma transcriptome data. A comparison of transcriptome data for the pheochromocytoma from patient F11 III.1 (with P138P mutation) vs Affymetrix data from the largest available cohort of paragangliomas/pheochromocytomas (recruited by the French COMETE network) that identified homogeneous molecular subgroups associated with susceptibility genes (Burnichon et al30).Download : Download high-res image (254KB)Download : Download full-size imageFigure 6. Functional study of synonymous mutations in VHL E2. (A) Functional hypoxia response element (HRE)–dependent reporter assays were performed in 786-O cells to evaluate the impact of VHL mutations in E2 (P138L and G144R) on VHL protein activity. The VHL protein lacking E2 (pVHL172/VHLΔE2) was used as a negative control. The results are expressed as firefly luciferase activity relative to Renilla luciferase as an internal control; 1.0 unit denotes the basal activity of endogenous HIF-2α using the HRE luciferase reporter plasmid. Immunoblots using an antibody specific for the hemagglutinin tag (HA) were used to detect HA-VHL. (B) Characterization of VHL E2 skipping by minigene analyses. Minigene experiments were performed in a variety of cell lines relevant to the studied diseases: renal (293T, 786-O, and HK2), pheochromocytoma (pheo; PC12), erythroid cell line (UT7 cultured with erythropoietin), and LCL. RT-PCR was performed on mRNA obtained from cell lines transfected with a minigene construct containing VHL E2 flanked by intronic sequences cloned between the SERPING1 exons (exons A and B; targeted by the RT-PCR primers). Bands corresponding to EA and EB spliced together or with VHL E2 are indicated on the right. (C) Sashimi plots from RNA-seq data. The positions of the different VHL exons are indicated, with the maximum number of reads for each exon indicated at the right. Splice junctions are denoted by the horizontal links, with details provided in supplemental Figure 15A. (D) Heatmap of pheochromocytoma transcriptome data. A comparison of transcriptome data for the pheochromocytoma from patient F11 III.1 (with P138P mutation) vs Affymetrix data from the largest available cohort of paragangliomas/pheochromocytomas (recruited by the French COMETE network) that identified homogeneous molecular subgroups associated with susceptibility genes (Burnichon et al30).Splicing dysregulation of VHL is causal in the development of diseaseRNA-seq confirmed that the synonymous mutations were not silent but instead induced potent E2 skipping (Figure 6C; supplemental Figure 15A). Additional transcriptome analyses of the pheochromocytoma carrying P138P showed an upregulation of HIF target genes (typically seen in VHL-related pheochromocytomas) compared with the pheochromocytoma carrying a RET mutation (supplemental Figure 15B).30 We then reanalyzed our independent cohort of pheochromocytomas30 using RNA-seq data from both tumors. After unsupervised classification, we observed a segregation of the P138P pheochromocytoma with other VHL-related tumors (C1B cluster), whereas the control pheochromocytoma bearing the RET mutation was grouped with other RET-related tumors (Figure 6D).
Figure 6. Functional study of synonymous mutations in VHL E2. (A) Functional hypoxia response element (HRE)–dependent reporter assays were performed in 786-O cells to evaluate the impact of VHL mutations in E2 (P138L and G144R) on VHL protein activity. The VHL protein lacking E2 (pVHL172/VHLΔE2) was used as a negative control. The results are expressed as firefly luciferase activity relative to Renilla luciferase as an internal control; 1.0 unit denotes the basal activity of endogenous HIF-2α using the HRE luciferase reporter plasmid. Immunoblots using an antibody specific for the hemagglutinin tag (HA) were used to detect HA-VHL. (B) Characterization of VHL E2 skipping by minigene analyses. Minigene experiments were performed in a variety of cell lines relevant to the studied diseases: renal (293T, 786-O, and HK2), pheochromocytoma (pheo; PC12), erythroid cell line (UT7 cultured with erythropoietin), and LCL. RT-PCR was performed on mRNA obtained from cell lines transfected with a minigene construct containing VHL E2 flanked by intronic sequences cloned between the SERPING1 exons (exons A and B; targeted by the RT-PCR primers). Bands corresponding to EA and EB spliced together or with VHL E2 are indicated on the right. (C) Sashimi plots from RNA-seq data. The positions of the different VHL exons are indicated, with the maximum number of reads for each exon indicated at the right. Splice junctions are denoted by the horizontal links, with details provided in supplemental Figure 15A. (D) Heatmap of pheochromocytoma transcriptome data. A comparison of transcriptome data for the pheochromocytoma from patient F11 III.1 (with P138P mutation) vs Affymetrix data from the largest available cohort of paragangliomas/pheochromocytomas (recruited by the French COMETE network) that identified homogeneous molecular subgroups associated with susceptibility genes (Burnichon et al30).
GroupID: 3708
DiseaseAssertion: assumed VHL
GroupSize: 2
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: Familial VHL stated; 2 family members recorded with this mutation.
GroupPresentingHPOs: HP:0010797; HP:0005584 (hemangioblastoma, renal cell carcinoma)
GroupHPOFreeText: both (2) members has RCC and 1 member had hemangioblastoma
GroupNotHPOs: HP:0009711; HP:0002666 (retinal capillary hemangioma, pheochromocytoma)
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: 8956040
SupplementalData: N/A
Variant: p.L184P (c.551T>C)
CaseProblemVariantFreeText: N/A
LegacyVariant: p.L255P (c.764T>C)
ClinVarID: 419447 https://www.ncbi.nlm.nih.gov/clinvar/variation/419447/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transition
CivicName: L184P (c.551T>C)
MultipleGeneVariants: N/A
Retinal abnormalities associated with a mutation of the nucleotide 683 in von Hippel-Lindau disease
PMID: 10955664
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
PMID: 29813026
Germline sequencing of the VHL gene was performed on patients who presented with VHL syndromic hemangioblastomas, and germline results were compared to sequencing results from matched tumor tissue samples. Patients were only identified by their tumor sample number. Sample 3 (patient 3) had a Glu94Lys missense mutation (c.280G>A) in the VHL gene. Genetic analysis was conducted as follows: peripheral blood samples were collected from patients, and genomic DNA was extracted, amplified, and purified using ExoSAP IT (ExoSAP IT (Thermo Scientific Inc., MA, USA). Sanger sequencing was performed on samples (Bigdye direct cycle sequencing v3.1, Life Technologies, CS, USA) and capillary electrophoresis was performed on an ABI Genetic Analyzer (ABI 3130xl, Life technologies, CS, USA). Deletion and duplication analysis of the VHL gene spanning the chr3p.25.3 locus was tested by the Multiplex Ligation-dependant Probe Amplification (MLPA) procedure. VHL gene locus-specific probes (P016-C2 VHL) were purchased from MRC Holland (MRC Holland, Amsterdam, Netherlands). ACMG evidence codes: PP4- Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
VHL germline variants
Pathogenic variants from 10,389 individuals across 33 cancer types were examined from The Cancer Genome Atlas (TCGA) cohort. 12 of these individuals had a germline mutation in the VHL gene. The Y98H (c.292T>C) missense VHL mutation was found in three white males aged 65Y0M, 31Y0M, and 23Y0M, who were all diagnosed with either pheochromocytoma and paraganglioma. No family information was provided for any of the patients.
p.R167Q/W
Pathogenic variants from 10,389 individuals across 33 cancer types were examined from The Cancer Genome Atlas (TCGA) cohort. 12 of these individuals had a germline mutation in the VHL gene. The R167Q (c.500G>A) missense VHL mutation was found in a white 30Y0M female diagnosed with pheochromocytoma and paraganglioma. No family information was provided.
583FemaleIYesAGND* AGLOH (G)
PatientID: 5
KindredID: 5
Case: F, 83Y0M, Taiwanese (East-Asian)
DiseaseAssertion: renal cell carcinoma
FamilyInfo: N/A
CohortInfo: 7 of 19 patients presenting with clear cell renal cell carcinoma were found to be heterozygous for the germline variant rs779805 (c.-195G>A) in VHL. All of these patients also presented with the germline variant rs1642742 in VHL (c.*294G>A).
CasePresentingHPOs: HP:0006770 (clear cell renal cell carcinoma)
CaseHPOFreeText: She had stage I clear cell renal cell carcinoma
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 21982469
SupplementalData: Yes - Additional file 1: Figure S1
Variant: c.-195G>A
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 342397 https://www.ncbi.nlm.nih.gov/clinvar/variation/342397
CAID: N/A
gnomAD: 0.5796 https://gnomad.broadinstitute.org/variant/3-10183337-G-A
VariantEvidence: RFLP analysis was used to screen for the allele genotype by BsaJ I digestion methods. Heterozygous for both, she also presented with the germline variant c.*294G>A in VHL. LOH (G) of rs1642742 was found in the tumor tissue as well
MutationType: 5_prime_UTR_variant
CivicName: c.-195G>A AND c.*294G>A
MultipleGeneVariants: Germline, VHL, c.*294G>A
351G→T Tv Exon 2 117 TGG W W117C
GroupID: 27
DiseaseAssertion: VHL
GroupSize: 5
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: French
GroupAgeRange: N/A
GroupInfo: 5 patients are listed with this mutation; any relation is unknown.
GroupPresentingHPOs: HP:0009711 (retinal capillary hemangioma)
GroupHPOFreeText: 4 members are said to have retinal HBs. Other manifestations are not clearly stated.
GroupNotHPOs: HP:0009711 (retinal capillary hemangioma)
GroupNotHPOFreeText: the other 1 member is specifically said to not have retinal HBs
GroupPreviousTesting: N/A
PreviouslyPublished: Possibly published in PMID:15300849
SupplementalData: N/A
Variant: p.W117C (c.351G>T)
CaseProblemVariantFreeText: N.A
LegacyVariant: N/A
ClinVarID: 167827 https://www.ncbi.nlm.nih.gov/clinvar/variation/167827/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: W117C (c.351G>T)
MultipleGeneVariants: N/A
467A→G Ts Exon 3 156 TAT Y Y156C
GroupID: 38
DiseaseAssertion: VHL
GroupSize: 3
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: French
GroupAgeRange: N/A
GroupInfo: 3 patients are listed with this mutation; any relation is unknown.
GroupPresentingHPOs: HP:0009711 (retinal capillary hemangioma)
GroupHPOFreeText: 1 member is said to have retinal HBs. Other manifestations are not clearly stated.
GroupNotHPOs: HP:0009711 (retinal capillary hemangioma)
GroupNotHPOFreeText: the other 2 members are specifically said to not have retinal HBs
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Y156C (c.467A>G)
CaseProblemVariantFreeText: N.A
LegacyVariant: N/A
ClinVarID: 43600 https://www.ncbi.nlm.nih.gov/clinvar/variation/43600/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transtition
CivicName: Y156C (c.467A>G)
MultipleGeneVariants: N/A
322insTG Fs Exon 1 108 CGC R Stop131
GroupID: 20
Case: Age unknown, Sex unknown, French
DiseaseAssertion: VHL
FamilyInfo: None - one member documented here
CasePresentingHPOs: N/A
CaseHPOFreeText: other manifestations are not clearly stated.
CaseNotHPOs: HP:0009711 (retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: Possibly published in PMID:15300849
SupplementalData: N/A
Variant: p.R108L*52 (c.322_323insTG)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: N/A
CAID: CA2501548609 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA2501548609
gnomAD: N/A
VariantEvidence: N/A
MutationType: plus_2_frameshift
CivicName: R108fs (c.322_323insTG)
MultipleGeneVariants: N/A
Patients and Methods The patients were recruited through the French VHL database, which was created in 1992. During the period of the study (1996–1999), 610 patients with VHL were registered in the database. Detailed systemic follow-up data were available for 211 patients from 111 distinct pedigrees. The patients were divided into two groups: one group of 103 (48.8%) patients from 60 pedigrees with ocular involvement and a second group of 108 (51.2%) from 66 pedigrees with no ophthalmic manifestation reported on the last follow-up. Fifteen families were involved in both groups. To be included, the patient had to meet the diagnostic criteria for VHL defined by the presence of two major manifestations, including at least one CNS or retinal hemangioblastoma, one major manifestation and a positive family history, or an isolated clinical feature with mutation in the VHL gene. 6 Patients with solitary retinal hemangioblastoma and no mutation detected in the VHL gene were excluded from the study.
ArticleReferenceSequence: Not specified – Assumption: variants assumed to have been documented by the author under reference sequence NM_000551.3
GenotypingMethod: To detect the presence of a mutation, PCR and single-strand conformation polymorphism (SSCP) were used systematically.
SamplingMethod: Blood
211insT Fs Exon 1 71 CCC R Stop131
A study of 103 patients with VHL retinal manifestations and 108 patients without VHL retinal manifestations extracted from the French VHL database revealed that the number of hemangioblastomas appeared higher in patients who had a substitution when compared with patients with a truncated protein. Detected by PCR and SSCP, this frameshift mutation (c.211insT, p.P71Lfs*61) was found in a 1 patient, without retinal hemangioblastomas, but other manifestations are not clearly stated. No family information or relation was provided. This is possibly previously published in PMID: 15300849
c.250G > T(p.Val84Leu)
74 patients (38 males, 36 females; 24 with prior sequencing data) with pheochromoctyoma were first analyzed by denaturing high performance liquid chromatography (dHPLC). PCR of all exons of VHL was performed on leukocyte DNA extracted from stored blood samples, and those showing variance were sequenced. These patients had presented with clinical features and/or family history suggestive of a germline mutation, leading to their referral for genetic testing. 2 patients found with the V84L (c.250G>T) VHL germline mutation were listed. No family history was mentioned.
Genomic DNA samples were extracted from 10 mL of ethylenediaminetetraacetic acid (EDTA)-treated peripheral blood samples using the Nucleosopin Blood Mini Kit (MACHEREY–NAGEL GmbH & Co. KG, Düren, Germany) according to the manufacturer’s instructions. The following seven genes were analysed: MAX ({"type":"entrez-nucleotide","attrs":{"text":"NM_002382.5","term_id":"1653960896","term_text":"NM_002382.5"}}NM_002382.5), SDHB ({"type":"entrez-nucleotide","attrs":{"text":"NM_003000.3","term_id":"1732746310","term_text":"NM_003000.3"}}NM_003000.3), SDHC ({"type":"entrez-nucleotide","attrs":{"text":"NM_003001.5","term_id":"1779948875","term_text":"NM_003001.5"}}NM_003001.5), SDHD ({"type":"entrez-nucleotide","attrs":{"text":"NM_003002.4","term_id":"1519245278","term_text":"NM_003002.4"}}NM_003002.4), TMEM127 ({"type":"entrez-nucleotide","attrs":{"text":"NM_017849.4","term_id":"1777425445","term_text":"NM_017849.4"}}NM_017849.4), VHL ({"type":"entrez-nucleotide","attrs":{"text":"NM_000551.3","term_id":"319655736","term_text":"NM_000551.3"}}NM_000551.3), and exons 10, 11 and 13–16 of the RET ({"type":"entrez-nucleotide","attrs":{"text":"NM_020630.4","term_id":"126273513","term_text":"NM_020630.4"}}NM_020630.4) proto-oncogene. A priority order was used for genetic analysis according to previous recommendations [5,6]. For instance, VHL and RET genes were analysed with priority for bilateral PCC, SDHB gene for retroperitoneum PGL or metastatic PCC/PGL, and SDHD gene for head and neck PGL. When a pathogenic variant was found in one of these genes, no further testing was performed in the remaining genes. After performing PCR using gel electrophoresis for each primer pair, Sanger sequencing was outsourced to a commercial service provider (Eurofins Genomics, Ota-ku, Tokyo, Japan) to detect variants, and the results were analysed at our department. The primers used for the PCR amplification are listed in Table S5. When no P/LP variant was found by the Sanger sequencing, all exons of the SDHB, SDHC, and SDHD gene were reanalysed using multiplex ligation-dependent probe amplification (MLPA) to examine copy number variation. The MLPA assay was carried out by a commercial service provider (FALCO Biosystems Ltd., Kumiyama, Kyoto, Japan). The sequence results were analysed using Sequence Scanner Software v2.0 (Thermo Fisher Scientific, Waltham, MA, USA) and CLC Sequence Viewer 8.0 software (QIAGEN, Aarhus C, Denmark).
ArticleReferenceSequence: NM_000551.3
GenotypingMethod: Seven genes were analysed (MAX, SDHB, SDHC, SDHD, TMEM127, VHL, and exons 10, 11 and 13–16 of RET. After PCR for each primer pair, Sanger sequencing was outsourced to detect variants, followed by the analysis of the results internally.
SamplingMethod: peripheral blood
variants of VHL in 18 probands
PatientID: 7
KindredID: 7
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: No family information provided.
CasePresentingHPOs: HP:0002666; HP:0002668 (Pheochromocytoma; paraganglioma)
CaseHPOFreeText: Patient had pheochromocytoma and/or paraganglioma (table 2).
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.T124I (c.371C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 36902, https://www.ncbi.nlm.nih.gov/clinvar/variation/36902/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant, transition
CivicName: T124I (c.371C>T)
MultipleGeneVariants: N/A
VHL Variants
This report studied the prevalence of germline variants in Japanese PPGL patients. Of the 370 PPGL original Japanese probands, this cohort consisted of 15 patients with pheochromocytoma and/or paragangliomas with germline VHL varaints. Blood samples were used to examine 7 genes: MAX, SDHB, SDHC, SDHD, TMEM127, VHL, and RET, using Sanger sequencing. Of these 15 VHL patients: 10 had bilateral PCC, 4 had PCC with abdominal/thoracic PGL, and one had metastatic PPGL. The variant T124P (c.370A>C) was one of the 15 found in a patient with PPGL. Their family history or further manifestations were not detailed.
Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in european kidney cancers
PMID: 7591282
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
third family with a VHL type 1 disease carried a c.475T>C/p.Trp88Arg exchange.
PatientID: CV2
KindredID: C
Case: M, 12Y0M, Serbian
DiseaseAssertion: Asymptomatic
FamilyInfo: Families were selected based on their clinical data and family history. Patient and his sister (CV1) are both currently asymptomatic, but possess the same variant as their father (CIV2), who was diagnosed with retinal hemangioblastoma at 12Y0M. Then, multiple pancreatic and kidney cysts were detected at 29Y0M and left kidney cancer was found at age 35Y0M. Patient’s grandfather, great grandfather and great uncle (CIII1; CII1, CII2) had retinal capillary hemangioma, CNS hemangioblastoma and renal cell carcinoma. Out of the three of them, only the great grandfather had genetic testing performed and was found to have the same mutation as the patient. See pedigree in figure 1.
CasePresentingHPOs: N/A
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.W88R (c.262T>A)
LegacyVariant: p.W88R (c.475T>A)
CaseProblemVariantFreeText: N/A
ClinVarID: 456577, https://www.ncbi.nlm.nih.gov/clinvar/variation/456577/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense variant; transversion
CivicName: W88R (c.262T>A)
MultipleGeneVariants: N/A
PatientID: 81
KindredID: 27
Case: M, 38Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: The proband (patient 81) had 3 family members confirmed with the mutation: his aunt 2 (patient 85) had pancreatic cysts and/or tumors at age 50, his cousin/ the son of Aunt 2 was asymptomatic at the time of assessment, and the granddaughter of aunt 2 was also asymptomatic at the time of assessment. The proband also had 3 family members who passed away before diagnosis/ before confirming the mutation: his mother (patient 82) had a CNS hemangioblastoma at 33, his Aunt 1 (patient 83) had a CNS hemangioblastoma at 32, and his cousin/ the son of Aunt 1 (patient 84) had a CNS hemangioblastoma at 30.
CasePresentingHPOs: HP:0010797; HP:0001732; HP:0001737; HP:0005584; HP:0002666 (Hemangioblastoma, Abnormality of the pancreas, Pancreatic cysts, Renal cell carcinoma, Pheochromocytoma)
CaseHPOFreeText: The proband presented with CNS hemangioblastoma at age 28, and renal cell carcinoma, multiple pancreatic cysts/tumors, and pheochromocytoma at age 38.
CaseNotHPOs: HP:0009711(Retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This patient was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.N90I (c.269A>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 223172; https://www.ncbi.nlm.nih.gov/clinvar/variation/223172/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: N90I (c.269A>T)
MultipleGeneVariants: N/A
PatientID: 160
KindredID: 61
Case: M, 44Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0005584 (Renal cell carcinoma)
CaseHPOFreeText: The proband presented with a renal cell carcinoma at age 44.
CaseNotHPOs: HP:0009711; HP:0002666; HP:0010797; HP:0001737; HP:0001732 (Retinal capillary hemangioma, Pheochromocytoma, CNS Hemangioblastoma, Pancreatic cysts, Abnormality of the pancreas)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This cohort was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.R161* (c.481C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2217, https://www.ncbi.nlm.nih.gov/clinvar/variation/2217/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R161* (c.481C>T)
MultipleGeneVariants: N/A
PatientID: 156
KindredID: 58
Case: F, 27Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: The proband (patient 155) has a sister (patient 156) and a nephew (son of sister, patient 157) that were both genetically confirmed with the mutation. The sister presented with a CNS hemangioblastoma at 21 and multiple pancreatic cysts/tumors at 27, and the nephew was asymptomatic at the time of analysis.
CasePresentingHPOs: HP:0001737; HP:0001732; HP:0010797 (Pancreatic cysts, Abnormality of the pancreas, Hemangioblastoma)
CaseHPOFreeText: The proband's sister presented with a CNS hemangioblastoma at 21, and multiple pancreatic cysts/tumors at 27.
CaseNotHPOs: HP:0002666; HP:0005584; HP:0009711 (Pheochromocytoma, Renal cell carcinoma, Retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This patient was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.E160Dfs*10 (c.480del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA432423139; https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA432423139
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant
CivicName: E160fs (c.480delG)
MultipleGeneVariants: N/A
PatientID: 8
KindredID: 5
Case: M, 30Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: The proband's grandfather, father, and uncle presented with a CNS hemangioblastoma at ages 30, 36, and 33, respectively, and all passed away before they could be diagnosed with VHL disease.
CasePresentingHPOs: HP:0001737; HP:0001732; HP:0010797 (Pancreatic cysts, Abnormality of the pancreas, Hemangioblastoma)
CaseHPOFreeText: The proband presented with a CNS hemangioblastoma at age 21 and a multiple pancreatic cysts/tumors at age 30.
CaseNotHPOs: HP:0005584; HP:0009711; HP:0002666 (Renal cell carcinoma, Retinal capillary hemangioma, Pheochromocytoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This cohort was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.S65L (c.194C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 182975; https://www.ncbi.nlm.nih.gov/clinvar/variation/182975/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: S65L(c.194C>T)
MultipleGeneVariants: N/A
A retrospective cohort study included all the VHL patients diagnosed at Peking University First Hospital (Beijing, China) prior to June 1 2016. A total of 291 patients from 115 different families were included for analysis. This mutation was confirmed in kindred 56. A female proband, patient 153, presented with a retinal angioma at 26 and multiple pancreatic cysts/tumors at 31. No family information was given. This cohort was also published in a paper by Wang et al., 2018 (PMID: 29330336).
A retrospective cohort study included all the VHL patients diagnosed at Peking University First Hospital (Beijing, China) prior to June 1 2016. A total of 291 patients from 115 different families were included for analysis. Genotyping confirmation was performed by PCR-direct sequencing on peripheral blood samples. Three individuals (one proband and two family members) were genetically confirmed to have the p.N78S(c.233A>G) familial mutation. The proband (patient #36) was a male from kindred (family) #12 who was diagnosed with a CNS hemangioblastoma, renal cell carcinoma, and multiple pancreatic cysts/tumors at the age of 34. His sister (patient #37) also possessed this germline mutation and presented with multiple pancreatic cysts/tumors at age 27. The proband's father (patient #38) also had this mutation and presented with renal cell carcinoma at age 55. A fourth individual, the proband's uncle, passed away before diagnosis. He presented with a CNS hemangioblastoma at age 19, but was not genetically confirmed to have the mutation. This cohort was also published in a paper by Wang et al., 2018 (PMID: 29330336).
PatientID: 280
KindredID: 110
Case: M, 22Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: The proband, patient 280, presented with a CNS hemangioblastoma at age 16, a retinal angioma at age 15, and multiple pancreatic cysts/tumors at age 22. Their father presented with a CNS hemangioblastoma at age 25, and retinal angioma at age 29.
CasePresentingHPOs: HP:0010797; HP:0001737; HP:0001732; HP:0009711 (Hemangioblastoma, Pancreatic cysts, Abnormality of the pancreas, Retinal capillary hemangioma)
CaseHPOFreeText: The proband, patient 280, presented with a CNS hemangioblastoma at age 16, a retinal angioma at age 15, and multiple pancreatic cysts/tumors at age 22.
CaseNotHPOs: HP:0002666; HP:0005584 (Pheochromocytoma, Renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This cohort was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: Exon 2-3 Deletion (c.341-?_642+?del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: exon_loss_variant
CivicName: Exon 2-3 Deletion
MultipleGeneVariants: N/A
PatientID: 97
KindredID: 33
Case: M, 37Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: The proband (patient 97) presented with a CNS hemangioblastoma at 37, retinal angioma at 20, and renal cell carcinoma and multiple pancreatic cysts/tumors at age 29. Their brother, patient 98, presented with a retinal angioma at age 32, and at age 43 presented with renal cell carcinoma and multiple pancreatic cysts/tumors.
CasePresentingHPOs: HP:0010797; HP:0001732; HP:0001737; HP:0005584; HP:0009711 (Hemangioblastoma, Abnormality of the pancreas, Pancreatic cysts, Renal cell carcinoma, Retinal capillary hemangioma)
CaseHPOFreeText: The proband, patient 291, presented with a CNS hemangioblastoma at 27, and at 31 presented with renal cell carcinoma, multiple pancreatic cysts/tumors, and pheochromocytoma.
CaseNotHPOs: HP:0002666 (Pheochromocytoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This cohort was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.P97Afs*35 (c.287_288insA)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA432420510, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.287_288insA
gnomAD: N/A
VariantEvidence: N/A
MutationType: plus_1_frameshift_variant
CivicName: P97Afs*35 (c.287_288insA)
MultipleGeneVariants: N/A
PatientID: 213
KindredID: 80
Case: M, 52Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: The proband's son and sister were both confirmed to have this VHL mutation. Their son had a retinal angioma at 26 and a pheochromocytoma at 31. Their sister had a pheochromocytoma at 14. Their mother had renal cell carcinoma at 56, however no genotyping information is available for her.
CasePresentingHPOs: HP:0010797 (Hemangioblastoma)
CaseHPOFreeText: The proband presented with a CNS hemangioblastoma at age 52.
CaseNotHPOs: HP:0009711; HP:0001737; HP:0001732; HP:0002666; HP:0005584 (Retinal Capillary Hemangioma, Pancreatic cysts, Abnormality of the pancreas, Pheochromocytoma, Renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This cohort was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.R167Q (c.500G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2216, https://www.ncbi.nlm.nih.gov/clinvar/variation/2216/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167Q (c.500G>A)
MultipleGeneVariants: N/A
PatientID: 29
KindredID: 10
Case: M, Age unknown, Chinese
DiseaseAssertion: Asymptomatic
FamilyInfo: The proband (patient 21) and his son were both confirmed with this mutation. His son was asymptomatic at the time of assessment.
CasePresentingHPOs: N/A
CaseHPOFreeText: The proband's son (patient 29) was asymptomatic at the time of assessment.
CaseNotHPOs: HP:0002666, HP:0009711; HP:0001737; HP:0001732; HP:0005584; HP:0010797 (Pheochromocytoma, Retinal capillary hemangioma, Pancreatic cysts, Abnormality of the pancreas, Renal cell carcinoma, Hemangioblastoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This patient was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.F76del (c.227_229del)
LegacyVariant: F76del (c.224_226delTCT)
CaseProblemVariantFreeText: The protein coding change for this variant is listed in this paper as p.F76Cfs*138. However the DNA change listed in this paper (c.224_226delTCT) is equivalent to c.227_229delTCT, and results in p.F76del. This variant is entered on CIViC with p.F76del. As a note the latter c. nomenclature is preferred due to the 3' rule.
ClinVarID: N/A
CAID: CA357012; https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.224_226del
gnomAD: N/A
VariantEvidence: N/A
MutationType: inframe_deletion
CivicName: F76del (c.224_226delTCT)
MultipleGeneVariants: N/A
A retrospective cohort study included all the VHL patients diagnosed at Peking University First Hospital (Beijing, China) prior to June 1 2016. A total of 291 patients from 115 different families were included for analysis. One female patient, patient 172, from kindred #68, was found with this germline mutation p.C162Y (c.485G>A). She was diagnosed with a CNS hemangioblastoma, renal cell carcinoma, and multiple pancreatic cysts/tumors at 43Y. This individual was also likely published in a later paper by Wang et al., 2018 (PMID: 29330336). No family information was described.
PatientID: 41
KindredID: 14
Case: F, 44Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0001737; HP:0001732; HP:0005584 (Pancreatic cysts, Abnormality of the pancreas, Renal cell carcinoma)
CaseHPOFreeText: The proband presented with renal cell carcinoma and multiple pancreatic cysts/ tumors at age 44.
CaseNotHPOs: HP:0010797; HP:0009711; HP:0002666 (Hemangioblastoma, Retinal capillary hemangioma, Pheochromocytoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: This patient was also published in a later paper by Wang et al., 2018 (PMID: 29330336).
SupplementalData: Patient and family genotype-phenotype information is listed in Supplementary Table 1.
Variant: p.S80Ifs*79 (c.239del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA913189245; https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.239del
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant
CivicName: S80fs (c.239del)
MultipleGeneVariants: N/A
Genetic testingThe proband’s maternal aunt, who lived a significant distance away had genetic testing; no pathogenic mutation was detected in either BRCA 1 or BRCA2 genes. A variant identified in the VHL gene c.74C>T(p.Pro25Leu) was thought to be pathogenic at the time, and the extended family was advised that family testing was available. On this basis, our proband was offered testing for the family-specific variant. The DNA sample obtained from the patient was independently amplified and sequenced in opposite directions from exon 1 of the VHL gene. Analysis of this exon has not detected the c.74C>T variant. Soon thereafter, this variant was revised as unlikely to be pathogenic.Subsequently, his aunt had next-generation sequencing (NGS) for MAX, RET, SDHAF2, SDHB, SDHC, SDHD, TMEM127 and multiplex ligation-dependent probe amplification (MLPA) for VHL, SDHA, MAX, SDHB, SDHC and SDHC. No pathogenic mutation was detected.Our proband was offered MLPA and NGS for VHL and TP53. Complete sequence screening of all coding exons and intron–exon boundaries of the TP53 gene did not reveal the presence of a pathogenic variant. In MLPA, none of the tested exons showed a significant deviation from the normal range of the tested population, and duplicate tests were concordantly indicating a normal copy number.Following his disease progression and with the recent diagnosis of papillary thyroid cancer as well as papillary urothelial cancer and the availability of broader panel testing, testing of72 cancer predisposition genes was offered for him. The heterozygous pathogenic variant, CHEK21100delC was found.
ArticleReferenceSequence: Not specified – Assumption: variants assumed to have been documented by the author under reference sequence NM_000551.3
GenotypingMethod: next-generation sequencing (NGS) for MAX, RET, SDHAF2, SDHB, SDHC, SDHD, TMEM127 and multiplex ligation-dependent probe amplification (MLPA) for VHL, SDHA, MAX, SDHB, SDHC and SDHC.
SamplingMethod: N/A
recognized in a large family that originated in Newfoundland but has some members who live in New Brunswick and Ontario. A collaborative investigation was begun in 1982 to document the number of affected members and the extent of their disease and to improve management of the disease. The condition has been documented in 38 members of the family, 28 living and 10 dead. The most common manifestations are retinal angioma (present in 60% of the gene carriers) and pheochromocytoma (present in 53%). Of the 28 living affected members 14 had been identified before the study began. Only 3 of the 14 patients in whom the disease was subsequently diagnosed presented with symptoms; in the remaining 11 the condition was detected by routine screening. Overall the mean age at the time of diagnosis was 23 years; in the 21 affected members of the fourth generation it was 18 years.
PatientID: II-1
KindredID: 1
Case: F, Age Unknown (deceased), Ethnicity Unknown
DiseaseAssertion: Assumed VHL
FamilyInfo: 38 family members had been affected at the date of 1986, and 10 had passed away. Pheochromocytoma, cerebellar, spinal and retinal hemangioblastomas, and various cysts were clinical manifestations of VHL seen throughout the family. This woman (II-1) appears to have inherited this disease from her father, and passed it onto her 6 children, and many kin thereafter. See Fig. 1 for family pedigree.
CasePresentingHPOs: HP:0006880; HP:0009711 (cerebellar hemangioblastoma, retinal capillary hemangioma)
CaseHPOFreeText: Described as “probable” cerebellar hemangioblastoma and “probable” retinal angioma. No further details were provided.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167W (c.499C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: Although never given at the time of this publication, the germline mutation is confirmed in this family in later publications (PMID 7987306; 29437867) for this specific family. It is only assumed this member had the VHL mutation.
ClinVarID: 2218, https://www.ncbi.nlm.nih.gov/clinvar/variation/2218/
CAID: N/A
gnomAD: 0.000007954, https://gnomad.broadinstitute.org/variant/3-10191506-C-T?dataset=gnomad_r2_1
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167W (c.499C>T)
MultipleGeneVariants: N/A
recognized in a large family that originated in Newfoundland but has some members who live in New Brunswick and Ontario. A collaborative investigation was begun in 1982 to document the number of affected members and the extent of their disease and to improve management of the disease. The condition has been documented in 38 members of the family, 28 living and 10 dead. The most common manifestations are retinal angioma (present in 60% of the gene carriers) and pheochromocytoma (present in 53%). Of the 28 living affected members 14 had been identified before the study began. Only 3 of the 14 patients in whom the disease was subsequently diagnosed presented with symptoms; in the remaining 11 the condition was detected by routine screening. Overall the mean age at the time of diagnosis was 23 years; in the 21 affected members of the fourth generation it was 18 years.
PatientID: III-1
KindredID: 1
Case: M, Age Unknown (deceased), Ethnicity Unknown
DiseaseAssertion: Assumed VHL
FamilyInfo: 38 family members had been affected at the date of 1986, and 10 had passed away. Pheochromocytoma, cerebellar, spinal and retinal hemangioblastomas, and various cysts were clinical manifestations of VHL seen throughout the family. This male (III-1) appears to have inherited this disease from his mother and passed it onto his kin thereafter. See Fig. 1 for family pedigree.
CasePresentingHPOs: HP:0006880; HP:0009711 (cerebellar hemangioblastoma, retinal capillary hemangioma)
CaseHPOFreeText: Patient had cerebellar hemangioblastoma, along with retinal hemangiomas described as “probable”. No further details were provided.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167W (c.499C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: Although never given at the time of this publication, the germline mutation is confirmed in this family in later publications (PMID 7987306; 29437867) for this specific family. It is only here assumed this member had the VHL mutation.
ClinVarID: 2218, https://www.ncbi.nlm.nih.gov/clinvar/variation/2218/
CAID: N/A
gnomAD: 0.000007954, https://gnomad.broadinstitute.org/variant/3-10191506-C-T?dataset=gnomad_r2_1
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167W (c.499C>T)
MultipleGeneVariants: N/A
Familial pheochromocytomas and paragangliomas: stories from the sign-out room
PMID: 17525482
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
c.499C>T p.Arg167Trp
During the period from 2009 to 2012, 39 families with VHL disease were diagnosed with hereditary VHL disease at Peking University First Hospital Department of Urology were described as part of a broader study examining telomere length and anticipation. In these families, 19 families had two or more than two patients in two or more than two generations, including one family with obscure onset age. Therefore, a total of 57 patients with VHL disease from 18 families were enrolled in this study. Using peripheral blood and southern blotting, DNA sequencing was completed on the following patients. Family 5 involved four members with a c.499C>T change leading to a p.Arg167Trp protein change. The first member, the father, presented with renal cell carcinoma at 63. His 3 daughters also presented. The first daughter presented with hemangioblastoma, renal cell carcinoma, ovarian cyst, and pancreatic cysts at 37, as well as pheochromocytoma at 39. The second daughter presented with pancreatic cysts at 36 and hemangioblastoma at 38. The third presented with retinal capillary hemangioma at 34. The first born son did not present with any symptoms nor the mutation. ACMG Evidence Code: 'PP4' because the patients' phenotypes and family histories are highly specific for VHL disease.
c.349T>G p.Trp117Gly
PatientID: III:7
KindredID: 7
Case: M, 13Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: 8 other members of this 3 generation family were observed to be affected with various presentations of VHL. This patient’s father and 3 cousins were confirmed with identical mutations. DNA samples were not available for all members in the family however.
CasePresentingHPOs: HP:0010797 (hemangioblastoma)
CaseHPOFreeText: had hemangioblastoma at 13Y
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.W117G (c.349T>G)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 862346 https://www.ncbi.nlm.nih.gov/clinvar/variation/862346/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: W117G (c.349T>G)
MultipleGeneVariants: N/A
CASE REPORT [Image Omitted. Please see PDF] A 19-year-old Saudi male presented to the emergency department with one-week history of polyuria and polydipsia. Physical examination findings were unremarkable. His father had died as a complication of metastatic renal carcinoma. Initial workup demonstrated random blood glucose of 16.3 mmol/L and HbA1C of 9.1%. Urinalysis was positive for ketone bodies, and blood analysis was positive for traces of ketone bodies. Patient was acidotic with pH of 7.3 and bicarbonate levels of 19 mmol/L. A presumptive diagnosis of diabetic ketoacidosis (DKA) was made; immune markers including glutamic acid decarboxylase (GAD) autoantibodies and islet cell autoantibodies were sent to exclude type I diabetes mellitus and maturity onset diabetes of the young. Intravenous insulin infusion and other appropriate management were initiated to control blood sugars and to correct the associated DKA. Later, the diagnosis of type I diabetes mellitus was confirmed with the presence of islet cell autoantibodies and that C-peptide level were within normal range. [Image Omitted. Please see PDF] Ultra-sound abdomen was performed as the patient complained of persistent abdominal pain even after correction of DKA. Ultrasound abdomen demonstrated an incidental finding of a well-defined hypo-echoic soft tissue mass measuring 3.7 x 4.7 cm in the left supra-renal region. Computerized tomography (CT) scan was performed for further evaluation. It demonstrated a 3.7 x 4.0 cm rounded lesion in the left adrenal gland with intense enhancement, suggestive of pheochromocytoma. A small hypo-dense lesion was also noted in the left renal upper pole, measuring 2.3 cm, with heterogeneous enhancement suggestive of a solid mass. The CT scan also demonstrated multiple rounded cystic lesions in the head, body, neck and tail of the pancreas representing pancreatic cysts. The above findings collectively were suggestive of phakomatosis disorders, in particular, vHL disease. Chromosomal studies were sent for detection of genetic mutations and confirmation of the diagnosis. MRI abdomen was highly suggestive of a left sided pheochromocytoma (Figure 1). It also demonstrated multiple cystic lesions in the pancreas (Figure 2) and bilateral cortical lesions in the kidneys, which demonstrated internal septal enhancement in the post gadolinium injection phase, highly indicative of renal cell carcinoma. Nuclear medicine scan demonstrated increased tracer uptake in the left suprarenal gland. Meanwhile, laboratory studies demonstrated increased serum normetanephrine level of 11.80 nmol/l, urine metanephrine level of 400nmol/24hrs, and urine normetanephrine level of 1210 nmol/24hrs. Serum cortisol, aldosterone and renin levels were within normal limits. A diagnosis of pheochromocytoma was confirmed and patient was started on anti-hypertensive medications and scheduled for surgical removal of the pheochromocytoma and the suspicious renal masses. Patient underwent robot assisted laparoscopic left adrenalectomy and left renal mass excision. Two renal nodules were removed. The post-operative course was unremarkable and patient was discharged home in stable condition. Histopathologic evaluation confirmed the diagnosis of pheochromocytoma; the renal masses were determined as renal clear cell carcinoma Furham grade I
PatientID: 1 (case)
KindredID: 1
Case: M,19Y0M, South Asian (Saudi)
DiseaseAssertion: assumed VHL
FamilyInfo: History of family showed that his father had died as a complication of metastatic renal carcinoma. Screening was done for the family. 3 of his 8 siblings tested positive for the 384delT mutation, although no phenotypes for them was given.
CasePresentingHPOs: HP:0100651; HP:0006748; HP:0001737; HP:0005584 (Type I diabetes mellitus; adrenal pheochromocytoma; pancreatic cysts; renal cell carcinoma)
CaseHPOFreeText: The young man presented with primary symptoms of polyuria and polydipsia, and was later found to be in diabetic ketoacidosis (diagnosed with diabetes mellitus type I). He had persistent abdominal pain (later showing left sided pheochromocytoma (3.7 x 4.0 cm rounded lesion in the left adrenal gland) and right sided renal cell carcinoma (measuring 2.3 cm, with heterogeneous enhancement suggestive of a solid mass)). The CT scan also demonstrated multiple rounded cystic lesions in the head, body, neck and tail of the pancreas representing pancreatic cysts. Bilateral cortical lesions in the kidneys also demonstrated internal septal enhancement in the post gadolinium injection phase, highly indicative of renal cell carcinoma.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.L129Trpfs*30 (c.384delT)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA70049452 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.384delT
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant
CivicName: N/A
MultipleGeneVariants: N/A
GroupID: V32
DiseaseAssertion: VHL
GroupSize:2
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: Two family members had the same VHL gene mutation.
FamilyInfo: Positive.
GroupPresentingHPOs: HP:0002666 (pheochromocytoma)
GroupHPOFreeText: N/A
GroupNotHPOs: N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R161Q(c.482G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 182983 https://www.ncbi.nlm.nih.gov/clinvar/variation/182983/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName:R161Q(c.482G>A)
MultipleGeneVariants: N/A
PatientID: V59
KindredID: V59
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: N/A
CaseHPOFreeText:N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R113* (c.337C>T)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 220414 https://www.ncbi.nlm.nih.gov/clinvar/variation/220414/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType:stop_gained
CivicName: R113* (c.337C>T)
MultipleGeneVariants: N/A
Clinical presentation of Von Hippel Lindau syndrome type 2B associated with VHL p.A149S mutation in a large Turkish family
PMID: 23673869
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
Nine patients were diagnosed with pheochromocytoma. Lumbal spinal hemangioblastoma and pancreatic neuroendocrine tumor without pheochromocytoma were detected in one patient. In patients with pheochromocytoma, additional tumors, such as retinal angioma, renal cell carcinoma, pancreatic serous cystadenoma, and pancreatic neuroendocrine tumors were detected. All patients were diagnosed as VHL syndrome type 2B.
PatientID: III-20
KindredID: 1
Case: M, 32Y0M, Turkish
DiseaseAssertion: VHL
FamilyInfo: 17 family members from three generations were examined with the c.445G>T mutation and diagnosed with VHL type 2B. 11 individuals had clinical manifestations and 6 were asymptomatic carriers. One additional member (II-9) had passed before testing however were likely a carrier of the mutation. This patient likely inherited this from his father, and passed it onto his son. See Fig. 1 for full family pedigree.
CasePresentingHPOs: HP:0006748 (adrenal pheochromocytoma)
CaseHPOFreeText: bilateral adrenal pheochromocytoma. He also had capsular invasion of his adrenal masses.
CaseNotHPOs: HP:0030393; HP:0009715 (endolymphatic sac tumor, papillary cystadenoma of the epididymis)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.A149S (c.445G>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 127829 https://www.ncbi.nlm.nih.gov/clinvar/variation/127829/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: A149S (c.445G>T)
MultipleGeneVariants: N/A
PatientID: 63
KindredID: N/A
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CohortInfo: The authors evaluated 64 VHL patients (32 women and 32 men) with renal involvement of whom 54/64 had undergone renal surgery or a radiofrequency thermal ablation procedure for RCC. In 10/64 VHL patients, at least one or more RCC were diagnosed, however at the time of diagnosis an indication for treatment was not yet present. For all patients several CT/MRI scans existed for retrospective description of tumour growth kinetics.
CasePresentingHPOs: HP:0005584 (Renal cell carcinoma)
CaseHPOFreeText: This is a tumor resolution study (VHL patients were investigated based on the presence of renal tumors.) No other phenotypic information is available.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Supplementary Table S2 describes 9 patients with nonsense mutations, including this patient.
Variant: p.R161* (c.481C>T)
LegacyVariant: c.694C>T
CaseProblemVariantFreeText: N/A
ClinVarID: 2217, https://www.ncbi.nlm.nih.gov/clinvar/variation/2217/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: R161* (c.481C>T)
MultipleGeneVariants: N/A
PatientID: 1
KindredID: N/A
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CohortInfo: The authors evaluated 64 VHL patients (32 women and 32 men) with renal involvement of whom 54/64 had undergone renal surgery or a radiofrequency thermal ablation procedure for RCC. In 10/64 VHL patients, at least one or more RCC were diagnosed, however at the time of diagnosis an indication for treatment was not yet present. For all patients several CT/MRI scans existed for retrospective description of tumour growth kinetics.
CasePresentingHPOs: HP:0005584 (Renal cell carcinoma)
CaseHPOFreeText: This is a tumor resolution study (VHL patients were investigated based on the presence of renal tumors.) No other phenotypic information is available.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Supplementary Table S3 describes 9 patients with splice mutations, including this patient.
Variant: c.340+1G>T
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA16621929, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.340%2B1G%3ET
gnomAD: N/A
VariantEvidence: N/A
MutationType: splice_site_variant
CivicName: Splice Site (c.340+1G>T)
MultipleGeneVariants: N/A
56 male patients age 12 to 76 years, from 40 families with VHL were examined as part of a larger screening program for VHL. VHL mutations were identified in 16 families. Individual patient phenotype-genotype data was not available, but the mutations found and whether the corresponding patient had epididymal cystadenoma (EC) was reported. A c.180delG VHL mutation was found in a VHL patient without EC. This mutation was referred to in the paper as c.393delG due to a difference in transcript sequence.
GroupID: 1
Case: M, Age unknown, Ethnicity unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: Unknown
CaseHPOFreeText: Other manifestations may be present although not matched with individuals so could not deduce.
CaseNotHPOs: HP:0009715 (Papillary cystadenoma of the epididymis)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.V62Cfs*5 (c.180del)
LegacyVariant: 393 del G
CaseProblemVariantFreeText: N/A
ClinVarID: 182986 https://www.ncbi.nlm.nih.gov/clinvar/variation/182986/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant
CivicName: V62Cfs*5 (c.180del)
MultipleGeneVariants: N/A
Case studies of three families affected by VHL and their children were described. The legacy mutation C712T in VHL was found in three members of family 1. The father was 48Y when he was found to have renal cell carcinoma and bilateral pheochromocytoma after initially presenting with loin pain, pyrexia and haematuria. He died one year after diagnosis despite chemotherapy treatments. His son was diagnosed with and treated for bilateral pheochromocytoma at 13Y and endolymphatic sac tumors at 19Y after noting tinnitus, increasing hearing difficulties in his left ear since the age of 16. The son had a sister who tested positive for the mutation and appears to be asymptomatic. It is unclear whether the mother and the second son were negative for the mutation or were not tested.
10 (67)
GroupID: 2a
DiseaseAssertion: VHL
GroupSize: 10
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: a retrospective cohort study from an eye centre in Germany involved 148 VHL patients and their genetic data involved in retinal capillary hemangiomas.
GroupPresentingHPOs: HP:0009711 (retinal capillary hemangioma)
GroupHPOFreeText: These 10/15 patients with a VHL gene deletion had retinal capillary hemangiomas. Other VHL manifestations were discussed but not per- variant.
GroupNotHPOs: N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Yes - Supplementary Table S1
Variant: VHL gene deletion
LegacyVariant: N/A
GroupProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: deletion
CivicName: Null (Complete Deletion)
MultipleGeneVariants: N/A
1 (100)
GroupID: 3
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
CohortInfo: a retrospective cohort study from an eye centre in Germany involved 148 VHL patients and their genetic data involved in retinal capillary hemangiomas.
CasePresentingHPOs: N/A
CaseHPOFreeText: This individual patient did NOT have retinal capillary hemangiomas. Other VHL manifestations were discussed but not per- variant.
CaseNotHPOs: HP:0009711 (retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Yes - Supplementary Table S1
Variant: Exon 1-2 deletion
LegacyVariant: N/A
GroupProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: exon_loss_variant
CivicName: Exon 1-2 deletion
MultipleGeneVariants: N/A
c.257C > A p.Pro86His
216 patients with clinically expected VHL disease due to family history or presence of VHL typical tumours were routinely examined in an eye centre in Germany between January 2019 and January 2020, majority of which were of European descent (~95%). Since data on the genotype–phenotype correlation of the onset of Retinal Hemangioblastoma (RH) is scarce in relation to VHL disease, this study wanted to inversitage the relationship between VHL gene variants (truncating vs single amino acid substitutions) and the ocular phenotype of the disease. 42 different rare VHL gene variants in 148 patients were detected - some of whom had RH and some who did not. Although date of onset of RH, as well as data on central nervous system haemangioblastomas (CNSH), pheochromocytoma/paraganglioma (PPGL), clear cell renal cell carcinoma (ccRCC) and pancreatic neuroendocrine neoplasm (PNEN) were collected, it was not reported on a per patient basis and therefore could not be discussed per variant. Out of the 4 patients with a p.P86H (c.257C>A) mutation, 50% (2/4) of individuals had RH while the other 50% (2/4) did not. No family information was provided.
PatientID: None
KindredID: 36
Case: M, 31Y0M, Spanish
DiseaseAssertion: VHL
FamilyInfo: Positive for familial antecedents. No known familial tumors.
CohortInfo: Probands belonging to 18 unrelated Spanish VHL families carrying germline VHL deletions.
CasePresentingHPOs: HP:0006880; HP:0001737 (Cerebellar hemangioblastoma, Pancreatic cysts)
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: Exon 1 Deletion (c.1-?_340+?del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: Germline HSPC300, ENST197804 and FANCD2 (unclear if partial or complete) gene deletions. Study provides evidence to show that loss of HSPC300 highly correlates with the absence of ccRCC in VHL patients.
MutationType: exon_loss_variant
CivicName: Exon 1 Deletion
MultipleGeneVariants: Germline, HSPC300, Deletion MultipleGeneVariants: Germline, ENST197804, Deletion MultipleGeneVariants: Germline, FANCD2, Deletion
PatientID: None (Proband)
KindredID: 53
Case: F, 18Y0M, Spanish
DiseaseAssertion: VHL
FamilyInfo: Positive for familial antecedents. Family history of clear cell renal cell carcinoma.
CohortInfo: Probands belonging to 18 unrelated Spanish VHL families carrying germline VHL deletions.
CasePresentingHPOs: HP:0006880; HP:0001737; HP:0009711 (Cerebellar hemangioblastoma, Pancreatic cysts, Retinal capillary hemangioma)
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: Exon 1 Deletion (c.1-?_340+?del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: Germline HSPC300 (Figure 2 appears to indicate an exon 2-3 deletion of this gene since it spans the same left-most distance as the mutation in patient 108 which is stated to be an exon 2-3 deletion) and ENST197804 deletion. Study provides evidence to show that loss of HSPC300 highly correlates with the absence of ccRCC in VHL patients.
MutationType: exon_loss_variant
CivicName: Exon 1 Deletion
MultipleGeneVariants: Germline, HSPC300, Exon 2-3 Deletion MultipleGeneVariants: Germline, ENST197804, Deletion
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients
PMID: 17311301
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
ProbandFemale
PatientID: 2
KindredID: 2
Case: F, 50Y0M, Chinese
DiseaseAssertion: VHL
FamilyInfo: See figure 3 for pedigree. In family 2, the proband (Patient 2 in the paper) was a 50 year old female who presented with bilateral renal cell carcinoma, pancreatic neuroendocrine tumor, and a renal cyst. The proband's sister was diagnosed with a pancratic NET and died of a hemorrhagic stroke at 40 years of age. Their mother also died of a stroke at 50 years of age. Genetic analysis revealed a c.232A>T (p.Asn78Tyr) mutation in the VHL gene of the proband. Based on her clinical presentation and family history, the proband was diagnosed with VHL type 1. Sanger sequencing on her family members detected the same mutation in her mother, sister, brother, and nephew.The proband's brother and nephew refused further VHL-related examination.
CasePresentingHPOs: HP:0005584, HP:0030405, HP:0000107 (renal cell carcinoma, pancreatic endocrine tumor, renal cyst)
CaseHPOFreeText: Referred to hospital in August 2011 for masses in her left kidney. The CT scan showed several masses in her left kidney and the largest one was about 3.1 × 2.4 cm. She underwent a radical nephrectomy 5 years ago for the tumor in her right kidney.
CaseNotHPOs:None
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.N78Y (c.232A>T)
LegacyVariant: N/A
CaseProblemVariant Free Text: N/A
ClinVar: 223167, https://www.ncbi.nlm.nih.gov/clinvar/variation/223167/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_transversion
CivicName: N78Y (c.232A>T)
MultipleGeneVariants: N/A
MotherFemale
PatientID: None
KindredID: 2
Case: F, 50Y0M, Chinese
DiseaseAssertion: N/A
FamilyInfo: (See figure 3 for pedigree). Mother of proband. In family 2, the proband (Patient 2 in the paper) was a 50 year old female who presented with bilateral renal cell carcinoma, pancreatic neuroendocrine tumor, and a renal cyst. The proband's sister was diagnosed with a pancreatic NET and died of a hemorrhagic stroke at 40 years of age. Their mother also died of a stroke at 50 years of age. Genetic analysis revealed a c.232A>T (p.Asn78Tyr) mutation in the VHL gene of the proband. Based on her clinical presentation and family history, the proband was diagnosed with VHL type 1. Sanger sequencing on her family members detected the same mutation in her mother, sister, brother, and nephew.The proband's brother and nephew refused further VHL-related examination.
CasePresentingHPOs: N/A
CaseHPOFreeText: Mother of proband, died of stroke at 50 years of age.
CaseNotHPOs:None
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.N78Y (c.232A>T)
LegacyVariant: N/A
CaseProblemVariant Free Text: N/A
ClinVar: 223167, https://www.ncbi.nlm.nih.gov/clinvar/variation/223167/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_transversion
CivicName: N78Y (c.232A>T)
MultipleGeneVariants: N/A
VCB0.04T VHL RTK2 0.57
PatientID: VCB.04T
KindredID: 5
Case: Sex Unknown, 24Y0M, Ethnicity Unknown
DiseaseAssertion: pheochromocytoma
FamilyInfo: N/A
CasePresentingHPOs: HP:0002668; HP:0002666 (paraganglioma, pheochromocytoma)
CaseHPOFreeText: Presented with bilateral pheochromocytoma
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: MAX, RET, SDHA, SDHB, SDHC, SDHD, TMEM127
PreviouslyPublished: 25545346 (see table S1 and S10)
SupplementalData: Yes
Variant: p.V166Dfs*9 (c.480_481insCGATGCCTCCAGGT)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA2573119327 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA2573119327
gnomAD: N/A
VariantEvidence: N/A
MutationType: plus_2_frameshift_variant
CivicName: V166Dfs*9 (c.480_481insCGATGCCTCCAGGT)
MultipleGeneVariants: N/A
VCB0.04T VHL RTK2 0.57
Of 38 PPGL (pheochromocytoma and paraganglioma) cases studied, one was associated with an individual carrying the germline mutation ENST00000256474.2:c.480_481insCGATGCCTCCAGGT (ENSP00000256474.2:p.Val166AspfsTer9) of the VHL gene. This mutation was identified using Sanger sequencing. The authors identified the reference sequence used as NM_000551.3. This patient presented with phechromocytoma and paraganglioma. This patient was previously published in PMID: 25545346. ACMG evidence codes: 'PP4' since the patient presents phenotypes highly specific for a disease with a single genetic etiology.
PatientID: None
KindredID: 1
Case: F, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: This patient's fourth oldest sister had bilateral retinal angiomas, metastatic islet cell cancer, liver lesions, pancreatic endocrine tumours, and cerebellar hemangioblastoma. Her third oldest sister had a pancreatic head tumour and bilateral renal cysts. Her youngest sister had bilateral angiomas, liver lesions, and metastatic islet cell cancer. The oldest sister did not carry the mutation or have any abnormal presentations. The patient's mother was found to harbor the mutation and had retinal angiomas, bilateral adrenal pheochromocytoma, and pancreatic cysts. The patient's maternal grandmother was suspected to have VHL as she developed progressive blindness at age 32 and was completely blind by age 36. She died at age 68 due to an acute hemorrhage into and around a vascular tumour. The patient's maternal aunt died suddenly at age 51 due to a cerebellar hemangioblastoma. One of the aunt's children died at age 25 due to a cerebellar hemangioblastoma and another had bilateral retinal angiomas and multiple pancreatic cysts. Refer to Figure 1 for pedigree.
CasePresentingHPOs: HP:0030405, HP:0000107, HP:0000138 (pancreatic endocrine tumour, Renal cyst, Ovarian cyst)
CaseHPOFreeText: The patient initially only presented with bilateral small ovarian cysts. On follow up four years later, it was found that she had two hypervascular pancreatic head tumours <1cm in diameter, a complex left renal cyst, and enlarged ovarian cysts. A pancreaticoduodenectomy and left heminephrectomy was performed, revealing two <1-cm islet cell tumours and a complex renal cyst with severe cellular atypia but no invasive maligancy.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: c.R167Q (c.500G>A)
LegacyVariant: c.R167Q (c.713G>A)
CaseProblemVariantFreeText: N/A
ClinVarID: 2216 https://www.ncbi.nlm.nih.gov/clinvar/variation/2216/
CAID: N/A
gnomAD: 0.000003977 https://gnomad.broadinstitute.org/variant/3-10191507-G-A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167Q (c.500G>A)
MultipleGeneVariants: N/A
GroupID: 8
Case: 37Y0M, Sex Unknown, Ethnicity Unknown
DiseaseAssertion: assumed VHL
FamilyInfo: 1 of the 573 patients discussed in this paper were found to have this variant. This mutation was found in 1 VHL family with a single patient.
CasePresentingHPOs: HP:0005584; HP:0009711; HP:0006880 (renal cell carcinoma; retinal capillary hemangioma; cerebellar hemangioblastoma)
CaseHPOFreeText: patient had retinal angiomas diagnosed at 28Y, cerebellar hemangioblastomas diagnosed at 22Y, and renal cell carcinoma diagnosed at 37Y.
CaseNotHPOs: HP:0002666 (pheochromocytoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Supplementary Table S1.
Variant: p.R177* (c.529A>T)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 625258 https://www.ncbi.nlm.nih.gov/clinvar/variation/625258/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: R177* (c.529A>T)
MultipleGeneVariants: N/A
GroupID: 32
DiseaseAssertion: assumed VHL
GroupSize: 2
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: 2 of the 573 patients discussed in this paper were found to have the following mutation belonging to 1 family.
GroupPresentingHPOs: HP:0006880; HP:0009711 (cerebellar hemangioblastoma; retinal capillary hemangioma)
GroupHPOFreeText: 1 patient had retinal hemangiomas diagnosed at an unknown age and 1 had cerebellar HB diagnosed at 31Y
GroupNotHPOs: HP:0002666; HP:0005584 (pheochromocytoma; renal cell carcinoma)
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Supplementary Table S1.
Variant: p.Y175* (c.525delC)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA913185019 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.525del
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: Y175* (c.525delC)
MultipleGeneVariants: N/A
GroupID: 81
DiseaseAssertion: assumed VHL
GroupSize: 4
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: 4 of the 573 patients discussed in this paper were found to have identical variants. This mutation (c.506T>C) was found in 1 VHL family with 4 patients.
GroupPresentingHPOs: HP:0005584; HP:0009711 (renal cell carcinoma; retinal capillary hemangioma)
GroupHPOFreeText: 3 patients had retinal angiomas with a mean age of diagnosis of 22Y, and 2 patients had RCCs with a mean age of diagnosis of 28Y.
GroupNotHPOs: HP:0002666; HP:0006880 (pheochromocytoma, cerebellar hemangioblastoma)
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Supplementary Table S1.
Variant: p.L169P (c.506T>C)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 428809 https://www.ncbi.nlm.nih.gov/clinvar/variation/428809/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: L169P (c.506T>C)
MultipleGeneVariants: N/A
VHL-25c.1 − ?_463 + ?Del ex 1 + 2[11]noA2Multiple–+––Renal
PatientID: VHL-25
KindredID: 25
Case: Sex Unknown, Age Unknown, Italian
DiseaseAssertion: VHL
FamilyInfo: No family history of VHL.
CohortInfo: Forty-three index cases were referred to the Service of Medical Genetics, Genova, for germline mutation analysis in the VHL gene between 1995 and 2008.
CasePresentingHPOs: HP:0010797; HP:0000107; HP:0001732 (Hemangioblastoma, Renal cyst, Abnormality of the pancreas)
CaseHPOFreeText: Multiple CNS hemangioblastomas. Clinical classification: A2.
CaseNotHPOs: HP:0002666; HP:0005584; HP:0009711 (Pheochromocytoma, Renal cell carcinoma, Retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: Exon 1-2 Deletion (c.1-?_463+?del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: exon_loss_variant
CivicName: Exon 1-2 Deletion
MultipleGeneVariants: N/A
both brothers with renal cell carcinoma with VHL gene mutation
PatientID: None (Brother 2)
KindredID: 1
Case: M, 70Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: One brother (proband, 75Y) presented with Hemangioblastoma, Hypertension, Cataract, Visual loss, Amblyopia, Diabetes mellitus, Adenocarcinoma of the colon, Clear cell renal cell carcinoma, Retinitis, Anal canal adenocarcinoma, Spinal hemangioblastoma, Gastrointestinal carcinoma, Cerebellar hemangioblastoma and the same VHL mutation as this patient. Mother with a brain tumor of unconfirmed pathology, and another brother (79Y) with renal cell carcinoma with the VHL gene mutation. Nephew (44Y) VHL mutation but is asymptomatic. Niece (40Y) had a brain hemorrhage, daughter had hematologic malignancy, nephew has pancreatic cancer; genetic information is unclear or not provided for either.
CasePresentingHPOs: HP:0005584 (Renal cell carcinoma)
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Figure 1
Variant: p.E70K (c.208G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 43598, https://www.ncbi.nlm.nih.gov/clinvar/variation/43598/
CAID: N/A
gnomAD: 0.000004365, https://gnomad.broadinstitute.org/variant/3-10183739-G-A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: E70K (c.208G>A)
MultipleGeneVariants: N/A
3 France c.499C>T p.Arg167Trp UK Germany
GroupID: 28
DiseaseAssertion: VHL
GroupSize: 3
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: French, German, and British
GroupAgeRange: N/A
GroupInfo: 3 registrants from were grouped in this study via the mutation of c.499C>T
GroupPresentingHPOs: HP:0030393 (Endolymphatic sac tumor)
GroupHPOFreeText: N/A
GroupNotHPOs: N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167W (c.499C>T)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 2218 https://www.ncbi.nlm.nih.gov/clinvar/variation/2218/
CAID: N/A
gnomAD: 0.000007954 https://gnomad.broadinstitute.org/variant/3-10191506-C-T
VariantEvidence: N/A
MutationType: missense_variant; transition
CivicName: R167W (c.499C>T)
MultipleGeneVariants: N/A
1 Spain c.404T>A p.Leu135*
GroupID: 18
Case: Sex unknown, Age unknown, Spanish
DiseaseAssertion: VHL
FamilyInfo: Unknown. 1 registrant was found with this variant; no family info was mentioned
CasePresentingHPOs: HP:0030393 (Endolymphatic sac tumor)
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.L135* (c.404T>A)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: N/A
CAID: CA351754021 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.404T%3EA
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: L135* (c.404T>A)
MultipleGeneVariants: N/A
1 France c.485G>A p.Cys162Tyr
Patients with ELSTs were identified and included in the International Endolymphatic Sac Tumor Registry. The registry contained 93 patients as of July 2014, and of those, 25 were sporadic, and 68 associated with VHL. Patients with ELSTs and clinically confirmed diagnoses of VHL were included in this study. Statistics of this VHL subgroup are as follows: mean age 30, 62% female, 91% symptomatic, 54% with retinal angioma, 72% with CNS hemangioblastoma, 46% with renal cell carcinoma, 19% with pheochromocytoma, and 12% with pancreatic neuroendocrine tumour. In the data from this study, only endolymphatic sac tumours can be confirmed as a phenotype for this mutation (c.485G>A), which was found in 1 individual from France.
c.345C>A (p.H115Q)
A family with VHL syndrome from a Han Chinese population was recruited for the present study in Hunan Cancer Hospital (Changsha, China). There were originally 23 patients in this pedigree; however, 6 patients succumbed to mortality prior to recruitment. In total, 17 subjects [including 8 males and 9 females; aged 4–65 years old; one patient suffering from VHL syndrome (proband)] were enrolled and underwent detailed clinical examinations. The proband (III:2) was a 28-year-old male, who presented with an episodic headache for 10 years. A cyst and a nodule were revealed via brain MRI. The cyst was demonstrated to be a hemangioblastoma tumor. A heterozygous mutation c.345C>A (p.H115Q) in exon 2 of the VHL gene was revealed to be present in the proband. In addition, two of the proband's maternal cousins were healthy individuals that were demonstrated to carry the mutation, as revealed by Sanger sequencing: III:4, male, and III:8, female. Genomic DNA was isolated from peripheral blood lymphocytes of all subjects using the standard phenol-chloroform method. VHL was amplified via polymerase chain reaction (PCR). Three pairs of primers were designed to cover all of the exons and splicing junctions of VHL. PCR amplification was performed using an ABI 2720 PCR system. Sanger sequencing was performed using an ABI 3100/3130 Genetic Analyzer automated sequencer. The sequencing results were analyzed using SeqMan 3.0. A further five affected members of the family had previously died from this syndrome, including the proband's mother, grandfather, two uncles, and a cousin. ACMG evidence codes: "flag for PP3 review"- Multiple lines of computational evidence support a deleterious effect on the gene/gene product. "flag for PP4 review"- patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Genomic DNA was isolated from peripheral blood lymphocytes of all subjects using the standard phenol-chloroform method (17). VHL was amplified via polymerase chain reaction (PCR). Three pairs of primers were designed to cover all of the exons and splicing junctions of VHL (Table I). The thermocycling conditions of PCR used were as follows: Initial Denaturation at 95°C for 30 sec; followed by 30 cycles of denaturation at 95°C for 30 sec, annealing at 58°C for 30 sec and elongation 72°C for 30 sec; and a final extension at 75°C for 5 min. PCR amplification was performed using an ABI 2720 PCR system (Thermo Fisher Scientific, Inc., Waltham, MA, USA) using a 10 µl mixture containing premixed DNA polymerase (5 µl; Takara Biotechnology Co., Ltd., Dalian, China), primers (2 µl), genomic DNA (1 µl) and double distilled H2O (2 µl). PCR products were detected using 6% polyacrylamide gel electrophoresis with silver staining. Sanger sequencing was performed using an ABI 3100/3130 Genetic Analyzer automated sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. The sequencing results were analyzed using SeqMan 3.0 (DNASTAR, Inc., Madison, WI, USA), and compared with the reference sequences listed in the National Center for Biotechnology Information database (https://www.ncbi.nlm.nih.gov/). Mutation naming followed the nomenclature recommended by the Human Genomic Variation Society (http://www.hgvs.org/).
ArticleReferenceSequence: Not specified – Assumption: variants assumed to have been documented by the author under reference sequence NM_000551.3
GenotypingMethod: Sanger sequencing of all VHL exons and splice junctions
SamplingMethod: peripheral blood
PMID: 7977367
Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and variants in all cell lines. All mutations cluster to the 3’ end of the VHL gene open reading frame, implicating this region as important for the tumor-suppressor function of the VHL protein. RT-PCR analysis in RCC cell lines found a p.R177* (c.529A>T) mutation, stated in the paper as c.742A>T due to an older transcript. It was seen in cell line Caki-2. Any family information or other manifestations apart from RCC were unclear.
PMID: 7977367
Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and variants in all cell lines. All mutations cluster to the 3’ end of the VHL gene open reading frame, implicating this region as important for the tumor-suppressor function of the VHL protein. Northern blot, SSCP and RT-PCR analysis from normal tissue found a germline p.T152Hfs*22 (c.452_453insA) mutation, stated in the paper as c.665insA due to an older transcript. It was seen in family [pedigree No] 11, with an unknown number of members described as ‘VHL-affected’ with RCC. Other manifestations are possible but not clear.
PMID: 7977367
PatientID: N/A
KindredID: Caki-2 (cell line)
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: Renal cell carcinoma
FamilyInfo: N/A
CasePresentingHPOs: HP:0005584 (renal cell carcinoma)
CaseHPOFreeText: Described as sporadic RCC from cell line Caki-2
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R177* (c.529A>T)
LegacyVariant: p.R248* (c.742A>T)
CaseProblemVariantFreeText: N/A
ClinVarID: 625258 https://www.ncbi.nlm.nih.gov/clinvar/variation/625258/
CAID: N/A
gnomAD: N/A
VariantEvidence:N/A
MutationType: stop_gained
CivicName: R177* (c.529A>T)
MultipleGeneVariants: N/A
A deletion of exon 3 in the VHL gene was found in this family.
PatientID: III-4
KindredID: Family A
Case: F, 38Y0M, Ethnicity unknown
DiseaseAssertion: VHL
FamilyInfo: Patient’s grandfather (I-1), now deceased, and aunt (II-1) had CNS/spinal hemangioblastoma and the confirmed VHL gene mutation. Her mom II-2 had confirmed VHL and CNS hemangioblastoma; and her cousin (III-6) has renal cell carcinoma and CNS/spinal hemangioblastoma and also the confirmed VHL gene mutation. Her uncle (II-3) has confirmed VHL gene and pancreatic and renal cysts. Her brother and sister (III-3; III-5) both were found with the confirmed VHL gene mutation; with retinal hemangioblastoma and CNS/spinal hemangioblastomas. IV-1 and IV-3, were confirmed with the VHL gene mutation although no other manifestations.
CasePresentingHPOs:HP:0001737; HP:0000138 (pancreatic cyst; ovarian cyst)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0005584; HP:0002666; HP:0009711; HP:0010797 (renal cell carcinoma, pheochromocytoma, retinal capillary hemangioblastoma, CNS hemangioblastoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: Deletion of exon 3 (c.464-?_642+?del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: exon_loss_variant
CivicName: Exon 3 deletion
MultipleGeneVariants: N/A
c.236G>C, p.R79P
PatientID: II-2
KindredID: Family B
Case: F, 20Y0M, Ethnicity unknown
DiseaseAssertion: VHL
FamilyInfo: Family positive pedigree showing patient’s father with RCC and CNS hemangioblastoma; as well as 2 siblings: brother and sister with CNS/spinal and retinal hemangioblastomas
CasePresentingHPOs: HP:0010797; HP:0009711 (hemangioblastoma; retinal capillary hemangioblastoma)
CaseHPOFreeText: born with oculoauriculo-vertebral (Goldenhar) syndrome (has an asymmetrical face, coloboma at the right optic nerve with secondary amblyopia in her right eye, and a VA of hand motion). Her right eye was also treated for a peripheral retinal hemangioblastoma. She suffers from a small CNS hemangioblastoma. She has had surgery for multiple skin tags on the left side of her face, bilateral epibulbar lipodermoids and right eyelid coloboma
CaseNotHPOs: HP:0005584; HP:0002666 (renal cell carcinoma, pheochromocytoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R79P (c.236G>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351749311 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.236G%3EC
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: R79P (c.236G>C)
MultipleGeneVariants: N/A
von Hippel-Lindau (VHL) disease is an autosomal dominant familial cancer syndrome predisposing to the development of retinal and central nervous system haemangioblastomas, pheochromocytomas, renal and pancreatic cancer. In the course of a molecular analysis conducted to detect germline mutations of this gene in von Hippel-Lindau patients and individuals affected by sporadic tumors, we have identified a case of somatic mosaicism in the asymptomatic mother of a VHL patient who was subsequently diagnosed with pheochromocytoma. This is the first report providing molecular evidence of somatic mosaicism in von Hippel-Lindau disease. Mosaicism could provide some genetic explanation for the clinical heterogeneity and variable severity of the VHL phenotype, and should be considered, as a possible event when evaluating sporadic cases of VHL or patients with isolated VHL-related tumors. Hum Mutat 15:114, 2000.
PatientID: 1 (case)
KindredID: 1
Case: M, 26Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: The 50 year-old father, 48 year-old mother and 22 year-old sister were asymptomatic. All were tested which confirmed the presence of mosaicism in the mother. This was said to be somatic mosaicism. She also presented with clinically silent renal cysts and pheochromocytoma.
CasePresentingHPOs: HP:0002666; HP:0000107; HP:0006880; HP:0009711 (pheochromocytoma; renal cyst; cerebellar hemangioblastoma; retinal capillary hemangioma)
CaseHPOFreeText: At 26Y, he had cerebellar hemangioblastoma, retinal hemangioma and multiple bilateral renal cysts. He also had bilateral pheochromocytomas which were removed.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R161G (c.481C>G)
LegacyVariant: p.R161G (c.694C>G)
CaseProblemVariantFreeText: N/A
ClinVarID: 618484 https://www.ncbi.nlm.nih.gov/clinvar/variation/618484
CAID: N/A
gnomAD: N/A
VariantEvidence: This mutation created a new FokI restriction site.
MutationType: missense_variant; transversion
CivicName: R161G (c.481C>G)
MultipleGeneVariants: N/A
PatientID: N/A
KindredID: 16
Case: Sex, Age, Ethnicity Unknown
DiseaseAssertion: pheochromocytoma
FamilyInfo: N/A
CasePresentingHPOs: HP:0002666 (pheochromocytoma)
CaseHPOFreeText: Nonsyndromic pheochromocytoma.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET, SDHB, SDHD
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R161P (c.482G>C)
CaseProblemVariantFreeText: N/A
LegacyVariant: p.R161P (c.695G>C)
ClinVarID: N/A
CAID: CA351756111 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.482G%3EC
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: R161P (c.482G>C)
MultipleGeneVariants: N/A
A long-term survivor of metachronous liver metastases of pancreatic serous cystic neoplasm associated with von Hippel-Lindau disease
PMID: 34191152
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
505 T/CY98H
42 CNS hemangioblastoma samples were obtained from 31 patients, who were consecutively treated between 1993 and 1997 at the Department of Neurosurgery of the Freiburg University Medical Centre were analyzed for VHL mutations. Three patients of 17 presenting with VHL germline mutations presented with the c.292T>C mutation (stated as c.505C>T in the paper which used the Latif sequence as reference). These patients were related but their relation is not made clear. Single strand conformation polymorphism and southern blotting for variant identification in the DNA found in blood samples. The patients were established as having VHL disease by standard of Neumann at al., 1987. The first two of these patients (patients 11 and 13) each presented with a single cerebellum tumor. The third of these patients presented with a medulla oblongata tumor and a spinal tumor at C8.
Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe
PMID: 8707293
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
VHL mutation c.239G>T; p.(Ser80Ile), which is associated with a severe phenotype
PatientID: 1
KindredID: 1
Case: F, 44Y0M, Ethnicity Unknown
DiseaseAssertion: assumed VHL
FamilyInfo: The patient has a notable family history. Her eldest brother had multiple RCCs in both kidneys, bilateral cerebellar hemangioblastomas, and pheochromocytoma in his left adrenal gland (see Patient 2). Her daughter also underwent cortex-sparing adrenalectomies for bilateral pheochromocytomas as well as hemangioblastoma resection in her left cerebellum at age of 19 years, although no testing for VHL was stated.
CasePresentingHPOs: HP:0006748, HP:0030405, HP:0006880, HP:0000107, HP:0005584 (adrenal pheochromocytomas, pancreatic endocrine tumour, cerebellar hemangioblastoma, renal cyst, renal cell carcinoma)
CaseHPOFreeText: Patient diagnosed at age 29 with bilateral pheochromocytomas when she presented with severe hypertension and two large masses (greater than 6 cm) in her bilateral adrenal glands. At 38 years old, she underwent a resection for a mass found on her pancreas, with pathological analysis of the mass revealing a pancreatic neuroendocrine tumor. At 42 years old, a follow-up CT scan revealed two heterogeneous contrast-enhanced masses, one on the right kidney and one on the left adrenal gland.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.S80I (c.239G>T)
LegacyVariant: N/A
ClinVar: 625229 https://www.ncbi.nlm.nih.gov/clinvar/variation/625229/
CAiD: CA16621914 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.239G%3ET
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: S80I (c.239G>T)
MultipleGeneVariants: N/A
V1-122MCerebellumc.216delCChr. 3 LOH——Yes−224MCerebellumc.216delC———
PatientID: V1
KindredID: 1
Case: M, 24Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: This patient’s brother also had this germline mutation and at least one brainstem hemangioblastoma at 30 years old.
CasePresentingHPOs: HP:0006880 (Cerebellar hemangioblastoma)
CaseHPOFreeText: Study reports 2 cerebellar hemangioblastomas at the ages of 22 and 24. Other phenotype information not provided.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Table 2
Variant: p.Q73Rfs*86 (c.216del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA432536422, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_canonicalid?canonicalid=CA432536422
gnomAD: N/A
VariantEvidence: The c.216delC variant was not genetically confirmed to be germline but was found in tumor samples from both the siblings.
MutationType: minus_1_frameshift_variant
CivicName: S72fs (c.216delC)
MultipleGeneVariants: N/A
PatientID: 9
KindredID: 19
Case: F, 8Y0M, Ethnicity Unknown
DiseaseAssertion: Asymptomatic
FamilyInfo: Positive. The patient's cousin was the proband (1). The proband's mother (2) and uncle (7) carried the mutation and presented with symptoms. The proband's first cousin once removed (22) was also found to have the mutation but was asymptomatic.
CohortInfo: 20 unrelated VHL families from an ethnically diverse cohort containing both affected and unaffected individuals.
CasePresentingHPOs: N/A
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0009711, HP:0005584, HP:0002666, HP:0001732, HP:0000077, HP:0010797 (retinal capillary hemangioma, renal cell carcinoma, pheochromocytoma, abnormality of the pancreas, abnormality of the kidney, hemangioblastoma)
CaseNotHPOFreeText: The patient did not have epididymal or ovarian cysts.
CasePreviousTesting: N/A
PreviouslyPublished: 31368132
SupplementalData: Supplementary file 1.
Variant: p.W88* (c.263G>A)
LegacyVariant: p.W88* (c.476G>A)
CaseProblemVariantFreeText: N/A
ClinVarID: 182978 https://www.ncbi.nlm.nih.gov/clinvar/variation/182978/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: W88* (c.263G>A)
MultipleGeneVariants: N/A
PatientID: 2 (Sister)
KindredID: 7
Case: F, 11Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: 6 members of this family were found to harbor the c.319C>G germline variant of the VHL gene. ID 11 presented with renal and pancreatic abnormalities, pheochromocytoma and other undefined phenotypes. ID 1 presented with pheochromocytoma. ID 24 presented with renal abnormalities, and pheochromocytoma, and died at age 62. ID 10 presented with CNS hemangioblastoma, pancreatic abnormalities and pheochromocytoma. ID 4 presented with pheochromocytoma.
CasePresentingHPOs: HP:0001732 (Abnormality of the pancreas)
CaseHPOFreeText: The patient presented with pancreatic abnormalities (9Y).
CaseNotHPOs: HP:0009711; HP:0005584; HP:0010797; HP:0002666; HP:0000077 (Retinal capillary hemangioma, Renal cell carcinoma, Hemangioblastoma, Pheochromocytoma, Abnormality of the kidney)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Supplementary Table 1.
Variant: p.R107G (c.319C>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 43599, https://www.ncbi.nlm.nih.gov/clinvar/variation/43599/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: R107G (c.319C>G)
MultipleGeneVariants: N/A
PatientID: 125 (Second cousin)
KindredID: 18
Case: F, 52Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: 11 members of this family tested positive for the c.712C>T/c.499C>T germline variant of the VHL gene. 14 members of this family were assumed to carry this variant due to family history/personal medical history. Members of this family range from asymptomatic to multi-organ involvement (pheochromocytoma, pancreatic and renal cysts/tumors and hemangioblastomas). The family was previously reported in PMID 3942913.
CasePresentingHPOs: HP:0009711; HP:0002666; HP:0005584 (Retinal capillary hemangioma, Pheochromocytoma, Renal cell carcinoma)
CaseHPOFreeText: This patient presented with retinal angioma (19Y). Age of diagnosis of pheochromocytoma and renal cell carcinoma is unknown.
CaseNotHPOs: HP:0000077; HP:0001732; HP:0010797 (Abnormality of the kidney, Abnormality of the pancreas, Hemangioblastoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 3942913 (some members of this family are previously reported (phenotypes only) but unable to match patients across papers with confidence)
SupplementalData: Supplementary Table 1.
Variant: p.R167W (c.499C>T)
LegacyVariant: c.712C>T
CaseProblemVariantFreeText: N/A
ClinVarID: 2218, https://www.ncbi.nlm.nih.gov/clinvar/variation/2218/
CAID: N/A
gnomAD: 0.000007954, https://gnomad.broadinstitute.org/variant/3-10191506-C-T?dataset=gnomad_r2_1
VariantEvidence: A point mutation (c.712C>T) was found. Being that this variant is out of bound with respect to the NM_000551.3 reference sequence, it was concluded that this variant is noted in the Latif et al. (1993) reference and was translated to c.499C>T (NM_000551.3).
MutationType: missense_variant;transition
CivicName: R167W (c.499C>T)
MultipleGeneVariants: N/A
Ninety-eight individuals were tested for VHL mutations--23 symptomatic and 75 asymptomatic individuals belonging to 16 families. Seven of the families had definite clinical criteria of VHL disease, five had sporadic hemangioblastoma, and four had CNS hemangioblastoma combined with minor visceral signs. Molecular genetic testing identified five germline mutations in six of the definite VHL families (sensitivity 85%), but none in the possible VHL and sporadic hemangioblastoma cases; four of these mutations had been previously described and one is a novel mutation present in two unrelated families. After patients carrying the mutation were identified, they underwent clinical screening and asymptomatic VHL-related lesions were identified in 43%.
Patients presenting with cerebellar hemangioblastomas at the Mexican National institute of Neurology and Neurosurgery to were prospectively enrolled alongside family members, resulting in 84 patients in 7 families with VHL mutations, and subjected to peripheral blood draw and PCR-based mutation screening, as well as full clinical screening for symptomatic individuals. One indiviudal presented with a c.362A>G mutation leading to a p.Asp121Gly missense change. This individual presented at 29Y with 2 cerebellar hemangioblastomas, bilateral retinal angioma, pancreatic cysts, kidney cysts, renal cell carcinoma, pheochromocytoma, and broad ligament cystadenoma. The family history of this patient is negative for the disease; one possibility is that she carries a de novo mutation, although the possibility of non-paternity could not be ruled out. Other affected individuals in Family D died at an early age. They were previously published in PMID: 20064270. ACMG Evidence Codes: 'PP2' because it is a missense variant in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease.
Ninety-eight individuals were tested for VHL mutations--23 symptomatic and 75 asymptomatic individuals belonging to 16 families. Seven of the families had definite clinical criteria of VHL disease, five had sporadic hemangioblastoma, and four had CNS hemangioblastoma combined with minor visceral signs. Molecular genetic testing identified five germline mutations in six of the definite VHL families (sensitivity 85%), but none in the possible VHL and sporadic hemangioblastoma cases; four of these mutations had been previously described and one is a novel mutation present in two unrelated families. After patients carrying the mutation were identified, they underwent clinical screening and asymptomatic VHL-related lesions were identified in 43%.
PatientID: 4
KindredID: A
Case: Sex Unknown, 11Y0M, Mexican (Latino/Admixed American)
DiseaseAssertion: asymptomatic
FamilyInfo: three other symptomatic members of family A had this mutation. The symptomatic individuals all had cerebellar hemangioblastomas, as well as spinal hemangioblastomas and renal cysts.
CasePresentingHPOs: N/A
CaseHPOFreeText: asymptomatic at 11Y, could be due to patient’s young age
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 20064270
SupplementalData: N/A
Variant: p.F76del (c.227_229del)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 223166 https://www.ncbi.nlm.nih.gov/clinvar/variation/223166/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: inframe_deletion
CivicName: F76del (c.227_229del)
MultipleGeneVariants: N/A
Ninety-eight individuals were tested for VHL mutations--23 symptomatic and 75 asymptomatic individuals belonging to 16 families. Seven of the families had definite clinical criteria of VHL disease, five had sporadic hemangioblastoma, and four had CNS hemangioblastoma combined with minor visceral signs. Molecular genetic testing identified five germline mutations in six of the definite VHL families (sensitivity 85%), but none in the possible VHL and sporadic hemangioblastoma cases; four of these mutations had been previously described and one is a novel mutation present in two unrelated families. After patients carrying the mutation were identified, they underwent clinical screening and asymptomatic VHL-related lesions were identified in 43%.
PatientID: 25
KindredID: E
Case: Sex Unknown, 32Y0M, Mexican (Latino/Admixed American)
DiseaseAssertion: assumed VHL
FamilyInfo: No family history discussed
CasePresentingHPOs: HP:0010797; HP:0000107; HP:0001737 (hemangioblastoma, renal cyst, pancreatic cysts)
CaseHPOFreeText: Symptomatic by 32Y, clinically manifested as 3 cerebellar hemangioblastomas, pancreatic and renal cyst
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 20064270
SupplementalData: N/A
Variant: p.R161* (c.481C>T)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 2217 https://www.ncbi.nlm.nih.gov/clinvar/variation/2217/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: R161* (c.481C>T)
MultipleGeneVariants: N/A
Endocrine Reviews, Volume 32, Issue Supplement, 1 June 2011, Pages 1–3095, https://doi.org/10.1093/edrv/32.supp.1
PatientID: N/A (daughter)
KindredID: 1
Case: F, 5Y0M, Ethnicity Unknown
DiseaseAssertion: asymptomatic
FamilyInfo: Her mother tested positive for the mutation: Q164R (c.491A<G), presenting with pheochromocytoma. Her cousin (26Y) had an adrenaland pancreatic tumors neuroendocrine carcinoma of uncertain origin, although no genetic testing.
CasePresentingHPOs: N/A
CaseHPOFreeText: asymptomatic likely due to young age
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Q164R (c.491A>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2238 https://www.ncbi.nlm.nih.gov/clinvar/variation/2238/
CAID: N/A
gnomAD: N/A
VariantEvidence: To date, this germline VHL mutation was said to have been described in only 3 cases, with variable phenotypes, and in 2 cases PHEO occurred at a very young age.
MutationType: missense_variant;transition
CivicName: N/A
MultipleGeneVariants: N/A
Pheochromocytomas and paragangliomas are rare tumors in the pediatric population that arise from neural crest cells. Prompt recognition and treatment are necessary to limit morbidity. Compared to adults, pheochromocytoma and paraganglioma in children are more likely to be associated with an underlying genetic syndrome, and genetic testing should be pursued. These tumors can produce catecholamines and present with symptoms such as sweating, nausea, emesis, hypertension, or diarrhea, or they can be nonfunctional and present with symptoms related to mass effect. Evaluation is initiated with measurement of urine and plasma metanephrines and diagnosis confirmed with magnetic resonance imaging. Definitive treatment occurs via surgical excision. A multidisciplinary team specifically trained in the management of pediatric PHEO and PGL is necessary for optimal patient care.
PatientID: 1 (case)
KindredID: 1
Case: M, 17Y0M, Ethnicity Unknown
DiseaseAssertion: assumed VHL
FamilyInfo: The patient’s father and paternal aunt both had a history of pheochromocytoma. No genetic testing for them was described.
CasePresentingHPOs: HP:0006748; HP:0002668 (adrenal pheochromocytoma, paraganglioma)
CaseHPOFreeText: Presented at 11Y with a 2-week history of nausea. He was noted to have tachycardia and a heart murmur, so an echocardiogram was obtained revealing moderate concentric hypertrophy and mildly decreased left ventricular systolic and diastolic dysfunction. An MRI of the abdomen revealed a 4.6 × 4.1 × 5.7 cm mass in the right adrenal gland and a 3.3 × 2.9 × 3.2 cm rounded lesion in the left adrenal gland. MIBG scan showed MIBG localization in bilateral retroperitoneal masses, compatible with bilateral pheochromocytoma. Patient underwent bilateral adrenalectomy. Two years later (13Y), imaging revealed a right paraspinal paraganglioma which was subsequently resected.
CaseNotHPOs: N/A
CaseNotHPOFreeText: An ophthalmology examination was notable only for hypertensive retinopathy.
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.V84M (c.250G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 428813, https://www.ncbi.nlm.nih.gov/clinvar/variation/428813/
CAID: N/A
gnomAD: 0.000004376, https://gnomad.broadinstitute.org/variant/3-10183781-G-A
VariantEvidence: At the time of publication, the mutation had not been previously characterized however was clinically consistent with a diagnosis of VHL.
MutationType: missense_variant;transition
CivicName: N/A
MultipleGeneVariants: N/A
GroupID: None (13)
DiseaseAssertion: VHL
GroupSize: 2
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: This family group of 2 individuals have clinically confirmed VHL disease. These individuals were found to harbor a c.280G>T variant causing a Glu94* missense mutation (noted in the paper as c.493G>T due to Latif reference transcript being used).
GroupPresentingHPOs: HP:0009711 (Retinal capillary hemangioma)
GroupHPOFreeText: Patients within this family were found to have a clinical diagnosis of VHL disease. No VHL clinical phenotypes were explicitly stated other than retinal angiomatosis in at least one patient.
GroupNotHPOs: N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.E94* (c.280G>T)
LegacyVariant: c.493G>T
CaseProblemVariantFreeText: N/A
ClinVarID: 584477, https://www.ncbi.nlm.nih.gov/clinvar/variation/584477/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion; stop_gained
CivicName: E94* (c.280G>T)
MultipleGeneVariants: N/A
41 non-related patients with retinal capillary hemangioma presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma, cerebellar hemangioblastoma, renal cysts, pancreatic cyst, renal carcinoma, and pheochromocytoma), molecular genetic testing, and/or family history. VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. Blood samples were genetically tested using PCR-SSCP sequencing. One patient with VHL-related retinal angiomatosis was found to have germline missense (c.452T>C) mutation in the VHL gene. 3 other affected relatives were also evaluated and found to have the variant but no phenotypes were provided. This variant was reported as c.665T>C (AF010238.1) and mapped to p.I151T (c.452T>C) (NM_000551.3).
41 non-related patients with retinal capillary hemangioma presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma, cerebellar hemangioblastoma, renal cysts, pancreatic cyst, renal carcinoma, and pheochromocytoma), molecular genetic testing, and/or family history. Blood samples were taken and analyzed by PCR and single-strand conformational polymorphism (SSCP). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. Group 20, consisted of a proband with retinal capillary hemangioma and a relative who also harboured the germline VHL mutation, R161 (c.481C>T). Group 21, consisted of one proband with retinal capillary hemangioma who also had the R161 mutation. It should be noted that this VHL mutation was stated as c.694C>T in the paper which used the Latif sequence as reference. No other affected family members were described for group 21. Other VHL lesions harbored by the patients were not specified.
p.Trp88X43M+CHB, RCC, pancreatic cyst, epididymal cyst
PatientID: 1
KindredID: 1
Case: M, 43Y0M, Ethnicity unknown
DiseaseAssertion: VHL
FamilyInfo: Positive family history but no further information
CasePresentingHPOs: HP:0010797; HP:0001737; HP:0005584; HP:0030424 (hemangioblastoma, pancreatic cyst, renal cell carcinoma, epididymal cyst)
CaseHPOFreeText: Patient had an age of diagnosis of VHL at 43
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Yes
Variant: p.W88* (c.264G>A) OR (c.263G>A) (see evidence statement)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 936684 https://www.ncbi.nlm.nih.gov/clinvar/variation/936684/ OR 182978 https://www.ncbi.nlm.nih.gov/clinvar/variation/182978/
CAID: N/A
gnomAD: N/A
VariantEvidence:N/A
MutationType: stop_gained
CivicName: W88*
MultipleGeneVariants: N/A
p.Arg161X39M+CHB, RCC, pancreatic cyst
PatientID: 5
KindredID: 4
Case: M, 39Y0M, Ethnicity unknown
DiseaseAssertion: VHL
FamilyInfo: Familial VHL mutation - Patient and their 4 relatives harbored p.Arg161X mutation - all with the same phenotypes hemangioblastoma, renal cell carcinoma and pancreatic cysts
CasePresentingHPOs: HP:0010797; HP:0005584; HP:0001737 (hemangioblastoma; renal cell carcinoma; pancreatic cysts)
CaseHPOFreeText: With an age of diagnosis of VHL at 39
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: Patients with clinical manifestations suggestive of VHL or MEN2 were first screened for VHL or RET mutation, respectively. Possible screening of RET, SDHB and SDHD as well
PreviouslyPublished: N/A
SupplementalData: Yes
Variant: p.R161* (c.481C>T)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 2217 https://www.ncbi.nlm.nih.gov/clinvar/variation/2217/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: R161* (c.481C>T)
MultipleGeneVariants: N/A
cases
Whole genome and exome sequencing of tumor-normal matched DNA of 463 patients with clinically sporadic pancreatic cancer were observed. Germline mutations were identified through next-generation sequencing (NGS) technology. One VHL gene mutation was specified: p.E52* (c.154G>T) in a patient who died due to pancreatic cancer. No family history or other phenotypic manifestations were detailed.
PatientID: V-19
KindredID: 1
Case: F, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL (Asymptomatic)
FamilyInfo: Family’s roots were traced to the German town of Leipzig in Saxony, from whence the original 11 siblings had immigrated to America around 1670. The following report is a 2011 updated pedigree on the previously reported Tisherman kindred. At the time of this study, 43/49 patients have undergone mutational analysis revealing the VHL familial mutation (Y112H) and 35/49 patients have clinical VHL manifestations. Phenotypic cumulative lifetime risk was 71% for Pheo/PGL, 15% for hemangioblastoma, 33% for retinal angioma, 3% for renal cell carcinoma, and 3% for pancreatic cysts. 6 members of the family (all deceased; 4 males, 2 females) had suspected VHL and 2 (males) of these were suspected to have had Pheo/PGL.
CasePresentingHPOs: N/A
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0005584; HP:0009711; HP:0002666; HP:0002668 (Renal cell carcinoma, Retinal capillary hemangioma, Pheochromocytoma, Paraganglioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: 9201016; 8239848 (no genetic information; only phenotypes)
SupplementalData: N/A
Variant: p.Y112H (c.334T>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2222, https://www.ncbi.nlm.nih.gov/clinvar/variation/2222/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: Y112H (c.334T>C)
MultipleGeneVariants: N/A
To our knowledge, 2 case reports have described genetically verified VHL patients with intracranial aneurysms.20, 44 Gelis et al44 reported a 26-year-old patient with a ruptured aneurysm of the middle cerebral artery and genetically proven VHL disease. Sharma and Jha20 reported a 17-year-old girl who suffered SAH of a right posterior communicating artery aneurysm. After she developed hemangioblastomas, gene sequencing revealed the mutation c.256C > T in the VHL gene (exon 1). This mutation led to a proline to serine substitution at amino acid position 86
The paper references 2 case reports which have described genetically verified VHL patients with intracranial aneurysms previously: PMID: 15492723 and 16506495. The first was a 26Y patient with genetically proven VHL disease, although unclear what the mutation is. The second was a 17-year-old girl who suffered from SAH of a right posterior communicating artery aneurysm. She later developed hemangioblastomas. Gene sequencing revealed the mutation c.256C>T in the VHL gene.
Genomic DNA was extracted from whole blood samples for genetic testing of SDHB, SDHC, SDHD, and VHL. Polymerase chain reaction–based bidirectional sequencing was performed by Mayo Medical Laboratories, Rochester, MN, or by the Division of Molecular Diagnostics, University of Pittsburgh Medical Center, as previously described [13]. Large deletions were detected using multiplex ligation-dependent probe amplification and Luminex Flex-Map Technologies [14]. None of the patients had clinical presentations suggestive of RET or NF1 mutations. Testing for MAX, TMEM127, SDHA, and SDHAF2 genes was not performed.
ArticleReferenceSequence: Not specified – Assumption: variants assumed to have been documented by the author under reference sequence NM_000551.3
GenotypingMethod: PCR–based bidirectional sequencing was performed. Large deletions were detected using multiplex ligation-dependent probe amplification (MLPA) and Luminex Flex-Map Technologies.
SamplingMethod: whole blood
his two brothers (32
PatientID: None
KindredID: 1
Case: M, 32Y0M, Danish
DiseaseAssertion: Asymptomatic
FamilyInfo: The patient's brother carried the mutation and presented with renal cell carcinoma. The patient's paternal uncle died from metastasizing RCC at 46 years of age, and the proband’s father died from urosepsis in relation to bladder cancer in situ at the age of 56. Neither of these men were able to undergo genetic testing. The patient's mother was found to carry the mutation and had breast cancer. The maternal grandmother as well as a half brother were found to harbour the mutation but were asymptomatic. See Figure 1 for family pedigree.
CasePresentingHPOs: N/A
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.P81S (c.241C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2233 https://www.ncbi.nlm.nih.gov/clinvar/variation/2233/
CAID: N/A
gnomAD: 0.0002179 https://gnomad.broadinstitute.org/variant/3-10183772-C-T
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName:P81S (c.241C>T)
MultipleGeneVariants: N/A
along with a silent mutation p.P2P (c.6C>G) in the VHL gene
PatientID: None
KindredID: 1
Case: M, 31Y0M, Danish
DiseaseAssertion: VHL
FamilyInfo: The patient's brother carried the mutation. The proband’s paternal uncle died from metastasizing RCC at 46 years of age, and the proband’s father died from urosepsis in relation to bladder cancer in situ at the age of 56. Neither of these men were able to undergo genetic testing. The patient's mother was found to carry the mutation and had breast cancer. The maternal grandmother as well as a half brother were found to harbour the mutation but were asymptomatic. The proband's child was found to have a different VHL mutation (p.P2P). See Figure 1 for family pedigree.
CasePresentingHPOs: HP:0005584 (renal cell carcinoma)
CaseHPOFreeText: The patient presented with renal cell carcinoma at age 29.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.P2= (c.6C>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 456593 https://www.ncbi.nlm.nih.gov/clinvar/variation/456593/
CAID: N/A
gnomAD: 0.000 https://gnomad.broadinstitute.org/variant/3-10183537-C-G
VariantEvidence: N/A
MutationType: synonymous_variant
CivicName: P2=(c.6C>G) and P81S(c.241C>T)
MultipleGeneVariants: Germline, VHL, c.241C>T (p.Pro81Ser)
c.293A>C (Novel)p.(Tyr98Ser)
150 index patients with pheochromocytoma/paraganglioma were evaluated. Phenotypic data were collected and germline mutations in five susceptibility genes (RET, VHL, SDHB, SDHD and SDHC) were tested. Out of 30 patients with familial presentation, 13 were clinically diagnosed as VHL syndrome. Using PCR and Sanger sequencing through peripheral blood, genetic testing confirmed a mutation at c.293A>C of the VHL gene in two unrelated probands. A 15 year old Asian Indian male presented with unilateral pheochromocytoma, sympathetic paraganglioma, renal and pancreatic cysts. Family history was positive. The second was a 31 year old Asian Indian female who presented with unilateral pheochromocytoma, CNS hemangioblastoma, and a pancreatic neuroendocrine tumor. Family history was also positive.
Genetic sequencing reported from the Hereditary Endocrine Cancer Panel at the Children’s Hospital of Philadelphia confirmed a VHL gene mutation localised to R167W that had been previously reported in a kindred from Newfoundland (Canada); none of the other genes in the panel were found to be pathogenic variants (CDC73, CDKN1B, MAX, MEN1, PRKAR1A, PTEN, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127 and TP53). Interestingly, she has no known family history of ancestors living in that region of Canada.
PMID: 30042107
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
93 families examined at the Clinical Center of the National Institutes of Health (Bethesda, MD) underwent genetic testing for germline mutations of the VHL gene. Whole blood was extracted and genomic DNA was amplified by PCR and products were sequences using a cycle sequencing kit with dye-labeled terminators and automatically sequenced. This nonsense mutation was found in a VHL type 1 family (lineage 20). The variant was reported as c.430C>T (AF010238.1) and was mapped to Q73* (c.217C>T) (NM_000551.3). This family is stated as being previously reported in PMID 7728151 and/or 8956040. Both these reports include a family presenting with this variant and it is unclear if one or both coincide with the current family.
GroupID: 97
DiseaseAssertion: VHL
GroupSize: N/A
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: VHL family found to have a germline rearrangement of the VHL gene. The number of family members included in this study is not specified.
GroupPresentingHPOs: N/A
GroupHPOFreeText: Patients within this family were found to have a clinical diagnosis of VHL disease, however, the presenting phenotypes were not specified.
GroupNotHPOs: HP:0002666 (Pheochromocytoma)
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167W (c.499C>T)
LegacyVariant: c.712C>T
CaseProblemVariantFreeText: N/A
ClinVarID: 2218, https://www.ncbi.nlm.nih.gov/clinvar/variation/2218/
CAID: N/A
gnomAD: 0.000007954, https://gnomad.broadinstitute.org/variant/3-10191506-C-T?dataset=gnomad_r2_1
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167W (c.499C>T)
MultipleGeneVariants: N/A
c.481C>T p.
Of 51 patients tested for VHL mosaic germline mutations, two returned with the c.481C>T (p.Arg161*) variant. The first was a 16 year old male presenting with several retinal haemangioblastomas and renal cysts where his first clinical manifestations presented at 16 years old and it is unknown if this is a familial variant. In this patient, next generation sequencing found 1.7% mutated allele in the blood, ddPCR found 1.9% mutated allele in the blood. The following patient returning positive. He presented with bilateral renal cell carcinoma at age 48 and had a daughter affected by the same heterozygous germline mutation. Next generation sequencing found 1.7% mutated allele in the blood and ddPCR found 1.8% mutated allele in the blood. Both of the patient were diagnosed with clinical VHL. This patient was previously published in 24301059.
In 1996, we described a 3 generation VHL 2A kindred with 11 mutation carriers. We aim to share our experience regarding the long-term follow-up of this family
PatientID: 29
KindredID: 1
Case: M, 10Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: This patient was a member of family 1, where 14/32 total patients were diagnosed with VHL. One of which (I-32) was a mutational carrier with down syndrome. The other 13 patients had varying phenotypes, including adrenal pheochromocytoma, pancreatic endocrine tumors, liver and bone metastases, paraganglioma, cerebellar, spinal, and retinal hemangioblastomas, polycythemia, and chondrosarcoma. See Fig. 1 for family pedigree.
CasePresentingHPOs: HP:0006748 (adrenal pheochromocytoma)
CaseHPOFreeText: Patient presented with his initial VHL-related clinical manifestations at 10Y0M. She had adrenal pheochromocytoma and diagnosed with VHL subtype 2A (see table 1).
CaseNotHPOs: HP:0002668 (paraganglioma)
CaseNotHPOFreeText: Patient does not have paraganglioma.
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.V166F (c.496G>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2224, https://www.ncbi.nlm.nih.gov/clinvar/variation/2224/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: V166F (c.496G>T)
MultipleGeneVariants: N/A
37 c.1-?_340+? Genomic deletion of exon 1 Familial VHL
GroupID/ KindredID: 37
DiseaseAssertion: VHL
GroupSize: 8
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: 8 registrants belonging to the same family (37) have the germline VHL deletion.
GroupPresentingHPOs: HP:0009711; HP:0010797; HP:0005584; HP:0001737 (retinal capillary hemangioma, hemangioblastoma, renal cell carcinoma, pancreatic cysts)
GroupHPOFreeText: all 8 members had hemangioblastomas, 7 had retinal capillary hemangiomas. 7 had renal cell carcinoma, 1 had pancreatic cysts, and 1 had hepatic carcinoma
GroupNotHPOs: HP:0002666; HP:0000107 (pheochromocytoma, renal cyst)
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: Exon 1 deletion (c.1-?_340+?)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: exon_loss_variant
CivicName: Exon 1 deletion
MultipleGeneVariants: N/A
4FProband1c.208G > Ap.Glu70Lys1–20, B––––14, 19
PatientID: Proband
KindredID: 4
Case: F, 20Y0M, Korean
DiseaseAssertion: VHL
FamilyInfo: Mother presented with bilateral retinal hemangioblastoma at 20Y but not genetically confirmed to have this VHL variant.
CohortInfo: Thirteen unrelated patients with germline VHL mutations who were diagnosed with VHL disease were evaluated.
CasePresentingHPOs: HP:0009711 (Retinal capillary hemangioma)
CaseHPOFreeText: Bilateral retinal hemangioblastoma at 20Y. Diagnosed with VHL Type 1.
CaseNotHPOs: HP:0002666; HP:0005584; HP:0001732; HP:0000107; HP:0010797 (Pheochromocytoma, Renal cell carcinoma, Abnormality of the pancreas, Renal cyst, Hemangioblastoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.E70K (c.208G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 43598, https://www.ncbi.nlm.nih.gov/clinvar/variation/43598/
CAID: N/A
gnomAD: 0.000004365, https://gnomad.broadinstitute.org/variant/3-10183739-G-A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: E70K (c.208G>A)
MultipleGeneVariants: N/A
PatientID: None
KindredID: 13
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: Mother of this patient was also found to harbor the c.436delC germline variant of the VHL gene and presented with spinal and cerebellar hemangioblastomas and multiple pancreatic cysts.
CasePresentingHPOs: HP:0009711; HP:0010797; HP:0005584; HP:0009726 (Retinal capillary hemangioma, Hemangioblastoma, Renal cell carcinoma, Renal neoplasm)
CaseHPOFreeText: CNS hemangioblastoma, retinal angioma, renal carcinoma and a renal tumor <3cm in size.
CaseNotHPOs: HP:0002894; HP:0002666 (Neoplasm of the pancreas, Pheochromocytoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.P146Lfs*13 (c.436del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA432421892, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.436del
gnomAD: N/A
VariantEvidence: This variant was not found in 120 alleles from normal subjects in the Brazilian population.
MutationType: deletion; minus_1_frameshift_variant
CivicName: P146fs (c.436del)
MultipleGeneVariants: N/A
5 I 0 28 1 retinal hb (17 years) T c.433C > T (p.Gln145X)
PatientID: I
KindredID: 5
Case: Sex Unknown, 28Y0M, Danish
DiseaseAssertion: VHL
FamilyInfo: 2 family members with the same VHL variant. Patient 5-II presented with 13 CNS hemangioblastomas (11Y, 13Y, 15Y and 17Y), retinal hemangioblastoma (13Y) and 2 pancreatic cysts (16Y). Patient 5-III presented with retinal hemangioblastoma (12Y), pancreatic cysts (12Y), CNS hemangioblastoma (15Y) and kidney disease (12Y).
CasePresentingHPOs: HP:0009711 (Retinal capillary hemangioma)
CaseHPOFreeText: Diagnosed with VHL at age 0Y. Presented with retinal hemangioblastoma at 17Y. Age at the end of study: 28Y.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Q145* (c.433C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 625249, https://www.ncbi.nlm.nih.gov/clinvar/variation/625249/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition; stop_gained
CivicName: Q145* (c.433C>T)
MultipleGeneVariants: N/A
8 I 15 35 6 CNS hb (15 years) 2 retinal hb (15 years) M c.319C > T and c.353 T > C (p.Arg107Cys) and (p.Leu118Pro)
PatientID: I
KindredID: 8
Case: Sex Unknown, 35Y0M, Danish
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0009711; HP:0010797 (Retinal capillary hemangioma, Hemangioblastoma)
CaseHPOFreeText: Diagnosed with VHL at age 15Y. Presented with 6 CNS hemangioblastomas (15Y) and 2 retinal hemangioblastomas (15Y). Age at the end of study: 15Y.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R107C (c.319C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351751195, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.319C%3ET
gnomAD: 0.000004522, https://gnomad.broadinstitute.org/variant/3-10183850-C-T?dataset=gnomad_r2_1
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R107C (c.319C>T)
MultipleGeneVariants: Germline, VHL, c.353T>C (p.L118P)
c.292T>C
A 37-year-old woman was admitted for adrenal diseases with bilateral adrenal tumors and multiple hepatic and pulmonary lesions for surgery. She was first diagnosed with VHL disease in 2000 due to a heterozygous c.292T>C mutation in exon 1 of the VHL gene, although methods used were unclear. Her father was also diagnosed with a VHL gene mutation. She lost 4-5-kg in 4 months, had increased daytime fatigue, and anxiety and revealed occasional past nicotine abuse. CT scan of chest, abdomen, and pelvis revealed bilateral adrenal tumors, multiple partially calcified hepatic lesions and multiple bilateral partially calcified pulmonary lesions and nodules. An MRI revealed bilateral adrenal tumors. Due to these CT and MRI findings, a diagnostic hypothesis of metastatic pheochromocytoma or adrenocortical carcinoma was made. A bilateral partial adrenalectomy, liver biopsy, and thoracoscopic atypical left lung excision were performed. Histopathologic examination confirmed bilateral pheochromocytomas and hepatic epithelioid hemangioendothelioma with pulmonary metastases. Other than father's VHL mutation, family history was not discussed.
21 missense mutations
PatientID: 1
KindredID: 81
Case: Sex unknown, Age unknown, French
DiseaseAssertion: VHL
FamilyInfo: One other member belonging to family 81 was mentioned (Patient: 9). This patient was found to have a pancreatic endocrine tumour and pheochromocytoma, without renal cell carcinoma.
CasePresentingHPOs: HP:0030405 (pancreatic endocrine tumour)
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0002666; HP:0005584 (pheochromocytoma, renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.V170G (c.509T>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351756196 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.509T%3EG
gnomAD: N/A
VariantEvidence:N/A
MutationType: missense_variant;transversion
CivicName: V170G (c.509T>G)
MultipleGeneVariants: N/A
VHL mosaicism: the added value of multi-tissue analysis
PMID: 35304467
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
In a study of 426 unrelated VHL patients, 111 were discovered to have alterations in the VHL gene. 18 novel variants were identified in VHL patients, but none were present in 200 unaffected control individuals. DNA samples from peripheral blood leukocytes underwent polymerase chain reaction (PCR) amplification, denaturing high-performance liquid chromatography (DHPLC), and direct sequence analysis of the entire coding sequence and intron-exon boundaries. Mutation G93C (c.277G>T) was identified in proband 43. Proband 43 presented with retinal capillary hemangioma and pheochromocytoma. Proband and mother were found to carry the V84L (c.250G>C) germline mutation of the VHL gene. No phenotype data was provided for the mother.
PatientID: 363
KindredID: 363
Case: Sex Unknown, 44Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0006770; HP:0009711 (Hemangioblastoma, Clear cell renal cell carcinoma, Retinal capillary hemangioma)
CaseHPOFreeText: Retinal hemangioblastoma, CNS hemangioblastoma and Clear cell renal cell carcinoma.
CaseNotHPOs: HP:0002666; HP:0000107; HP:0001732 (Pheochromocytoma, Renal cyst, Abnormality of the pancreas)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Table S1, S2 and S3
Variant: p.L184R (c.551T>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351756355, https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.551T%3EG
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: L184R (c.551T>G)
MultipleGeneVariants: N/A
PatientID: 204
KindredID: 204
Case: Sex Unknown, 45Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: Family history is positive but no details provided.
CasePresentingHPOs: HP:0010797; HP:0000107; HP:0001732 (Hemangioblastoma, Renal cyst, Abnormality of the pancreas)
CaseHPOFreeText: CNS hemangioblastoma, renal cyst and pancreatic cyst or tumor.
CaseNotHPOs: HP:0006770; HP:0002666; HP:0009711 (Clear cell renal cell carcinoma, Pheochromocytoma, Retinal capillary hemangioma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished:N/A
SupplementalData: Table S1, S2 and S3
Variant: Complete Deletion
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: deletion
CivicName: Null (Complete deletion)
MultipleGeneVariants: N/A
PatientID: 77
KindredID: 77
Case: Sex Unknown, 23Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: None
CasePresentingHPOs: HP:0010797 (hemangioblastoma )
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0009711, HP:0001737, HP:0002666, HP:0000107, HP:0006770 (retinal capillary hemangioma, pancreatic cyst, pheochromocytoma, renal cyst, clear cell renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Table S1, S2, S3.
Variant: p.R113*(c.337C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 220414 https://www.ncbi.nlm.nih.gov/clinvar/variation/220414/
CAID: CA348491 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.337C%3ET
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: R113*(c.337C>T)
MultipleGeneVariants: N/A
nt 477 G/C88Trp→CysW88CMissense
A cohort of 141 patients with hemangioblastomas of the central nervous system was analyzed. 81 patients had germline mutations in the VHL gene, analyzed through peripheral blood by Southern blotting andd SSCP analysis. This missense mutation (c.264G>C) was recorded in the paper as c.477G>C due to a difference in transcript sequence. It was found in one patient with hemangioblastomas of the central nervous system. No other phenotype described.
nt 544 A/C* 111 Ser→Arg S111R Missense 1
PatientID: 17
GroupID/ KindredID: 17
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: hemangioblastoma
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797 (hemangioblastoma)
CaseHPOFreeText: other phenotypes unknown.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.S111R (c.331A>C)
LegacyVariant: p.S111R (c.544A>C)
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351751320 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.331A%3EC
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: S111R (c.331A>C)
MultipleGeneVariants: N/A
PatientID: 10
KindredID: 10
Case: 39Y0M, Sex and Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: Recorded as a familial tumor; one other family info present (Patient ID: 9) who is a 47 year old patient with an abdominal paraganglioma
CasePresentingHPOs: HP:0002666 (pheochromocytoma)
CaseHPOFreeText: Unilateral pheochromocytoma reported with an age at diagnosis of 39 years of age.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET, SDHB/SDHC/SDHD
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Q164H (c.492G>C)
CaseProblemVariantFreeText: Paper stated this as c.491G>C; p.Q164H. cDNA position of 492 is most likely correct and matches up. Error by authors to say c.491.
LegacyVariant: N/A
ClinVarID: 618485 https://www.ncbi.nlm.nih.gov/clinvar/variation/618485/
CAID: N/A
gnomAD: 0.000007954 https://gnomad.broadinstitute.org/variant/3-10191499-G-C
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: Q164H (c.492G>C)
MultipleGeneVariants: N/A
Preimplantation genetic diagnosis using fluorescent in situ hybridization for cancer predisposition syndromes caused by microdeletions
PMID: 19278970
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
1020Fnt 430, C to T, Gln to stop
PatientID: 10
KindredID: 2735
Case: F, 20Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0030405 (pancreatic endocrine tumour)
CaseHPOFreeText: She presented with one pathologic pancreatic endocrine tumour.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Q73* (c.217C>T)
LegacyVariant: p.Q73* (c.430C>T)
CaseProblemVariantFreeText: N/A
ClinVar: 223164 https://www.ncbi.nlm.nih.gov/clinvar/variation/223164/
CAID: CA357036 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.217C%3ET
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: Q73* (c.217C>T)
MultipleGeneVariants: N/A
Germline mutations were identified in 300/469 (63%) of the families tested; 137 distinct intragenic germline mutations were detected.
GroupID/ KindredID: 113CA
DiseaseAssertion: VHL
GroupSize: N/A
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: This germline familial VHL mutation was taken from the Cambridge, Department of Pathology database, with an unknown number of members belonging to family ID Family 113CA. Table 5 lists all ID and mutations associated with individuals without detailed clinical information.
GroupPresentingHPOs: N/A
GroupHPOFreeText: Described as a VHL family without detailed clinical information. Other phenotypes are possible, however not detailed here.
GroupNotHPOs: N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.E186del (c.558_560del)
LegacyVariant: delGlu (c.771_773delGlu)
CaseProblemVariantFreeText: N/A
ClinVarID: 625264 https://www.ncbi.nlm.nih.gov/clinvar/variation/625264/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: inframe_deletion
CivicName: E186del (c.558_560delAGA)
MultipleGeneVariants: N/A
Germline mutations were identified in 300/469 (63%) of the families tested; 137 distinct intragenic germline mutations were detected.
Germline mutational data on VHL was gathered from various countries to assess variation in germline mutations that produce disease within different populations. Families were grouped according to three possible outcomes of disease: renal cell carcinoma without pheochromocytoma, renal cell carcinoma with pheochromocytoma, or pheochromocytoma alone. SSCP and denaturing gradient gel electrophoresis identified mutations in 300/469 (63%) of families affected with VHL. This germline familial VHL mutation (C162W (c.486C>G)) was taken from two databases: the Munich, university of Freiburg and Institute of Pathology database and the National Cancer Institute database. There was an unknown number of members belonging to Family IDs: 42CE and 3618NCI. It was reported in the paper as c.699C>G due to a difference in transcript reference. As reported in Table 3, this mutation is found in VHL families without pheochromocytoma, and with renal cell carcinoma. Later publications reference this cohort as being reported in PMIDs: 10458336; and 7728151.
Germline mutations were identified in 300/469 (63%) of the families tested; 137 distinct intragenic germline mutations were detected.
GroupID/ KindredID: 52CA
DiseaseAssertion: VHL
GroupSize: N/A
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: N/A
GroupAgeRange: N/A
GroupInfo: This germline familial VHL mutation was taken from the Cambridge, Department of Pathology database, with an unknown number of members belonging to Family ID 52CA. Table 3 lists all ID and mutations associated with individuals possessing renal carcinoma, without phechromocytoma.
GroupPresentingHPOs: HP:0005548 (renal cell carcinoma)
GroupHPOFreeText: Described as a VHL familywith RCC, without pheochromocytoma. Other phenotypes are likely, however not detailed in this publication
GroupNotHPOs: HP:0002666 (pheochromocytoma)
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.S65L (c.194C>T)
LegacyVariant: p.S65L (c.407C>T)
CaseProblemVariantFreeText: N/A
ClinVarID: 182975 https://www.ncbi.nlm.nih.gov/clinvar/variation/182975/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transition
CivicName: S65L (c.194C>T)
MultipleGeneVariants: N/A
Germline mutations were identified in 300/469 (63%) of the families tested; 137 distinct intragenic germline mutations were detected.
Germline mutational data on VHL was gathered from various countries to assess variation in germline mutations that produce disease within different populations. Families were grouped according to three possible outcomes of disease: renal cell carcinoma without pheochromocytoma, renal cell carcinoma with pheochromocytoma, or pheochromocytoma alone. SSCP and denaturing gradient gel electrophoresis identified mutations in 300/469 (63%) of families affected with VHL. This germline familial VHL mutation (V74G (c.221T>G)) was taken from the Munich, university of Freiburg and Institude of Pathology database (reported in Table 3, found in VHL family without pheochromocytoma, and with renal cell carcinoma) with an unknown number of members belonging to Family ID 53CE, as well as Family ID 9CE (reported in Table 4, found in VHL families with pheochromocytoma). It was reported in the paper as c.434T>G due to a difference in transcript reference. Other phenotypes are likely, however not detailed here.
von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene
PMID: 12644949
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
Subject and methodsAt age 48, a female VHL patient presented with pain in her left arm. She was diagnosed with VHL at age 25. Genetic testing of peripheral blood had confirmed a c.500G > A (p.Arg167Gln) VHL gene mutation. Her medical history included surgery for central nervous system hemangioblastomas at age 26, 28, 39 and 45 as well as a retinal hemangioma for which she underwent a coagulation procedure at age 26. Imaging studies suggested a lytic lesion in the left distal ulna (Fig. 1). A biopsy was taken that was suggestive of clear cell chondrosarcoma. Additional immunohistochemical analysis showed strong S-100 staining. Antibodies directed at cytokeratins 8, 18, AE1-3 and also inhibin, which are used for the identification of renal cell carcinoma or hemangioblastoma, were negative. Bone scintigraphy did not reveal any other bone lesions. Surgical resection resulted in complete removal of the tumor. Tumor tissue was frozen after surgery. DNA was isolated and after PCR amplification the VHL gene locus was analyzed by Sanger sequencing [3]. In addition, tumor DNA was subjected to comprehensive genetic and epigenetic analysis using an Ion Ampliseq Cancer Hotspot v2 panel (Thermo Fisher Scientific), Infinium CytoSNP-850 K and Infinium MethylationEPIC-850 K beadchip (Illumina). In parallel, tissue was processed for immunohistochemical analysis using monoclonal antibodies directed at pVHL and the pVHL-suppressed target Cyclin D1 (VHL, Cat.no. 556347, 1:200, BD Biosciences; Cyclin D1(SP4), Cat.no. 241R-15, 1:100, Cell Marque). The patient was informed and gave written permission for this case report.
PatientID: N/A (case)
KindredID: 1
Case: F, 48Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0009711; HP:0006765 (Hemangioblastoma; Retinal capillary hemangioma; Chondrosarcoma)
CaseHPOFreeText: Patient presented at 48Y with pain in her left arm. She was diagnosed with VHL at 25Y. She had surgery for CNS HB at ages 26, 28, 39, and 45Y. She also had retinal HB and underwent a coagulation procedure at 26Y. A lytic lesion was found in the left distal ulna (clear cell chondrosarcoma)
CaseNotHPOs: HP:0005584; HP:0010797 (renal cell carcinoma; hemnagioblastoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: An unspecified gene panel analysis was performed, where no additional mutations were found (except for a non-pathogenic, variant of the ATM gene (c.1810C>T; p.(Pro604Ser))).
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167Q (c.500G>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 2216, https://www.ncbi.nlm.nih.gov/clinvar/variation/2216/
CAID: N/A
gnomAD: 0.000003977, https://gnomad.broadinstitute.org/variant/3-10191507-G-A
VariantEvidence: Loss of wild type VHL during tumour development.
MutationType: missense_variant;transition
CivicName: R167Q (c.500G>A)
MultipleGeneVariants: N/A
PatientID: III-9
KindredID: 1
Case: F, 32Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: Large multigenerational family with a history of both VHL and spinocerebellar ataxia type 2 (SCA2). Screening for clinical and genetic diagnostics were gathered as well as thorough information on non-living members. See family pedigree (Fig. 1).
CasePresentingHPOs: HP:0010797; HP:0009711; HP:0000541; HP:0002542; HP:0001737; HP:0000107; HP:0030405; HP:0001272; HP:0007366; HP:0010873; HP:0001251; HP:0001260; HP:0001310 (hemangioblastoma, Retinal capillar hemangioma, Retinal detachment, Olivopontocerebellar atrophy, Pancreatic cysts, Renal cyst, Pancreatic endocrine tumor, Cerebellar atrophy, Atrophy/Degeneration affecting the brainstem, Cervical spinal cord atrophy, Ataxia, Dysarthria, Dysmetria)
CaseHPOFreeText: diagnosed with VHL in her early teenage years. She had retinal involvement beginning at the age of 13 treated by cryotherapy and laser therapy (presumably for retinal angiomas); and retinal detachment at the age of 23 requiring eye surgery. She had cysts of the pancreas and kidney detected at 22 years. She has also carried the diagnosis of OPCA since the age of 26-28 (new onset slurred speech and illegible handwriting). Patient had multiple renal cysts without renal tumours, however a large infiltrative enhancing mass in the tail of the pancreas was suggestive of a neuroendocrine/islet cell carcinoma, and liver metastatic foci
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.E160Sfs*10 (c.477delA)
LegacyVariant: c.688delA
CaseProblemVariantFreeText: c.477del, p.Glu160Serfs10 should be used. Details: 477del same as 475delA bc that codon is AAA so doesn't matter which A gets deleted: there is an A at 475 476 477 so for HGVS we say that 477 (the latter) is deleted since that follows HGVS nomenclature. Thus use c.477del: p.Glu160Serfs10
ClinVarID: 182959 https://www.ncbi.nlm.nih.gov/clinvar/variation/182959/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant
CivicName: E160fs (c.477del)
MultipleGeneVariants: SCA2 (an abnormal increase in CAG repeats in one allele of her ataxin-2 gene. This abnormal trinucleotide expansion is consistent with the diagnosis of spinocerebellar ataxia type 2)
A 23-yr-old asymptomatic female presented with a palpable mass on the left side of the neck during a routine check-up for her VHL p.Arg64Pro family-specific mutation, already previously identified in this patient’s family. No other clinical manifestations had been detected until then. Somatostatin receptor scintigraphy revealed a hotspot near the left carotid artery, indicating a paraganglioma. No hypertension or increase in catecholamines was observed. The removed 2.5-cm tumor was histopathologically a paraganglioma. At age 33, there was no recurrence, nor did the patient have other tumors. Interestingly, the VHL disease had a heterogeneous presentation in the family, with bilateral pheochromocytomas and clear cell renal carcinoma as the initial presentation in the father. In addition, the patient’s son underwent a unilateral adrenalectomy for pheochromocytoma at the age of 7.
PatientID: 4
KindredID: 4
Case: F, 23Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: The patient had a family specific p.Arg64Pro mutation, and VHL disease had a heterogeneous presentation in the family. The patient’s father initially presented with bilateral pheochromocytomas and clear cell renal carcinoma, and the patient’s son underwent unilateral adrenalectomy for pheochromocytoma at the age of 7.
CasePresentingHPOs: HP:0002668 (Paraganglioma)
CaseHPOFreeText: The patient was asymptomatic and presented with a palpable mass on the left side of the neck during a routine check-up. Somatostatin receptor scintigraphy revealed a hotspot near the left carotid artery, which indicated a paraganglioma. The paraganglioma was 2.5cm in size, and histological examination of it post-resection confirmed it was a paraganglioma. The patient did not present with any later tumors, although the length of follow-up is not specified.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R64P (c.191G>C)
ClinVarID: 2226, https://www.ncbi.nlm.nih.gov/clinvar/variation/2226/
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: R64P(c.191G>C)
MultipleGeneVariants: N/A
Three of her four sons were found to carry the mutation. Clinical screening of all 3 disclosed a 2.4-cm abdominal paraganglioma in one of them but no lesion in the other brothers.
PatientID: N/A (son 3)
KindredID: 12
Case: M, Age Unknown, Ethnicity Unknown
DiseaseAssertion: asymptomatic
FamilyInfo: His mother and two other brothers presented with the mutation. One brothers was asymptomatic, while the youngest had a paraganglioma lesion; his mother had pheo and paragangliomas
CasePresentingHPOs: N/A
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: Nothing was found through screening
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Y156C (c.467A>G)
LegacyVariant: p.Y156C
CaseProblemVariantFreeText: The publication only provides the p., the mutation was able to be deduced to p.Y156C (c.467A>G)
ClinVarID: 43600 https://www.ncbi.nlm.nih.gov/clinvar/variation/43600/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transition
CivicName: Y156C (c.467A>G)
MultipleGeneVariants: N/A
Case description: A suprasellar mass was found in a 33-year-old woman with retinal HBL and bilateral adrenal pheochromocytomas. The diagnosis of von Hippel-Lindau (VHL) disease was confirmed preoperatively not only by these clinical manifestations but also by germline mutation study. The existence of VHL disease indicated a diagnosis of HBL for the suprasellar mass. The results of our mutation study indicated that this patient had type II VHL disease, suggesting that careful follow-up is essential for the early detection of renal cell carcinoma, which is often associated with type II VHL disease. Here, we summarize the previously reported features of sellar and suprasellar HBLs.
PatientID: 1
KindredID: 1
Case: F, 33Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: her younger sister had previously undergone surgery for bilateral adrenal pheochromocytomas, a hereditary disease was suspected. No familial testing was provided
CasePresentingHPOs: HP:0006748; HP:0009711; HP:0010797; HP:0040277; HP:0009713 (adrenal pheochromocytoma; retinal capillary hemangioma; hemangioblastoma; Neoplasm of the pituitary gland; spinal hemangioblastoma)
CaseHPOFreeText: With a 10-year history of irregular menstruation, developed abdominal pain, she was found to have bilateral adrenal lesions which were subsequently removed and confirmed to be bilateral adrenal pheochromocytomas. Later, a suprasellar mass was found in a this patient with retinal HB. The diagnosis of von Hippel–Lindau (VHL) disease was confirmed preoperatively not only by these clinical manifestations but also by germline mutation study. The existence of VHL disease indicated a diagnosis of HB for the suprasellar mass.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R161Q (c.482G>A)
LegacyVariant: c.695G>A
CaseProblemVariantFreeText: N/A
ClinVarID: 182983, https://www.ncbi.nlm.nih.gov/clinvar/variation/182983/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R161Q (c.482G>A)
MultipleGeneVariants: N/A
1515, 17FbPCC, TA PGLHTN, sDMNENoNoVHLc.284C>Gbp.(Pro95Arg)No
PatientID: 15
KindredID: 1
Case: F, 17Y0M, Spanish
DiseaseAssertion: VHL
FamilyInfo: None
CohortInfo: 36 pediatric patients with pheochromocytomas and/or parangangliomas.
CasePresentingHPOs: HP:0002666, HP:0002668 (pheochromocytoma, paraganglioma)
CaseHPOFreeText: The patient was admitted due to hypertension and secondary diabetes mellitus. She was found to have a norepinephrine secreting bilateral pheochromocytoma at age 15 and a thoracic-abdominal paraganglioma at age 17.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, MAX
PreviouslyPublished: Yes source unknown.
SupplementalData: N/A
Variant: p.P95R (c.284C>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351750809 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.284C%3EG
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: P95R (c.284C>G)
MultipleGeneVariants: N/A
In the 14 VHL patients
PatientID: Case 11
KindredID: 11
Case: Gender Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0006880 (Cerebellar hemangioblastoma)
CaseHPOFreeText: No individual phenotypic information was given.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Y98C(c.293A>G)
LegacyVariant: N/A
ClinVarID: 223176, http://www.ncbi.nlm.nih.gov/clinvar/variation/223176
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: Y98C(c.293A>G)
MultipleGeneVariants: N/A
Meanwhile, it was also found that the guanine replaced the 559th cytosine on one patient and two carriers from the third family, which made the 116th leucine replaced by valine.
PatientID: II-4
KindredID: 3
Case: M, Age Unknown (deceased), Chinese
DiseaseAssertion: CNS Hemangioblastoma
FamilyInfo: The transition mutation was found and confirmed in 1 patient (II-3) and 2 carriers (III-7, IV-2). 5 members, including II-4, had hemangioblastomas of the CNS, but had all passed away before genetic testing. Could be assumed and deduced the genetics due to pedigree showing future linear relations of this mutation.
CasePresentingHPOs: HP:0010797 (hemangioblastoma)
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.L116V (c.346C>G) [assumed]
LegacyVariant: p.L116V (c.559C>G) [assumed]
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351753642 https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.346C%3EG
gnomAD: N/A
VariantEvidence: No genetic testing was done prior to death, however family history and presentation leads to this assumption
MutationType: missense_variant;transversion
CivicName: L116V (c.346C>G)
MultipleGeneVariants: N/A
TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes
PMID: 27411289
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
PatientID: None
KindredID: 2
Case: M, 11Y0M, Ethnicity unknown
DiseaseAssertion: assumed VHL
FamilyInfo: Familial/syndromic (FS) association
CasePresentingHPOs: HP:0002666; HP:0030405 (Pheochromocytoma; pancreatic neuroendocrine tumor)
CaseHPOFreeText: Benign bilateral pheochromocytoma and PNET at age 11
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: SDHB,SDHC, SDHD, and exons 10, 11, 13, 14, 15 and 16 of RET proto-oncogene
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167W (c.499C>T)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 2218 https://www.ncbi.nlm.nih.gov/clinvar/variation/2218/
CAID: N/A
gnomAD: 0.000007954 https://gnomad.broadinstitute.org/variant/3-10191506-C-T
VariantEvidence: N/A
MutationType: missense_variant; transition
CivicName: R167W (c.499C>T)
MultipleGeneVariants: N/A
germline mutations
Mutational analysis for 16 patients with clinically diagnosed VHL disease, revealed 12 germline mutations. This missense mutation was found in a 45-year-old VHL type 1 patient with hemangioblastomas of the central nervous system, renal cell carcinoma, and pancreatic cysts (proband no. 4) and no family history. HPO terms: hemangioblastoma, renal cell carcinoma, multiple pancreatic cysts.
We observed 10 different intragenic mutations in 10/15 (66.7%) patients: five missense mutations
Germline VHL mutations were found in all Korean patients who fulfilled clinical criteria for VHL disease. No mutation of VHL was detected in other patients who did not meet clinical criteria. In all cases, samples from both parents were not available and evidence of de novo mutations could not further be evaluated. Mutation (p.C162W) was detected using direct sequencing/MLPA methods in and 39Y old male patient referred to Samsung Medical Center, Seoul, Korea. Patient shows CNS hemangioblastoma and was positive for 'other' phenotypes which included either pancreatic neuroendocrine tumors, renal cysts, pancreatic cysts, or central nervous system tumors. The patient had a negative family history for VHL disease but details were not available. ACMG PP4
DIP–22–22Renal cysts, pancreatic cyst, and accessory spleen1
PatientID: IP (Proband)
KindredID: D
Case: F, 22Y0M, Hungarian
DiseaseAssertion: VHL
FamilyInfo: Index patient was a young woman who presented with cerebellar hemangioblastoma, multiple renal cysts, retinal detachment with vitreous hemorrhage, pancreatic cyst, spinal cord hemangiomas, and recurrence of the cerebellar lesion. Family members were not available for clinical and genetic screening, but family history revealed that the patient's father died of metastatic renal cell carcinoma.
CasePresentingHPOs: HP:0006880; HP:0005562; HP:0001737; HP:0000541; HP:0007902; HP:0009713 (Cerebellar hemangioblastoma, Multiple renal cysts, Pancreatic cysts, Retinal detachment, Vitreous hemorrhage, Spinal hemangioblastoma)
CaseHPOFreeText: Patient underwent surgery for cerebellar hemangioblastoma at the age of 22 years. Multiple renal cysts and retinal detachment with vitreous hemorrhage were also observed. At the age of 26 years, pancreatic cyst, spinal cord hemangiomas, and recurrence of the cerebellar lesion were found. Diagnosed with VHL Type 1.
CaseNotHPOs: HP:0002666; HP:0009711; HP:0005584 (Pheochromocytoma, Retinal capillary hemangioma, Renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: Exon 2 Deletion (c.341-?_463+?del)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: exon_loss_variant
CivicName: Exon 2 Deletion
MultipleGeneVariants: N/A
PatientID: 11
KindredID: 11
Case: F, 24Y0M, Ethnicity Unknown
DiseaseAssertion: Adrenal pheochromocytoma
FamilyInfo: N/A
CasePresentingHPOs: HP:0006748 (adrenal pheochromocytoma)
CaseHPOFreeText: The patient was found to have a single benign tumour 9 cm in size in her adrenal gland.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET/SDHC/SDHB/SDHD
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Y98H (c.292T>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVar: 2223 https://www.ncbi.nlm.nih.gov/clinvar/variation/2223/
CAID: N/A
gnomAD: 0.00001343 https://gnomad.broadinstitute.org/variant/3-10183823-T-C
VariantEvidence: The patient had LOH of SDHB as indicated in Table 1.
MutationType: missense_variant;transition
CivicName: Y98H (c.292T>C)
MultipleGeneVariants: N/A
We report on a Japanese VHL family
PatientID: 2
KindredID: 1
Case: F, 39Y0M, Japanese
DiseaseAssertion: assumed VHL
FamilyInfo: Her older daughter (P1) with cerebellar hemangioblastoma, retinal capillary hemangioma, pancreatic cysts and a hearing impairment, and her younger daughter (P3) with cerebellar hemangioblastoma, spinal cord tumor, retinal capillary hemangioma, pancreatic and renal cysts both had the p.P86L VHL mutation. Her husband did not.
CasePresentingHPOs: HP:0006880; HP:0009711 (Cerebellar hemangioblastoma; retinal capillary hemangioma)
CaseHPOFreeText: At age 39, suffering from retinal angiomas and a cerebellar hemangioblastoma, she underwent surgery for removal of the brain tumor in another hospital. After the operation she suffered from left facial palsy.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.P86L (c.257C>T)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 182977 https://www.ncbi.nlm.nih.gov/clinvar/variation/182977/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: P86L (c.257C>T)
MultipleGeneVariants: N/A
detected point germline vhl mutations in 14 patients
PatientID: 13
KindredID: 13
Case: 20Y0M, sex unknown, ethnicity unknown
DiseaseAssertion: VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0010797; HP:0009711 (hemangioblastoma; retinal capillary hemangioma)
CaseHPOFreeText: See Table 1&2 for retinal capillary hemangioma information
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Y98N (c.292T>A)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: N/A
CAID: CA351750883 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.292T%3EA
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: Y98N (c.292T>A)
MultipleGeneVariants: N/A
R238W
PatientID: None
KindredID: 386
Case: F, 41Y0M, Polish
DiseaseAssertion: Pheochromocytoma
FamilyInfo: Of the patient’s three sons, two carried the mutation; one son presented with unilateral pheochromocytoma at 15Y, and another son presented with bilateral pheochromocytoma at 11Y.
CasePresentingHPOs: HP:0002666 (Pheochromocytoma)
CaseHPOFreeText: The patient presented with bilateral pheochromocytoma at 41Y.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167W(c.499C>T)
LegacyVariant: p.R238W(c.712C>T)
ClinVarID: 2218, http://www.ncbi.nlm.nih.gov/clinvar/variation/2218
gnomAD: 3:10191506 C / T, http://gnomad.broadinstitute.org/variant/3-10191506-C-T
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167W(c.499C>T)
MultipleGeneVariants: N/A
B3 CHB 40 c.713G → A, R167Q No 1 y 11 m Phaeo 41 y 2 FDRs mutation positive: (i) HB 18 y, RA 18 y; (ii) renal cyst 17 y
PatientID: B3
KindredID: 3
Case: Sex Unknown, 41Y11M, Ethnicity Unknown
DiseaseAssertion: Assumed VHL
FamilyInfo: The patient (B3) had two first degree relatives who were positive for the VHL mutation. The first family member had a hemangioblastoma and retinal angioma at 18 years old and the second family member had a renal cyst at 17 years old.
CasePresentingHPOs: HP:0006880; HP:0002666 (cerebellar hemangioblastoma, pheochromocytoma)
CaseHPOFreeText: The patient was diagnosed with the cerebellar hemangioblastoma at the age of 40 and after a follow up 1 year 11 months later was found to have a pheochromocytoma at the age of 41
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R167Q (c.500G>A)
LegacyVariant: p.R167Q (c.713G>A)
ClinVarID: 2216 (https://www.ncbi.nlm.nih.gov/clinvar/variation/2216/)
CAID: N/A
gnomad: 0.000003977 (https://gnomad.broadinstitute.org/variant/3-10191507-G-A)
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: R167Q (c.500G>A)
MultipleGeneVariants: N/A
the patient’s mother aged 38 was diagnosed with bilateral pheochromocytoma resected when she was the age of 18 years. She presented several relapses, the most recent one at the age of 32, when she was also diagnosed with cerebral angioma. Genetic testing revealed the presence of the VHL c 244 C>G (p. Arg 82 Gly) heterozygote mutation, while the tests for RET, SDHB, SDHC and SDHD were negative.
PatientID: None
KindredID: 1
Case: F, 38Y0M, Ethnicity Unknown
DiseaseAssertion: VHL
FamilyInfo:
CasePresentingHPOs: HP:0002666; HP:0001028 (Pheochromocytoma, Hemangioma)
CaseHPOFreeText: Was diagnosed with bilateral pheochromocytoma resected when she was the age of 18 years. She presented several relapses, the most recent one at the age of 32, when she was also diagnosed with cerebral angioma.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: RET, SDHB, SDHC, SDHD
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R82G (c.244C>G)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 1297059, https://www.ncbi.nlm.nih.gov/clinvar/variation/1297059/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: R82G (c.244C>G)
MultipleGeneVariants: N/A
Frequent Genetic Changes in Childhood Pheochromocytomas
PMID: 17102083
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
Gene copy number analysis based on quantitative PCR revealed partial deletion of Exon 1 in VHL gene in the peripheral blood, brainstem hemangioblastoma and meningiomas.
ArticleReferenceSequence: Not specified- Assumption: Nucleotide change is not specified in the paper, nor protein coding change. Reported based on VHL reference sequence NM_000551.3
GenotypingMethod: Gene copy number analysis based on quantitative PCR
SamplingMethod: Peripheral blood and tumor tissue
Of the 13 individuals tested, V:2, IV:4, IV:6, III:2, III:3, and III:11 were all found to carry the P25L mutation in the VHL gene.
PatientID: III:2
KindredID: 1
Case: F, 62, Ethnicity Unknown
DiseaseAssertion: Asymptomatic
FamilyInfo: The patient's father (II:3) had a brain tumour at age 53 and died at age 78. The patient's paternal aunt (II:1) died of stomach cancer at age 80. The patient's paternal grandfather died at age 50 due to a brain tumour. The patient had three children all of whom carried the P25L mutation and were asymptomatic (IV:4 and IV:6) except patient IV:2 who presented with a retinal hemangioma and renal cyst. Her daughter (IV:2) had three children and one was found to carry the mutation. The patient had seven siblings, five of whom underwent genetic testing. Two were found to carry the mutation but both were asymptomatic (patient III:3 and III:11). Patient III:3 had six children one of whom died due to clear cell renal carcinoma at age 48 but did not carry the P25L mutation. Of the 13 family members tested, V:2, IV:4, IV:6, III:3, and III:11 were all found to carry the P25L mutation in the VHL gene. Refer to Figure 1 for pedigree.
CasePresentingHPOs: N/A
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.P25L (c.74C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 93330 https://www.ncbi.nlm.nih.gov/clinvar/variation/93330/
CAID: N/A
gnomAD: 0.002988 https://gnomad.broadinstitute.org/variant/3-10183605-C-T
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName:P25L (c.74C>T)
MultipleGeneVariants: N/A
R167L
301 were enrolled in a prospective clinical protocol to evaluate the natural history of vHL-associated pancreatic lesions (NCT00062166). Of these, 69 patients with pancreatic manifestations of vHL disease and missense VHL mutations were included in the current study. Individual patient phenotype was not described, but overall of the 60 patients, 57 had RCC, 41 had CNS hemangioblastomas, 28 had retinal hemangioblastoma, 23 had pheochromocytoma. 36/69 patients were female and the mean age was 50.5 years old. All patients underwent genetic testing using Sanger sequencing and Southern Blotting. Two patients were listed with this missense mutation, c.500G>T.
S111N (30) 4
GroupID: None
DiseaseAssertion: VHL
GroupSize: 4
GroupNumberMales:N/A
GroupNumberFemales:N/A
GroupEthnicity: N/A
GroupAgeRange: ≥12
GroupInfo: The four patients were grouped by mutation.
GroupPresentingHPOs: HP:0001732 (abnormality of the pancreas)
GroupHPOFreeText: N/A
GroupNotHPOs:N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.S111N (c.332G>A)
CaseProblemVariantFreeText: N/A
LegacyVariant: N/A
ClinVarID: 223186 https://www.ncbi.nlm.nih.gov/clinvar/variation/223186/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: S111N (c.332G>A)
MultipleGeneVariants: N/A
W117C (20) 2
GroupID: None
DiseaseAssertion: VHL
GroupSize:2
GroupNumberMales:N/A
GroupNumberFemales:N/A
GroupEthnicity: N/A
GroupAgeRange: ≥12
GroupInfo: The two patients were grouped by mutation.
GroupPresentingHPOs: HP:0001732 (abnormality of the pancreas)
GroupHPOFreeText: N/A
GroupNotHPOs:N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.W117C (c.351G>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 167827 https://www.ncbi.nlm.nih.gov/clinvar/variation/167827/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: W117C (c.351G>T)
MultipleGeneVariants: N/A
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
PMID: 26984080
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
The coding exons and flanking regions of genes implicated in PHEO/PGL (MYC associated factor X (MAX; {"type":"entrez-nucleotide","attrs":{"text":"NM_002382.3","term_id":"21704260","term_text":"NM_002382.3"}}NM_002382.3), rearranged during transfection tyrosine kinase receptor gene (RET; {"type":"entrez-nucleotide","attrs":{"text":"NM_020975.4","term_id":"126273511","term_text":"NM_020975.4"}}NM_020975.4), succinate dehydrogenase subunit A (SDHA; {"type":"entrez-nucleotide","attrs":{"text":"NM_004168.3","term_id":"661567358","term_text":"NM_004168.3"}}NM_004168.3), succinate dehydrogenase complex assembly factor 2 (SDHAF2; {"type":"entrez-nucleotide","attrs":{"text":"NM_017841.2","term_id":"300795354","term_text":"NM_017841.2"}}NM_017841.2), succinate dehydrogenase subunit B (SDHB; {"type":"entrez-nucleotide","attrs":{"text":"NM_003000.2","term_id":"115387093","term_text":"NM_003000.2"}}NM_003000.2), succinate dehydrogenase subunit C (SDHC; {"type":"entrez-nucleotide","attrs":{"text":"NM_003001.3","term_id":"78711818","term_text":"NM_003001.3"}}NM_003001.3), succinate dehydrogenase subunit D (SDHD; {"type":"entrez-nucleotide","attrs":{"text":"NM_003002.2","term_id":"222352156","term_text":"NM_003002.2"}}NM_003002.2), transmembrane protein 127 (TMEM127; {"type":"entrez-nucleotide","attrs":{"text":"NM_017849.3","term_id":"305682550","term_text":"NM_017849.3"}}NM_017849.3), fumarate hydratase (FH; {"type":"entrez-nucleotide","attrs":{"text":"NM_000143.3","term_id":"299758401","term_text":"NM_000143.3"}}NM_000143.3), neurofibromatosis type I (NF1; {"type":"entrez-nucleotide","attrs":{"text":"NM_001042492.2","term_id":"270132520","term_text":"NM_001042492.2"}}NM_001042492.2), malate dehydrogenase 2 (MDH2; {"type":"entrez-nucleotide","attrs":{"text":"NM_005918.3","term_id":"538919612","term_text":"NM_005918.3"}}NM_005918.3), Endothelial PAS domain protein 1 (EPAS1; exon 9 and 12, {"type":"entrez-nucleotide","attrs":{"text":"NM_001430","term_id":"1519312014","term_text":"NM_001430"}}NM_001430) and von Hippel-Lindau gene (VHL; {"type":"entrez-nucleotide","attrs":{"text":"NM_000551.3","term_id":"319655736","term_text":"NM_000551.3"}}NM_000551.3)) were analyzed using a combination of next-generation sequencing (NGS, Illumina Miseq TSCA Librairies) and multiplex ligand probe assay (MLPA). The allelic variants found by NGS were confirmed using Sanger method. In silico analysis of variants was performed using Polyphen2 (http://genetics.bwh.harvard.edu/pph2/), UMD-predictor® [4], and ALAMUT 2.2.0 (http://www.interactive-biosoftware.com/) software. Blood samples for genomic DNA analysis were taken after written informed consent and patient gave written (signed) informed consent after being given a detailed explanation of the publication. Genetic researches were carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki).
ArticleReferenceSequence: NM_000551.3
GenotypingMethod: A combination of next-generation sequencing (NGS, Illumina Miseq TSCA Librairies) and multiplex ligand probe assay (MLPA) analyzed a gene panel. The allelic variants found by NGS were confirmed using Sanger method. In silico analysis of variants was performed using Polyphen2 (http://genetics.bwh.harvard.edu/pph2/), UMD-predictor® [4], and ALAMUT 2.2.0 (http://www.interactive-biosoftware.com/) software.
SamplingMethod: Blood
A female patient was diagnosed with a 3cm, right adrenal, metanephrine-secreting (PHEO) at age 47, and 11 years later, developed a Furhman grade I-II RCC with typical features of clear cell type. She remains disease-free after 18 and 7 years of follow up, respectively. She had two siblings with PHEOs, detected at 44 and 51 years of age, but no other RCCs. A germline truncating TMEM127 mutation, c.532_533dupT; p.Y178LfsX48, hereafter referred to as TMEM127-532dupT, was identified after a targeted, exome-based next generation sequencing screening (Fig.1C). No other pathogenic germline mutation was detected in other 35 pheochromocytoma and/or renal cancer susceptibility genes screened. Furthermore, no somatic mutations were found at high-depth sequencing (average 180x) of the proband’s frozen PHEO using Illumina TruSeq Cancer Panel screening of 42 cancer genes. The TMEM127-532dupT mutation was also detected in germline DNA from one affected sister (Fig.1A, ,1B)1B) and three other family members, their mother and two brothers, who have no evidence of PHEO or RCC (Fig. 1A). The proband’s mother was diagnosed with a lung adenocarcinoma at age 78. Analysis of the proband’s fresh-frozen PHEO DNA revealed loss of the wild-type TMEM127 allele (Fig.1B). These results support the germline TMEM127 mutation as the main driver event in this family (Qin et al. 2010). In contrast, no TMEM127 loss was found in three separate regions dissected from the proband’s formalin-fixed paraffin embedded (FFPE) RCC (Fig.1C). Similar to the proband’s PHEO, the FFPE PHEO from the proband’s sister displayed clear loss of heterozygosity (LOH) of the wild-type allele (Fig.1C), excluding potential artifacts due to fixed tissue quality. The lack of TMEM127 LOH in the RCC is in agreement with our earlier observation of retention of heterozygosity in a limited set of renal cancers with germline TMEM127 mutations(Qin et al. 2014). Interestingly, in this earlier report we noted decreased TMEM127 transcription in the tumors carrying these heterozygous variants, potentially suggesting a dosage effect of the TMEM127 mutation in renal tissue.Open in a separate windowFigure 1A) Partial pedigree of a family with a germline TMEM127 mutation (c.532dupT, p.Y178LfsX48). Clinical features are indicated in the labels. Clinically unaffected mutation carriers are 87 (I-2), 62 (II-3) and 60 (II-4) years old. One additional, 54-year-old sibling (not shown) is negative for the mutation. B) Electropherograms of germline DNA from the proband (II-1) and one affected sister (II-2), and fresh-frozen PHEO from the proband, compared to the reference sequence. The single nucleotide insertion site is indicated with an arrow; the PHEO sample has no wild-type allele sequence. C) Electropherograms of archival, formalin-fixed and paraffin embedded tumor DNA: PHEO from affected sister and three separate subregions of the proband’s RCC, referred to as RCC-1, RCC-2 and RCC-3, compared to the reference sequence. Note loss of the wild-type allele in the PHEO but not in the RCC subregions. D) Western blot of lysates from the proband’s PHEO, two unrelated PHEOs carrying distinct TMEM127 mutations, and four PHEOS of other genetic backgrounds (mutated gene indicated), a separate gel of HEK293T cells expressing wild-type or c.532dupT TMEM127 construct containing an HA tag are shown to indicate the expected size of truncated c.532dupT TMEM127; Membranes were probed with TMEM127 (Bethyl Labs), phospho-Thr389- S6 kinase (S6K) and total S6K (Cell Signaling Technology), and β-actin (Sigma) as a loading control. E) Confocal microscopy images of HEK293T cells transiently transfected with GFP-tagged wild-type (WT) TMEM127 and GFP-TMEM127-532dupT mutant protein; a previously reported pathogenic mutant, GFP-TMEM127-S147del, was included as a positive control. WT-TMEM127 has a punctate pattern, S147del is diffusely distributed, and 532dupT is predominantly diffuse. F) GuideRNA (sgRNA) sequence used to genome-edit HEK293 cells, indicating the protospacer adjacent motif (PAM) sequence and the position of the nucleotide insertion of a clone. Corresponding electropherogram is shown below (arrow indicates inserted T at position c.532 on the TMEM127 sequence).G) Western blot of lysates from HEK293 control and 532dupT cells after amino acid starvation followed by exposure for 15 minutes. No TMEM127 protein is detected in the HEK293-TMEM127-532dupT cells. Phosphorylation of mTOR targets S6 kinase (S6K) and downstream S6 are shown and β-actin was used as a loading control. H) Electropherograms of germline and tumor samples spanning a VHL 3’UTR SNP (dbSNP rs1642742) used to estimate copy number at the VHL gene. DNA from proband’s germline and archival RCCs, as well as PHEO from proband and her sister PHEO. Percentage of the ‘A’ allele representation of each sample was estimated by the Mutation Surveyor program, as reported(Toledo, et al. 2016).To further investigate whether the TMEM127-532dupT mutation was pathogenic, we explored its consequences in tumor tissue. No frozen material was available from the RCC and, in the absence of a reliable TMEM127 antibody for immunohistochemistry, no additional analysis of TMEM127 protein was available from this tumor. However, Western blot of protein lysates from the proband’s frozen PHEO using a polyclonal antibody that recognizes the TMEM127 N-terminus (Bethyl labs) (Qin et al. 2014) revealed neither full-length nor truncated TMEM127 bands (Fig 1D). Other TMEM127-mutant PHEOS included as controls also showed no TMEM127 expression, while TMEM127 protein was clearly detectable in PHEOs of other genetic origins but with intact TMEM127 sequence (Fig.1D), in support of instability of mutant TMEM127 protein. In addition, in agreement with our previous observations suggesting that the mTORC1 kinase pathway is activated after TMEM127 loss (Qin et al. 2010), phosphorylation of the mTORC1 downstream target S6 kinase (S6K) was increased in the TMEM127-532dupT PHEO and in the other TMEM127 mutant tumors, compared to TMEM127 wild-type PHEOs (Fig.1D).Next, we examined TMEM127 subcellular distribution as another functional readout by expressing in HEK293T kidney cells a construct carrying this mutation fused with a green fluorescent protein (GFP) made by site directed mutagenesis, as described (Qin et al. 2010). The TMEM127-532dupT mutant showed a diffuse cytoplasmic pattern, similar to a previously reported pathogenic TMEM127 mutant (Qin et al. 2014), but distinct from the punctate endomembrane distribution of wild type TMEM127 (Fig.1E). We were unable to generate cells that retained stable expression of this mutant, further supporting its instability. To study the effects of the mutation in a more physiological context in renal cells, we generated HEK293 cells carrying homozygous TMEM127-532dupT mutation by CRISPR-Cas9-based genome modification using previously published protocols(Sanjana, et al. 2014) and a guide RNA that targeted the mutated nucleotide site or a control (Fig.1F). Stable clones carrying the c.532dupT mutation in homozygosity were obtained and verified by sequencing (Fig 1F). Similar to the proband’s PHEO, HEK293 TMEM127-532dupT cells had no detectable TMEM127 protein (Fig1G). Moreover, incubation of these cells with amino acids following 2 hours of amino acid deprivation, a powerful mTORC1 pathway activation input(Sancak, et al. 2010), led to higher mTOR target phosphorylation in HEK293 TMEM127-532dupT cells compared with control (Fig. 1G), suggesting that kidney cells with mutant TMEM127-532dupT have increased mTORC1 activation. Taken together, our data indicate that the TMEM127-532dupT mutation leads to loss of TMEM127 function both in primary PHEO and in renal cells, consistent with its pathogenic role.In view of the lack of TMEM127 LOH in the RCC, we investigated other possible genetic causes. Immunohistochemistry for SDHB was positive, excluding an SDH mutation. We sequenced the coding region of the VHL gene in three subsections of proband’s RCC and found no mutations. We also evaluated VHL copy number using a SNP located in the 3’UTR of the gene (dbSNP rs1642742, c.*294G>A) that was heterozygous in the proband germline
PatientID: N/A (case)
KindredID: 1
Case: F, 56Y0M, Ethnicity Unknown
DiseaseAssertion: pheochromocytoma
FamilyInfo: She had two siblings with pheochromocytoma (PHEO), detected at 44 and 51 years of age, but no other renal cell carcinomas (RCC).
CasePresentingHPOs: HP:0006770; HP:0002666 (clear cell renal cell carcinoma, pheochromocytoma)
CaseHPOFreeText: Patient was diagnosed with a right adrenal pheochromocytoma at 47Y0M, and 11 years later, developed renal cell carcinoma with typical features of clear cell type. She remains disease-free after 18 from initial diagnosis. Patient’s mother was diagnosed with a lung adenocarcinoma at age 78. The initially identified TMEM127-532dupT mutation was detected in the germline DNA from one affected sister and three other family members, the mother and two brothers, who do not have f PHEO or RCC.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: TMEM127
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: c.*294G>A
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 342407, https://www.ncbi.nlm.nih.gov/clinvar/variation/342407/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: 3_prime_UTR_variant
CivicName: c.*294G>A
MultipleGeneVariants: Germline, TMEM127, c.532_533dupT (p.Y178Lfs*48)
Twelve (75%) of 16 gene carriers were found to have ocular hemangioblastomas(Figure 1 and Figure 2), and 7 of these had bilateral disease (Table 1). The mean number of angiomas was 3.3. However, 1 individual had 22 angiomas, most of which were in an area of previous exudative retinal detachment (see the "Comment" section) (Table 2). Exclusion of this individual resulted in a mean number of angiomas of 2.1. Six eyes had optic disc angiomas (Figure 2). Six of the 19 eyes with ocular hemangioblastomas had visual acuity less than 20/40. Two patients had no light perception in one or both eyes. The average age at diagnosis of ocular angiomatosis was 37 years.
PatientID: 2
KindredID: 1
Case: Sex Unknown, 24Y0M, Ethnicity Unknown
DiseaseAssertion: asymptomatic
FamilyInfo: Significant family history. Pedigree follows 8 generations (see Figure 3). Family immigrated to Iowa, US, from Baden-Baden, Germany, in 1832; Likely sharing a common ancestor to the traced lineage of the Black Forest region of Germany.
CasePresentingHPOs: None
CaseHPOFreeText: N/A
CaseNotHPOs: HP:0010797; HP:0002666; HP:0009711; HP:0005584 (hemangioblastoma, pheochromocytoma; retinal capillary hemangioma; renal cell carcinoma)
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Y98H (c.292T>C)
LegacyVariant: p.Y98H (c.505T>C)
CaseProblemVariantFreeText: N/A
ClinVar: 2223 https://www.ncbi.nlm.nih.gov/clinvar/variation/2223/
CAID: N/A
gnomAD: 0.00001343 https://gnomad.broadinstitute.org/variant/3-10183823-T-C
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: Y98H (c.292T>C)
MultipleGeneVariants: N/A
Sinonasal renal cell-like adenocarcinoma arising in von Hippel Lindau (VHL) syndrome
PMID: 34998175
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
Lung adenocarcinoma has never before been reported to be associated with von Hippel-Lindau (VHL) disease. Here, we report a case of VHL disease in a patient who had metachronous multiple lung adenocarcinomas. The patient is a 64-year-old-woman with VHL disease. She underwent surgical resection of one adenocarcinoma and one atypical adenomatous hyperplasia. A second lung adenocarcinoma developed metachronously. A point mutation in the VHL gene was confirmed in DNA from a blood sample, and loss of heterozygosity at the VHL locus was detected in the lung adenocarcinoma. The VHL dysfunction may have a role in the development of multiple lung adenocarcinomas.
PatientID: 1
KindredID: 1
Case: F, 64Y0M, Japanese
DiseaseAssertion: VHL
FamilyInfo: Her father was killed in an accident when she was young. Her older brother died of renal cell carcinoma associated with VHL disease at the age of 58. Her younger sister was also diagnosed with renal cell carcinoma that was associated with VHL disease. No members past the proband had been genetically tested.
CasePresentingHPOs: HP:0006880; HP:0030078; HP:0005584; HP:0001737 (cerebellar hemangioblastoma; lung adenocarcinoma; renal cell carcinoma; pancreatic cysts)
CaseHPOFreeText: of a hemangioblastoma of the cerebellum when she was 37 years old. Her right kidney was resected because of renal cell carcinoma at the age of 59. Concurrently, she received a pancreatojejunostomy for a pancreatic cyst. At the age of 63, radiofrequency ablation was performed for renal cell carcinoma of her left kidney. In the same year, computed tomography screening of the patient’s lungs detected nodules in the right middle lobe and left upper division. A computed tomography–guided needle biopsy of the nodule in the right middle lobe resulted in a diagnosis of adenocarcinoma (Fig 1). We concurrently performed a lobectomy of the patient’s right middle lobe and a partial resection of the left upper division.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.S65L (c.194C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 182975, https://www.ncbi.nlm.nih.gov/clinvar/variation/182975/
CAID: N/A
gnomAD: https://gnomad.broadinstitute.org/variant/3-10183725-C-T
VariantEvidence: Loss of heterozygosity (LOH) at the VHL locus was detected in the lung adenocarcinoma. The hepatic adenocarcinoma was found with somatic EGFR mutations and loss of heterozygosity at the VHL locus; authors speculate that dysfunctional pVHL may promote mutations on the EGFR gene.
MutationType: missense_variant;transition
CivicName: S65L (c.194C>T)
MultipleGeneVariants: N/A
12 missenses
GroupID/ KindredID: 4
DiseaseAssertion: assumed VHL
GroupSize: 3
GroupNumberMales: N/A
GroupNumberFemales: N/A
GroupEthnicity: Chinese
GroupAgeRange: N/A
GroupInfo: With a family history, 3 family members were recorded in this group with the given mutation.
GroupPresentingHPOs: HP:0010797; HP:0009711; HP:0001732 (hemangioblastoma; retinal capillary hemangioma; pancreatic lesion)
GroupHPOFreeText: 2 members had CNS hemangioblastomas, 1 member had retinal angiomas, and 1 had pancreatic cysts or tumors (an abnormality of the pancreas)
GroupNotHPOs: HP:0005584; HP:0002666 (renal cell carcinoma, pheochromocytoma)
GroupNotHPOFreeText: No family members appeared to have the above manifestation.
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.V74G (c.221T>G)
CaseProblemVariantFreeText: N/A
LegacyVariant: p.V74G (c.434T>G)
ClinVarID: N/A
CAID: CA70042528 http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.221T%3EG
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant; transversion
CivicName: V74G (c.221T>G)
MultipleGeneVariants: N/A
c.463+
All patients that were operated between 1995 and 2010 in the University Medical Center Groningen from who frozen hemangioblastoma tissue was available in the tissue bank of the Department of Pathology were eligible. One patient sample was confirmed with this germline splice mutation in the VHL gene, reported as c.463+3A>C in the supplemental information. Should note that the only time the text mentions a splice site mutation however is at: c.463+2T>C p.(?). No other phenotypic or demographic information was available.
In 1998, a 20-year-old male was admitted to the General Hospital of Tianjin Medical University (Tianjin, China) with symptoms of dizziness, unsteadiness and nausea for three weeks, as well as vomiting for one week. Magnetic resonance imaging (MRI) revealed a mass in the cerebellar vermis and surgery was performed to excise the tumor. The pathological examination identified a hemangioblastoma. Three years later, the patient was readmitted to hospital due to dizziness lasting for one week. An MRI examination showed recurrence of the hemangioblastoma in the cerebellum and the patient underwent surgery to resect the tumor. In April 2012, the patient was readmitted to hospital for the third time due to jaundice. An enhanced computed tomography (CT) scan of the abdomen revealed multiple RCCs in the kidneys, and a nodule with a rich blood supply in the pancreatic head. In addition, numerous cysts were identified throughout the pancreas (Fig. 1). These observations were confirmed by magnetic resonance cholangiopancreatography, which revealed that the nodule in the pancreatic head was ~2.9×2.2 cm in size and possibly a NET. Due to the size and location of the tumor, the bile duct in the pancreas was compressed and the upper parts of the common bile and hepatic ducts were dilated. Since it was not possible to excise the RCCs, the patient also refused surgery to resect the pancreatic head mass. A metallic stent was placed at the stenosis site of the common bile duct, which alleviated the jaundice (Figs. 2 and and3).3). Nine months later, the patient returned to the hospital with a fever, abdominal pain and jaundice. An enhanced abdominal CT was performed, which revealed no change in the size of the pancreatic head mass. The patient’s symptoms were relieved following anti-inflammatory therapy for one week. However, the patient continued to suffer the same symptoms every two months, and gradually, anti-inflammatory therapy failed to alleviate the symptoms. Radiography tests revealed complete blockage of the stent and thus, percutaneous transhepatic cholangiography (PTCD) surgery was performed.
PatientID: 1 (proband)
KindredID: 1
Case: M, 34Y0M, Ethnicity Unknown
DiseaseAssertion: assumed VHL
FamilyInfo: Recorded family history of VHL disease, with the patient’s mother, grandmother, two uncles and three aunts also suffering from the disease. Additionally, one uncle had succumbed to RCC and five other individuals in the family had succumbed to cerebral hemangioblastomas. No mutation was stated.
CasePresentingHPOs: HP:0006880; HP:0005584; HP:0030405 (cerebellar hemangioblastoma; renal cell carcinoma; pancreatic endocrine tumour)
CaseHPOFreeText: At 20Y was admitted to hospital with symptoms of dizziness, unsteadiness and nausea for three weeks, as well as vomiting for one week (cerebellar hemangioblastoma found in MRI); reoccured at 23Y. At 34Y patient had jaundice (multiple RCCs in the kidneys, and a nodule with a rich blood supply in the pancreatic head observed through CT). Numerous cysts were also identified throughout the pancreas (a possible PNET).
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.L158P (c.473T>C)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 182980 https://www.ncbi.nlm.nih.gov/clinvar/variation/182980/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transition
CivicName: L158P (c.473T>C)
MultipleGeneVariants: N/A
PMID: 21528239
Two Swedish families with von Hippel-Lindau disease (VHL) were analyzed. Family A was previously reported (PMID 7700111; Wiklund et al., 1995) and the following provides an update on the family. Family A consists of 21 individuals over four generations, 8 of which are carriers, affected by, or suspected to be affected by VHL disease. 3 of the 8 members had died from VHL related tumors, and it is unclear if they were genetically tested for the family mutation. Genetic analysis from available blood samples revealved a germline familial VHL frameshift mutation S183fs (c.548delC, originally written in paper as legacy notation c.761delC). The remaining 5 of the 8 family members were found with this mutation, identifying 3 individuals with VHL disease, 1 individual who developed VHL disease during the time of the study (renal carcinoma and symptomatic cerebellar hemangioma), and 1 asymptomatic carrier. Individual patient phenotypic and demographic data was not available. The paper does describe that overall, 5 of the 8 family members had renal carcinoma, 5/8 multiple cerebellar hemangiomas, 2/8 angiomatosis retinae and 1/8 had an epidymidal tumor. ACMG: PP4 PP1
Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease
PMID: 9402176
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
3.2. Molecular analysisSNP Array Assay: Samples were processed with a formalin-fixed, paraffin-embedded optimized protocol based on the GeneChip Mapping 10 K Xba or 250 K Nsp Assay Kits (Affymetrix, Santa Clara, CA). For quality control, polymerase chain reaction products were analyzed by capillary electrophoresis with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). All samples passed quality control. The samples were then hybridized on GeneChip Mapping 10 K 2.0 or 250 K Nsp arrays (Affymetrix), for 16 hours at 48°C in a GeneChip 450 hybridization oven (Affymetrix) at 60 rpm. The arrays were washed and stained according to the manufacturer’s genotyping protocol for each array type.
ArticleReferenceSequence: Not specified – Assumption: variants assumed to have been documented by the author under reference sequence NM_000551.3
GenotypingMethod: SNP Array Assay was used for molecular analysis. PCR was also used for analysis.
SamplingMethod: formalin-fixed, paraffin-embedded tissue samples
(D126N), was detected in a patient with sporadic right jugulotympanic PGL, diagnosed at 53 years.
112 unrelated patients with pheochromocytoma or paraganglioma were screened for mutations in the VHL gene, as well as the SDHx related genes (SDHD, SDHB, SDHC). Mutation analysis was performed on patient blood samples: DNA was extracted using a DNA purification kit (Gentra), exon-intron boundaries of the VHL gene were amplified by PCR, mutation screening was performed by single strand conformation polymorphism (SSCP) and heteroduplex analysis, or by denaturing high performance liquid chromatography (dHPLC) analysis (WAVE 3500 HT system (Transgenomic, Inc., Omaha, NE, USA)) with confirmatory sequencing on CEQ2000 capillary sequencer (Beckman Coulter).Two patients without features suggestive of VHL syndrome were found to have germline VHL mutations. One patient was found to have a germline p.Asp126Asn mutation, and presented with sporadic right jugulotympanic paraganglioma, diagnosed at 53 years. Only the amino acid change was given in the paper, the nucleotide change was not specified in the paper, inferred change is c.376G>A (D126N).
Polycystic Kidney Disease Caused by Bilineal Inheritance of Truncating PKD1 as Well as PKD2 Mutations
PMID: 33102977
Gene: VHL
StandardizedReferenceSequence: NM_000551.3
A female patient observed reduced vision in the right eye at age 17 years. She was diagnosed with retinal angiomatosis of the right eye. Laser therapy and brachytherapy were performed. Vision of the right eye remained reduced to 15%. At age 24, a hemangioblastoma of the cervical spinal cord was resected. At age 27, she underwent craniotomy for a cerebellar hemangioblastoma. Genetic testing revealed the mutation VHL c.394 C > T, which predict a truncated VHL protein (Q132X). In 2007, a 20 mm diameter left renal tumor was detected but not resected owing to its small size, as internationally recommended [1].In 2009 at age 38, abdominal MRI and CT angiography showed, in the axial view, a solid, 3.6 × 3.3 cm tumor of the pancreatic tail (Fig. 2a). Early arterial phase imaging after contrast injection revealed that the tumor had significant hyperperfusion. In addition, multiple pancreatic cysts were noted.
PatientID: 2
KindredID: 2
Case: F, 38Y0M, German
DiseaseAssertion: VHL
FamilyInfo: N/A
CohortInfo:All patients from the German registry for VHL with PNETs >3 cm diameter with tumours located in the pancreatic body or tail region.
CasePresentingHPOs: HP:0009711, HP:0009713, HP:0006880, HP:0009726, HP:0030405, HP:0001737 (retinal capillary hemangioma, spinal hemangioblastoma, cerebellar hemangioblastoma, renal neoplasm, pancreatic endocrine tumour, pancreatic cysts)
CaseHPOFreeText: Retinal angiomatosis at age 17, hemangioblastoma of the cervical spinal cord at age 24, cerebellar hemangioblastoma at age 27, left renal tumor at age 36. Pancreatic endocrine tumour and pancreatic cysts at age 38. She had a laparoscopy which found an 8-cm retrogastric cyst, 3.2-cm benign PNET, and a serous cystadenoma.
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.Q132* (c.394C>T)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: 288749 https://www.ncbi.nlm.nih.gov/clinvar/variation/288749/
CAID: N/A
gnomAD: N/A
VariantEvidence: N/A
MutationType: stop_gained
CivicName: Q132* (c.394C>T)
MultipleGeneVariants: N/A
PatientID: 86
KindredID: 86
Case: Sex Unknown, Age Unknown, Ethnicity Unknown
DiseaseAssertion: Assumed VHL
FamilyInfo: N/A
CasePresentingHPOs: HP:0002666 (Pheochromocytoma)
CaseHPOFreeText: N/A
CaseNotHPOs: N/A
CaseNotHPOFreeText: N/A
CasePreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: Patient information pulled from Supplemental Table 1b.
Variant: p.L163I (c.487C>A)
LegacyVariant: N/A
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351756131
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: L163I (c.487C>A)
MultipleGeneVariants: N/A
KindredID: 40
GroupID: 22
GroupSize: Unknown
GroupNumberMales: Unknown
GroupNumberFemales: Unknown
GroupEthnicity: Unknown
GroupAgeRange: Unknown
DiseaseAssertion: VHL
GroupInfo: Kindred no. 40 describes a family where at least one member (unspecified how many) had this mutation in the VHL gene. Pheochromocytoma was observed in this kindred.
GroupPresentingHPOs: HP:0002666 (Pheochromocytoma)
GroupHPOFreeText: Pheochromocytoma was observed in this kindred indicating VHL disease type 2.
GroupNotHPOs: N/A
GroupNotHPOFreeText: N/A
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.G114C (c.340G>T)
LegacyVariant: p.G185C (c.553G>T)
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA351751376; https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.340G%3ET
gnomAD: N/A
VariantEvidence: N/A
MutationType: missense_variant;transversion
CivicName: G114C (c.340G>T)
MultipleGeneVariants: N/A
KindredID: 54
GroupID: 49
GroupSize: Unknown
GroupNumberMales: Unknown
GroupNumberFemales: Unknown
GroupEthnicity: Unknown
GroupAgeRange: Unknown
DiseaseAssertion: VHL
GroupInfo: Kindred no. 54 describes a family where at least one member (unspecified how many) had this mutation in the VHL gene. Pheochromocytoma was not observed in this kindred indicating VHL disease type 1.
GroupPresentingHPOs: N/A
GroupHPOFreeText: N/A
GroupNotHPOs: HP:0002666 (Pheochromocytoma)
GroupNotHPOFreeText: Pheochromocytoma was not observed in this kindred indicating VHL disease type 1.
GroupPreviousTesting: N/A
PreviouslyPublished: N/A
SupplementalData: N/A
Variant: p.R177Dfs*25 (c.528del)
LegacyVariant: p.247FS (c.741delG)
CaseProblemVariantFreeText: N/A
ClinVarID: N/A
CAID: CA432423454; https://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/allele?hgvsOrDescriptor=NM_000551.3%3Ac.528del
gnomAD: N/A
VariantEvidence: N/A
MutationType: minus_1_frameshift_variant
CivicName: R177fs (c.528del)
MultipleGeneVariants: N/A